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SUMMARY
The development of a suitable screening assay for the 
detection of monoclonal antibodies of a required specificity, is
essential to the overall success of the technique.
An antibody capture enzyme immunoassay has been developed 
for the detection of anti-acetylcholine receptor (AChR) antibodies 
in tissue culture supernatants using biotinylated alpha- 
bungarotoxin (B-alpha-BGT). Immunoglobulins in culture 
supernatants were bound indirectly to microtitre plates via an 
anti-globulin antibody already coupled to polyvinyl plates. 
Anti-AChR antibodies were then detected by incubation with AChR
crude extract. Bound AChR was revealed by incubation with
B-alpha-BGT followed by horseradish peroxidase conjugated avidin 
(HRP-avidin). This latter reagent was subsequently replaced by 
HRP-Streptavidin, after the discovery that the very basic avidin, 
interacted with the casein used as a non-specific blocker in the 
assay buffers. Casein was also replaced for this reason by fish 
skin gelatin. The assay was shown to be more specific and 
sensitive than the commonly used double antibody radioimmunoassay 
(RIA), avoids the use of radioactive material, is practical for 
large numbers of samples and is particularly suitable for 
detecting anti-AChR antibodies in tissue culture supernatants.
All assay conditions were subsequently optimised by utilising 
murine monoclonal anti-Torpedo AChR antibodies.
This approach was favoured over an anti-idiotypic assay,
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wHtek
\ was also being developed, due to the fact that the biotin/avidin 
ELISA was applicable to antibodies raised from any patient, 
whereas the anti-idiotype approach is only suitable for use in 
detecting the idiotypes against which the anti-idiotypes were 
raised. The idiotypes being obtained from one patient.
Even with the development of a highly sensitive assay for 
the detection of human monoclonal antibodies, directed ■'against 
the nAChR, little success was achieved in the generation of human 
monoclonal anti-AChR antibodies. Partial success was achieved in 
the detection of anti-AChR antibodies, by utilising the direct 
Torpedo ELISA, and culture supernatants from EBV transformed 
lymphocytes and heterohybridomas. Observations made during the 
course of cell manipulations and immortalisations, confirmed 
previously held reports on the instability of antibody production 
seen within lymphoblastoid/heterohybridoma cells with antibody 
production declining unless vigorous and early cloning is carried 
out. Consequently, the techniques themselves are labour 
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INTRODUCTION
1. THE IMMUNE RESPONSE
Our immune system saves us from certain death by infection. 
Any child born with a severely defective immune system will die 
unless the most exti^dinary ■ measures are taken to isolate it 
from a host of infectious agents - bacterial, viral, fungal and 
parasitic.
The immune response is highly specific. An individual who 
recovers from measles is protected against future exposure to the 
virus, but he is not protected against other common viruses, such 
as mumps and chicken pox. This specificity is a fundamental 
characteristic of the immune response.
Yet another fundamental characteristic of the immune 
response is its ability to distinguish between foreign and self 
molecules. This is essential when it is considered that the 
majority of the reactions carried out by the immune system are of 
a destructive nature. Occasionally it fails to make this 
distinction and reacts against self components, such as in the 
autoimmune diseases.
There are two classes of immune response:
1) Humoral Antibody Response.
2) Cell Mediated Immune Response.
These responses and their interactions will be briefly 
considered in an overview of the body's immune responses.
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Further discussions are to be found in, Alberts et al (1983), 
Roitt (1987 & 1989), and Feinberg & Jackson (1983).
1.1 Humoral Antibody Responses
Antibody responses are mediated by B-lymphocytes, which 
account for 5 -1 5?o of the circulating lymphocytes. Each B-cell 
during its development from haematopoietic stem cells, becomes 
committed to the recognition of one particular antigenic component, 
and to the subsequent production of one specific type of antibody 
towards it.
B cells display characteristic markers on their cell 
surface, some of which are antigen receptors, predominantly surface 
bound immunoglobulins. Other cell surface markers include, MHC 
class II antigens (HLA-DP, DQ and DR) used in cooperation with T- 
cells: receptors for the complement components C3b (CR1, CD35) 
and C3d (CR2, CD21), (CR2 is also the receptor used by EBV in 
gaining entry to the cell), and Fc receptors for IgG (FcRII,
CDw32). Other markers, CD19, CD20, and CD22 also occur and it is, 
in fact, these that are mainly used to identify human B-cells.
Upon stimulation, the B cells develop into plasma cells. 
These cells are larger than the immature cells and are character­
ised by large amounts of rough Endoplasmic Reticulum. Despite 
their name, they are not found in the plasma, but are associated 
with secondary lymphoid tissues, and only survive for 1-2 days 
producing vast amounts of immunoglobulin.
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Although B-lymphocytes are capable of producing five 
different classes of immunoglobulin, during their development 
they become committed to the production of antibodies of only 
one class and specificity.
1.1.1 The Immunoglobulins
The immunoglobulins are a group of blood glycoproteins 
sharing similar structures. The basic structural unit of an 
immunoglobulin consists of four polypeptide chains, two identical 
light chains (approx. 220 a.a. units, Mwt approx. 23,000) and two 
identical heavy chains (approx. 440 a.a. units, Mwt approx.
50,000 -  77,000) associated together to give two antigen binding 
sites (see Fig. 1 which gives a diagramatic summary of IgG). The 
two heavy chains are joined together by interchain disulphide 
bridges, and each light chain is joined to one heavy chain by 
another disulphide bridge (this was first proposed as a model in 
1962 by Porter). There are five different classes of 
immunoglobulin, known as isotypes, (IgG, IgM, IgA,AIgD), differing 
in heavy chains (gamma, mu, alpha, epsilon, delta) and biological 
properties. Within the IgG and IgA classes are differing sub­
classes, also isotypes (IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2). 
They all, however, share the same two light chains (kappa or 
lambda)
IgG is a monomeric glycoprotein, accounting for 70 -  75?o of 
total serum immunoglobulin, and is the major antibody of the 
secondary immune response. As can be seen in Fig. 1, it is made 
up of four polypeptide chains, two heavy chains and two light 
chains. Amino acid sequencing and protein folding experiments
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have established that both the heavy and the light chains are 
characterised by domains sealed with intrachain disulphide bridges, 
and each domain has a particular function (see Fig. 1). Both the 
heavy and light chains have constant and variable domains, with 
the variable domains of both the light and heavy chains located 
at the antigen binding site. Further to this, it has also been 
shown that there are three hypervariable regions within the 
variable region of each chain and together, all six form the 
antigen binding site. Each different binding site specificity is 
known as an idiotype.
IgM is found as pentamer of the four chain basic structure 
linked by disulphide bridges, together with a J or joining chain. 
It accounts for 10% of total serum immunoglobulin, and is the main 
antibody in the primary immune response. Due to its pentameric 
structure, which tends to make it more rigid, it is much larger 
than IgG, has more domains, 10 antigen binding sites, and binds 
complement with greater affinity than IgG. This is due to the 
rigid structure, holding the individual units in the correct 
orientation for complement fixation. IgM, along with IgD, is also 
found in a monomeric membrane bound form on the cell surface of B 
lymphocytes, where it acts as an antigen receptor.
IgA and IgE have the same basic structure as IgG, IgA being 
found in a dimeric form, and each has its own function which will 
not be considered here (see Roitt, 1989)
1.1.2 Generation of Antibody Diversity
The immune system has to be able to recognise millions of
different antigenic determinants, and produce antibodies towards 
them. This constitutes a problem of genetics rather than of 
protein chemistry.
The greatest structural variation in immunoglobulins 
involves the antigen binding site, and most workers have studied 
the gene rearrangements in both mouse and man, which bring about
these variations. Whereas, most work has been carried out usihg
the mouse system, it is generally believed that the mechanics 
involved in the mouse, with subtle variations, apply to man.
In man, the genes encoding the heavy chains are located on 
chromosome 14, and those encoding the light chains are on
chromosomes 22 and 2 (lambda and kappa respectively). The genes
are a highly complex family consisting of multiple variable (V^ )
and joining genes, and a single constant (C|_) gene, with
respect to the light chains (see Fig. 2), with additional 
diversity (D-|_n) genes and five heavy chain genes in the heavy 
chain gene family (see Fig. 3). The gene rearrangements involved 
are also highly complex, and apply to both the heavy chain and 
light chain genes. They are too complex for an adequate review 
to be given. However, Fig. 2 gives a diagramatic summary of the 
DNA rearrangements in the light chain gene family, whereas,
Fig. 3 gives the same details for the heavy chain genes. Both 
diagrams show how multiple variable regions are obtained through 
the joining of genes by DNA deletion. In addition, Fig. 3 shows 
diagramatically how membrane bound IgM and IgD is obtained, 
through differential RNA splicing, and how the isotype switch 
occurs upon antigenic stimulation. The rearrangements, class
-  7  -
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switch and control of antibody production, in relation to primary 
and secondary antigenic stimulation, are given in Fig. 4.
1.2 Lymphocyte Activation and Intercellular Cooperation in 
Antibody Responses.
There are two main theories which explain B cell activity 
by T cell independent and T cell dependent antigens:
1) Critical Matrix Theory - simple cross linking of cell
surface receptors.Ig provides the 
required signal (explains T-ind 
responses).
2) Signal Theory - binding of antigen at the cell surface
provides the primary signal for 
activation followed by a secondary 
signal for full activation, provided 
by soluble factors from helper T cells 
(explains T-dep responses).
It is probable that both mechanisms operate together, with 
activation of B-cells by T-dependent antigens requiring a complex 
series of cellular interactions, together with augmentation of 
their response by the release of lymphokines and cytokines. The 
cellular interactions involved in B cell activation are summarised 
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antigen in a more immunogenic form to both T and B cells. 
Interaction with B cells occurs through membrane bound Ig's, and 
with T cells through the T cell receptor (Introduction, section 
1.2.1). The result is activation of the B cell, and release of 
soluble factors, interleukins (IL-1 to 6), which further influence 
the B cells causing them to divide and mature into AFCs.
Control of these interactions is by the expression of certain 
glycoprotein antigens on the cell surfaces. These antigens, in 
man, are known as the human leucocyte antigens (HLA) of the major 
histocompatibility complex (MHC) gene cluster located on chromosome 
6 (see Fig. 6 for gene organisation). The MHC codes for several 
different classes of gene product, each of which has its own role 
in recognition and control, the most important of which are:
MHC class I antigens are transmembrane glycoproteins, non- 
covalently associated with beta-2-microglobulin (see Fig. 7 for 
structure) and are found on all nucleated cells, platelets and 
erythrocytes. These antigens are particularly important in the 
control and generation of cell mediated immune responses.
MHC class II antigens are transmembrane glycoproteins 
consisting of an alpha and a beta chain (see Fig. 8 for structure) 
and are found on most cells of the immune system. APCs express 
processed antigen in association with class II antigens when 
presenting it to helper T cells and B cells during the development 
of an antibody response.
1.2.1 T-Cell Antigen Receptor
The activation of Th cells by antigen in association with
-  13 -
D Locus
C lass III 
Loc us
F i g . 6 - Diagran Sho wi n g  Org an i sa ti o n  Of H un an  M HC  On C h r on o so ne  G
chronosone 6
f S, w .  c  m,c lass III ^
■ ■ ■ ///.V.mumm
c lass II class III c lass I c la ss  I c la s s  I
r— dp— ! r I r D R  i
dz do ![•*] ; ;
=  C4B =  = C4A i Bf =  C2
21: 21-
IHF. TNF,
C lass I Locus
The a bove gene Map s hows that the MHC  D  reg io n  is s u b - d i v i d e d  into 
3 regions, DP, DQ, + DR. E a c h  r e g i o n  cod es  for a  n u M b e r  of «  and  P 
chains.
C la ss  III r egion c odes for: 04  (C4A + C4B) and C2 c o M pl e we nt  factors, 
together w i t h  F actor B (Bf).
G enes for Tu/iour N e c ro s is  F a c to r  (TNF) lie b etween the C la ss  III 
and C lass I loci.
2 1 - O H B  / 21-OHA - g enes c oding for C yt oc h r o M e  P 4 5 0  2 1- H y d r o x y l a s e
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Fig. 7 -  Dia gr a na ti c  R e p re s en ta t io n  of 
C lass I MHC Antigens
a l l o a n ti ge n ic  
s it e s  \
c ar bo h yd ra t e
n ciety
w ic ro g lo bu l in
p l a s m a
w eM brane
cytoplasM
F i g . 8 - Sch ew a ti c  R e p r e s en ta t io n  
Of C lass II A nt igens
A l p h a  Beta
cha in  chain




p l a s H a  Mentrane
c g t op l as M
F i g . 9 - B i a g r a a a t i c  R e p r e s e n t a t i o n  o f u t a R e c e p t o r
di sul ph i de  bonds
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Fig,1 0 -  D i a g r a M  S h o w i n g  M o l e c u l a r  I n t e r a ct io n s  B e t w e e n  M H C  Ant ig e ns  
P r o c e s s e d  Antigen, T-Cell R e c e p t o r  A n d  C M / 8 / 3
p r o c e s s e d
a n t ig e n
p r o c e s s e d
ant ig e n
Ant ig e n  P r e s e n t i n g  Cell
An t i g e n  P r e s e n t i n g  Cell
A )  MHC Class II restricted activation of helper T cells 
Antigen presented to T cells in association with Class II 
protein. Interaction occurring through the CD4/3/TCR-2 
complex on the T cell.
B) MHC Class I  restricted actication of cytotoxic T cells 
Antigen presented to T cells in association with Class I 
protein. Interaction occurring through the CD8/3/TCR-2 
complex on the T cell.
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class II MHC antigens on APCs, occurs through a T-cell receptor 
(TCR), of which there are several types. The TCR-2 receptor is 
the one which has been most closely studied, and comprises of a 
heterodimer of alpha and beta chains (see Fig. 9), which is 
associated with another membrane bound antigen, CD3, consisting 
of three peptide chains. The alpha and beta chains of the TCR-2 
have been found to consist of a constant and a variable region, 
as in the immunoglobulins. Each region forming a closed domain 
by the use of disulphide bridges.
As with the structure of the TCR, the gene arrangements 
also bear a striking resemblance to those of the immunoglobulins. 
It is believed that the same mechanisms of gene Rearrangements are 
used for forming the antigen binding site of the TCR, that are 
used in forming the variable region of the immunoglobulins.
It has been found that the TCR/CD3 complex is in fact 
associated with another membrane glycoprotein, CD4. This antigen 
appears to be crucial to the recognition of class II MHC antigens 
on APC's and is found on T|-| cells (see Fig. 10A). Similarly, 
association of TCR/CD3 with the glycoprotein CD8 confers on the 
cell the ability to recognise class I MHC antigens, and is found 
on Tc cells (see Fig. 10B).
1.3 Cell Mediated Immune Responses
Cell mediated immunity (CMI) involves the specific 
activation of certain lymphoid cells of the immune system.
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The resulting responses being, in the main, cellular based instead 
of antibody based. It is generally responsible for immunity to 
micro-organisms, viruses, grafts and tumour cells.
Whereas antibody responses are MHC class II restricted, most 
cell mediated responses are MHC class I restricted. As class I 
antigens are found on all nucleated cells, then CMI is dependent 
on recognising such cells either as foreign by the class I 
antigens displayed or with foreign antigen associated with self 
class I antigens.
As with antibody responses, the central cells involved are 
APCs and T|_| cells. Cellular interactions, in this case, occur 
through antigen and class II recognition. The activation of T^ 
cells in this way then results in the activation of killer cells 
by the release of lymphokines.
In the first instance, cytotoxic T cells (Tc cells) are 
activated which recognise the target cell through a MHC class I 
restricted interaction, associated with antigen. In the second 
instance, non-specific MHC unrestricted killer cells are activated, 
in particular, Natural Killer cells (NK cells), and Lymphokine 
Activated Killer cells (LAK cells). NK cells recognise 
determinants expressed on neoplastic cells, and K cells, along 
with monocytes, interact with antibody via Fc receptors, in what 
is known as antibody dependent cell mediated cytotoxicity (see 
Fig. 11) where antibody acts as a marker for antigen. Fig. 11 






Cyt ok i ne s
Fig,1 1 -  ft SuMMary Of Cell H ed i a t e d  iMwune R es ponses
[ft] - Antigen uptake, p o s s e s s i n g  and p re se n ta ti o n
to T hel pe r  c el ls  by Antigen P r e se n ti ng  Cells.
[ H  - Act iv a ti on  of I h e l pe r  c ells by presentation,
T hel pe r  c ells a ct ivate f u r t h e r  cell M e d ia t ed  
ihMune r es ponses through direct i nt eractions 
and r elease of lyHphokines,
Hodulation of cell Mediated iHMune reponses 
through release of cytokines,
[c] - Presen ta ti o n  is MHC C la s s  II restricted,
[i] - T hel pe r  / I c yt otoxic cell interactions
are MHC Cla ss  I restricted.
A n t ib o dy  Dep en d en t 
Cell M e d i a t e d  
C y t o t o x i c i t y  (ADCC)
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1.4 Immunorequlation
In the individual, the normal immune responses must be 
subject to strict control.. The control of the immune system 
exists on several levels.
Firstly, the primary regulator is the antigen itself* 
which can either produce a reaction or generate tolerance.
Secondly, there is the antibody which has been shown to 
have a regulatory function through feedback mechanisms 
directly. Along with these feedback mechanisms, is the ability 
to produce anti-idiotypic antibodies directed against the 
antigen binding site of an antibody idiotype, thereby neutralising 
that antibody. As can be seen, this is a self perpetuating 
system of subtle control and such a network was first postulated 
by Jerne. If immune complexes formed in this way have a 
regulatory effect then it follows by the same reasoning that 
antigen-antibody immune complexes would also have some effect. It 
has been shown that immune complexes can influence antibody 
responses by either inhibiting or augmenting B cell reactions.
Thirdly, there are cellular regulatory mechanisms, through 
suppressor T cells and contrasuppressor T cells. It has been 
shown that Ts cells suppress the response of normal cells, whereas 
Tcs interfere with the suppression by Ts cells. The exact 
mechanisms by which these cells bring about their functions, are 
not completely understood, but they have been shown to be MHC 
restricted and appear to involve soluble factors (see Fig. 12 for 
summary).
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Fig,1 2 -  Sueeary Of R e g u l a t o r y  M ec ha n i s e s  I n v ol v ed  In Control  
Of The Inhune R e s po n se
f e e d b a c k  inhibition
a n t ig e n
suppression
h e l p
antibody
idiotype n e t w o r k  int er a ct io n s
Diagraci shows i MM unoregulation involving :
i) F e e d b a c k  Inhibi t ion
ii) I d i ot y pe  N e t w o r k s
iii) I m u n e  C o m p l e x e s
iv) S u p p r e s s i o n  by Ts c e l l s
v) C o n f r a - s u p p r e s s i o n  by Tcs cells
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Underlying all these mechanisms is the genetic control of 
the immune response by immune response genes which are closely 
allied with the MHC. However, there are other IR genes which can 
act at various stages of the immune response.
2. AUTOIMMUNITY
2.1 General
If immune responses towards self components are allowed to 
occur without the normal control processes being fully operative, 
then disease states may be caused. Such diseases are known as 
autoimmune diseases, and are usually characterised by the 
production of auto-antibodies. Nydegger (1985) has stated that 
the term, autoimmune, should be confined to diseases where 
the pathogenic role of the auto antibodies can be shown to be a 
causal factor in the disease process, and should not be used to 
describe situations in which harmless auto-antibodies are a 
secondary phenomenon in tissue damage (eg. anti-heart muscle 
antibodies produced following Myocardial infarction).
2.2 Classification of Autoimmune Diseases
The wide variety of autoimmune diseases have been classified 
according to two systems.
The first, and simpler, involves determination of the site 
of autoimmune attack, and then establising whether or not it is
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organ specific attack (see Table 1.) In organ specific diseases 
the antigen is essentially localised to a given organ, which is 
the only site of attack, whereas in non-organ specific diseases, 
the antigen is widespread throughout the body, with the systemic 
deposition of immune complexes particularly in the kidneys, 
joints and skin.
Table 1 Spectrum of Autoimmune Diseases 
(taken from Roitt (1989))




Autoimmune atrophic gastritis 
Addison's disease 
Premature menopause (rare)




















Mixed connective tissue disease 
^ Discoid lupus erythematosus
Non-organ specific Systemic lupus erythematosus (SLE)
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Table 2 Classification of Autoimmune Diseases 
(taken from Smith & Steinberg (1983))
Class Description
A A defect in the afferent limb of the immune 
system initiated without requirement for 
a specific external agent (SLE)
With important genetic requirements.
Without important genetic requirements.
B A defect in the afferent limb of the immune 
system initiated by a specific external 
agent (acute rheumatic fever).
With important genetic requirements.
Without important genetic requirements.
C A defect in effector mechanisms of immunity 
without a requirement for a specific 
external agent (hereditary angioedema).
D A defect in effector mechanisms of immunity 
initiated by a specific external agent 
(certain nervous system viral infections).
E Combinations of the above.
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The second system of classification is more complex, and is 
based on locating the immune defect in either the afferent limb 
or in the effector mechanisms. This classification is coupled 
with a suggested possible cause, ie. genetics or external agents. 
Under this system, classical autoimmune disease fall within 
Class A, in that they are initiated without requirement for a 
specific external agent, with the abnormality lying in the self 
antigen, the immune response to it, or both (see Table 2: Smith & 
Steinberg (1983)).
Whatever classification is used, it must be stressed that 
autoimmune diseases are multifactorial, being influenced to a 
greater or lesser extent, by the genetic background of the 
individual, the state of the immune system and enviromental 
factors (Smith & Steinberg (1983)).
2.3 Mechanisms of Autoimmune Attack
Many autoimmune diseases (eg. arthritis or glomerulonephritis) 
have common features, such as circulating auto-antibodies, 
inflammation, kidney damage etc. Such features are believed 
to result from the limited number of immune mechanisms that are 
operable in autoimmune diseases.
Mechanisms involved include, hypersensitivity reactions:
Type I (anaphylactic: Type II (cytotoxic): Type III (antibody- 
antigen complexes): and Type IV (cell mediated). These specific 
mechanisms can be augmented by non-specific measures, such as,
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cellular (via lymphokines) or humoraL (complement, coagulation, 
kinin, and fibrolytic) amplification systems. The overall 
interaction of these complex processes leads to the specific 
outcome of each disease.
The cytotoxic (Type II) mechanism can involve.the reaction 
of circulating autoantibody with antigen bound to cell surfaces. 
The antigen may be the cell membrane, a receptor on that membrane, 
or an antigen such as a virus or drug, that has become attached 
to the cell surface. The pathology of many of the autoimmune 
diseases is believed to be initiated by this mechanism. The final 
outcome of the cytotoxic process may be mediated by complment, 
or by an antibody dependent cell mediated cytotoxic reaction 
(ADCC). ADCC may, in general, be the most important mechanisms. 
The final effect, irrespective of mediation, is usually cell 
lysis, elimination or inactivation (Smith & Steinberg (1983): 
Coombe & Gell (1977)).
2.4 Aetiology of Autoimmune Diseases
When trying to delineate the aetiology of autoimmunity, it 
is first necessary to consider it in relation to the mecl^nisms of 
tolerance to self antigens.
In 1959 Burnett proposed the clonal selection theory of 
immune selectivity (see Fig. 13), from which it was proposed that 
tolerance was generated through clonal deletion or abortion 
of self reactive lymphocytes, and that immunological memory 
was obtained by the generation of specific memory cells following 
primary and secondary exposure to antigen.





' Primary ImMune 
v Response
p r o l i f e r a t i o n  &  
d i f f e r e n t i a t i o n
antigen- MM
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p r o l i f e r a t i o n  &  d i f f e r e n t i a t i o n
e f f e c t o r  cells memory cell pool
Fig, 13- Clonal Expansion of L y mphocytes in P r imary and 
Secondary Immune R e s ponses
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During fetal development, none of the cells of the immune 
system are mature. It is at this stage that the immune system 
develops the ability to recognise, but not to react to, self 
antigens. This phenomenon of tolerance is largely developed in 
the immature cells of the immune system, although mature-cells 
can also develop tolerance depending on dosages of antigen and 
form of antigen presentation.
The mechanism of self tolerance was originally ascribed to 
the elimination of anti-self lymphocytes prior to full maturity, 
however, evidence was subsequently obtained which proved the 
presence of quiescent self reactive B lymphocytes (Rose et al# 
(1963); Bankhurst et al> (1973)) and T lymphocytes (Kong et al , 
(1979)) in the normal individual. It also became increasingly 
apparent that self reactivity was, indeed essential as shown by 
MHC Class I/II controlled cellular recognition and idiotype- 
anti-idiotype interactions. These observations have led 
immunologists to rethink self tolerance, leading to two models 
which account for this apparent unreactiveness in the normal 
individual:
1 ) Tf_| cell deletion (Fig. 14B)
B cell clones are unable to respond due to lack of 
T cell help resulting from clonal deletion of 
anti-self TH cells. Breakdown occurs where non-self 
T|_j cells react to a similar antigen (see Fig. 14)
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Fig.14- Mechanises of Self Tolerance
A: H is to r ic a l  - proposed by Burnet & Fenner. S e lf-an t igens  
induce el in i na tion  o f s e l f  re a c t ive  luMPhocutes. Aufo- 
iMMunity occurs through Mutation in the a d u lt .
B: T helper de le t ion  - prevents B c e l ls  froM reac t ing  by 
reMoving T c e l l  help. Breakdown occurs through cross­
r e a c t i v i t y .
C: Suppression - o f  T and B cel Is by T suppressor c e l ls  
loss of which re s u l ts  in an antoiMMune reac t ion .
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2) Suppression (Fig. 14C)
Suppression of T[-|/B cells by Tg cells. Breakdown 
occurs with the loss of T5 cells (see Fig. 14). A
similar effect is the veto cell effect, where self
reactive T cells are controlled by further T cells.
Both these mechanisms are believed to operate in adult life, 
but functional deletion of cells is probably the primary 
mechanism, with suppression acting as a safeguard.
As it is believed that tolerance is due to either helper T 
cell deletion or through the development of suppressor T cell 
circuits (see Fig. 14), then these mechanisms themselves, 
suggest how possible abnormalities may occur, leading to a 
breakdown of tolerance and uncontrolled autoimmunity. Figs. 15 
and 16 summarise the mechanisms which may give rise to auto­
immunity through bypass of the control networks. Fig. 15 gives 
an overall view of how the regulatory mechanisms interact with
one another and of the several points which are susceptible to
breakdown. Fig. 16 gives a more detailed description of each of 
the suggested defects. These mechanisms may originate through 
viral/microbial action, drug modification of antigen, idiotype- 
anti-idiotype interactions or be genetically induced.
2.5 Auto-antibodies In Autoimmune Diseases
One of the characteristic features of many autoimmune 
diseases is the production of auto-antibodies. However, it
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Fig.15; Induction of Autoinnunity through bypass of regulatory 
Mechanises
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fij.16: Induction of ‘ tg I Cell Bypass (ajaptea fro* Roitt (1989))
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has been shown that there is continuous production of low levels 
of circulating auto-antibodies in normal healthy individuals.
Such antibodies tend to be of the IgM isotype with a short half 
life (Cohen & Cooke (1986)). As an individual ages there is an 
increase in the quantity of auto-antibodies directed against 
nucleoproteins, DNA>immunoglobulins (rheumatoid factors, anti- 
idiotypes), complment (immunoconglutinins) and various other 
tissue antigens (Nydegger^(1985): Hallgren et al,(1973): Goodwin 
et al,(1982): Kunkel,(1982): Bullock et al,(l979)).
These observations give direct evidence for the presence of 
self reactive B lymphocytes within normal healthy individuals 
(Schatter (1986/87), and raise the question as to their function 
and regulation. Grabar (1983) proposed that auto-antibodies 
act to clear self antigens from sites of tissue damage and from 
ageing tissues, thus explaining the observed increase in such 
antibodies during ageing. A role for auto-antibodies in the 
maintenance of homeostasis, was later supported by Khansari & 
Fudenberg (1984). However, Cohen & Cooke (1986) argue from 
Darwinian logic, that the presence of such antibodies must have 
some intrinsic survival value. They further suggested that auto­
antibodies help in the avoidance of autoimmune diseases within 
the healthy individual, by blinding the immune system to 
environmental epitopes that are cross reactive with self antigens, 
but their production is kept under strict control. Holmberg & 
Coutinho (1985) state that this control is via idiotype-anti- 
idiotype mechanisms.
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If auto-antibodies are produced in normal individuals, and 
have a physiological role, how are they involved in disease 
processes? It is not sufficient to postulate that a simple 
increase in the quantity of auto-antibodies will lead to disease, 
because in certain of the diseases (eg. Myasthenia gravis) there 
is little correlation between auto-antibody titre and disease 
severity. Some individuals show no symptoms but high antibody 
titres and others display severe disease and low antibody titres. 
It may be that a specific antibody sub-population, or isotype, 
is responsible for the disease. An isotype switch may accordingly 
be important, as natural auto-antibodies tend to be IgM, whereas 
those associated with the disease process tend to be of the IgG 
isotype (Schattner,(1986/87): Cohen & Cooke,(1986): Clough & 
Valenzuela,(1980)).
Apart from changes in the nature of the auto-antibodies, 
changes in the regulation of their formation may be important.
Fig. 16 shows mechanisms by which regulatory systems can be 
circumvented. As B cell function is regulated by the activities 
of helper/suppressor T cells, NK cells and idiotype-anti- 
idiotype interactions, then a dysfunction of any of them 
may result in B cell activation and unregulated auto-antibody 
production. However, much of the evidence available points to an 
important role for diminished suppressor T cell activity, with 
possible anti-idiotypic involvement (Schattner (1986/87)). Such 
changes could be brought about by both environmental and genetic 
factors.
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2.6 Genetic Influences In Autoimmunity
A striking feature of autoimmune diseases is their linkage 
to particular MHC alleles and antigens (Svejgaard et al (1983)). 
The influence of the MHC in autoimmunity was reviewed by 
Strominger (1986) who put forward a plausible theory of auto­
immunity (Introduction, Section 2.7)
In some cases the linkage is very high. For example, 95%
of patients with ankylosing spondylitis carry the HLA-B27 allele, 
compared to 7% of controls. In others, however, linkage is much 
lower, as in MS where 59% of patients are HLA-DR2, compared with 
26% of controls.
When the disease is tightly linked to an HLA allele, as 
with ankylosing spondylitis, it is assumed that the HLA gene/ 
protein itself is in some way related to the disease. However,
when the degree of association is lower, ie. in MS (DR2),
rheumatoid arthritis (DR4), or juvenile onset diabetes (DR3 or 4) 
several other explanations exist, as eg:-
a) The actual gene associated with the disease is in 
linkage disequilibrium with the gene being assayed.
Linkage disequilibrium (failure of adjacent genes to 
segregate in the population) is a well known phenomenon 
of the HLA system (Awdeh et al*(1983)), and the 
relatively low extent of correlation of MS with HLA-DR2, 
for example, may be due to the fact that MS is related 
to a gene in linkage disequilibrium with DR2 itself.
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In coeliac disease, in which 45?£ of patients are HLA-DR7 
and 28?o DR3, 95% have been shown to carry the DQ2 allele 
in linkage disequilibrium with DR3 and 7 (Tosi et alj 
(1983)). Congenital adrenal hyperplasia is known to be 
caused by deletion of a 2 1 -steroid hydroxylase gene, which 
is linked to HLA-B47. The gene is actually located between 
the C4B locus in the Class III region and the HLA-B locus 
in the Class I region. Thus the disease association may 
be to a gene in the MHC region that is not an HLA gene.
b) Linkage of a disease with DP genes, which have little 
or no linkage disequilibrium with DQ or DR loci. There is 
at least one 'hot spot1 for recombination between DP-DX and 
DQ-DR. Thus a disease with two forms, one linked to DP and 
the other to DQ or DR, would only show linkage to the 
latter.
c) HLA alleles are heterogenous within themselves, and
a disease may be linked with a particular HLA polymorphism.
d) Promiscuous epitopes may account for lower linkage, 
as the epitopes of the HLA genes are the functional 
units of these genes/proteins, but, they are not entirely 
fixed to one gene/protein and can be shuffled to other 
genes/proteins within the system.
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e) The disease itself may be heterogenous, eg. Type 1 
but not Type 2 diabetes is HLA linked.
2.7 A Possible Theory Of Autoimmunity
Several other points have been made concerning autoimmune 
diseases. These include:
i) At least two genes are involved in the disease process, one 
of which is an MHC gene (Spielman & Nathanson,(1982): Buse & 
Eisenbarth>(1985)).
ii) Viruses, or some other environmental agent, may play some 
role in the genesis of at least some of the diseases (Nathanson & 
Miller,(1978): Manser et al,(1978)).
iii) The disease process is, in many instances, specific for 
a particular target tissue.
iv) Concordance is low in monozygotic twins (although higher 
than in dizygotic twins or families) (Williams et al,(1980): 
Barnett et al,(1981)).
All these factors, along with HLA linkage, led Strominger 
(1986) to postulate the following theory with respect to the 
generation of autoimmune diseases. He has concentrated on cell 
mediated mechanisms but his arguments apply to antibody mediated 
autoimmune diseases.
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He postulated that infection with a virus initiates 
development of Class II restricted virus specific cytotoxic 
T cells, which have broad specificity, and cross react with a 
determinant on some cell surfaces on normal cells. Equally it is 
conceivable that another environmental agent may. be responsible 
for provoking the primary immune response. However, unlike 
viral infections, autoimmunity is rare, and susceptibility to a 
particular autoimmune disease may be linked to the possession of 
a second gene (either a polymorphism in the target antigen or 
T cell receptor). This basic theory explains how possession of 
certain HLA alleles, environmental agents and possession of 
certain antigenic polymporphisms, may result in an autoimmune 
disease, and also explains why monozygotic twins show relatively 
low concordance. This latter fact arises because during the 
maturation of the immune system, each individual will undergo a 
different set of T cell receptor and immunoglobulin gene 
rearrangements. Con^juently, each twin will possess different 
sets of idiotypes, each with differing potentials for cross 
reactivity. Thus, chance may play a prominent role in the 




It is now well accepted that Myasthenia gravis (MG) is an 
autoimmune disease, characterised by muscle weakness-and fatigue. 
The primary defect is the loss of nicotinic acetylcholine 
receptors (nAChR) on the post synaptic membrane of the 
neuromuscular junction (NMJ), brought about largely by antibody 
mediated immune responses.
There are several very good general reviews available, 
covering all aspects of MG, since its discovery nearly 300 years 
ago (see Lindstrom, 1979: Vincent, 1980: newsom-Davis & Vincent, 
1982: Lisak et al, 1985: Drachman, 1981, 1978: Oosterhuis, 1981: 
Fuchs, 1979: Engel, 1987, 1980, 1979: Harrison & Behan, 1986: 
Pachner, 1988). Consequently, this section is designed only to 
summarise the information currently available, including research 
on the nAChR, synaptic organisation and nerve/muscle physiology.
3.2 NEUROMUSCULAR JUNCTION AND THE NICOTINIC AChR
3.2.1 Neuromuscular Transmission
In the normal sequence of events, muscular contraction 
begins with the generation of an action potential in the cell 
body of a motor neurone in the spinal cord. This action
I
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potential travels as a wave of depolarisation along the axonal 
membrane of the neurone until it reaches the nerve terminal 
at the muscle endplate or neuromuscular junction (NMJ) and is 
the result of the sequential opening of sets of Na+ and K+ 
ion channels, with the corresponding passive movement of the ions 
along their respective electrochemical gradients, polarising 
the membrane from its normal negative resting potential. As this 
action potential invades the NMJ it initiates the release of the 
neurotransmitter, acetylcholine (ACh) stored within synaptic 
vesicles in the terminal (See Fig. 17). This release is through 
a process of exocytosis, and is Ca^+ dependent, with a net 
influx of Ca^+ ions through voltage dependent cation channels, 
caused as a direct result of the action potential's invading 
the nerve terminal (Reichardt & Kelly, 1983). Upon release, ACh 
diffuses across the synaptic cleft and associates with AChR's 
located on the fold crests of the post-synaptic membrane 
(See Fig. 17)
The binding of ACh results in a conformational change in 
the receptor which is coupled with the transient opening (1-2 msec) 
of a cation selective ion channel. This allows Na+/K+ ions to 
flow down their respective electrochemical gradients with Na+ 
flowing through the receptor channel resulting in local 
depolarisation of the muscle membrane. This local depolarisation 
produces a miniature end plate potential (MEPP). If sufficient
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ACh is released then the MEPP's summate to produce an end plate 
potential (EPP). If the EPP approaches the threshold value 
(-15mV) then an action potential is generated in the muscle fibre 
resulting in contraction.
The ACh is not covalently attached to the receptor, and its 
action is terminated by dissociation from the receptor and 
subsequent hydrolysis by acetylcholine esterase (AChE). This 
enzyme is membrane bound and is located in the folds of the 
post-synaptic membrane (See Fig. 17).
In both the neurone and the muscle fibre, the membranes
resting potentials are re-established by membrane bound Na+/K+ 
ATPases.
It has also been established that there is a safety margin 
in transmission which allows for some fall in either ACh release 
or AChR numbers, while still maintaining sufficiently high EPP's 
for contraction to occur. This is because the ACh is released in 
excess, but very little actually interacts with receptors, which 
are also present in excess.
3.2.2 Nicotinic Acetylcholine Receptors
There are several good reviews covering the nAChR, see 
Dolly & Barnard, 1984: Dreyer, 1982: Stroud & Finer-Moore,
1985: Dolly, 1979, Anholt et al, 1984: Hucho, 1986,1987:
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McCarthy et al, 1986: Karlin, 1980: Changeux, 1981: Conti- 
Tronconi & Raferty, 1982, 1983: Wonnacott, 1990.
AChR's can be subdivided into two distinct types, nicotinic 
AChR's (nAChR) and muscarinic AChR's (mAChR), both of which have 
different distributions and pharmacologies.
The mAChR is found on smooth muscle, cardiac muscle and in 
the brain. As well as interacting with ACh, it also responds to 
muscarine but not to nicotine, and can be blocked by atropine.
The nAChR is found in the brain, at autonomic ganglia and at the 
skeletal muscle NMJ. It responds to nicotine as well as ACh, but 
not to muscarine, and can be blocked by d-tubocurarine.
Nicotinic AChR's, themselves have been historically 
divided on the basis of their responses to hexamethonium (C6 
receptors) and decamethonium (C10 receptors). Ganglionic 
nAChR's respond to hexamethonium and NMJ nAChR respond to 
decamethonium. Such divisions are now superseded by the 
recognition of multiple subtypes based on molecular cloning data.
Characterisation of mammalian nAChR is hindered by the low 
levels of receptor present in skeletal muscle and the relatively 
high levels of proteolytic enzymes (Dolly, 1979). However, the 
discovery of a rich source of nAChR's from the electic organs of 
electric fish (Torpedo genus) and eels (Electrophorus electricus), 
coupled with the isolation of the ar-neurotoxins from the venom of 
certain snakes, which bind specifically and with high affinity to
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nAChRs, have led to isolation and structural studies (Chang & Lee, 
1962: Lee,1972, 1979: Hunter, 1978: Wang & Schmidt, 1980:
Barnard et al,1972: Chang et al,1973: Dolly et al,1981).
The electric organs of both the electric fish and eels are 
phylogenetically evolved from striated muscle, but they have lost 
the ability to contract. Instead their function is to generate a 
charge upon excitation by nerve stimulation. It is generally 
assumed that the electric organ AChR has all the important 
properties of vertebrate muscle AChR, with characteristic 
nicotinic pharmacology, but can be obtained in 1000 fold greater 
quantities (electric organ approx. 100mg/kg, muscle 0.5mg/kg). 
For reviews see Harrison & Behan, 1986: Anholt et al*1984: Stroud 
& Finer-Moore.,1985: Huchoj1986: McCarthy et al,1986.
3.2.3 Isolation of nAChRs
Purifications were originally carried out using electric 
organs and were based on the extraction of the receptor protein 
from its membrane environment using non-ionic detergents, such 
as Triton X-100 or Tween-20, or anionic detergents such as sodium 
deoxycholate. The use of these detergents results in the 
receptor's being solubilised in detergent micelles, but still 
retaining pharmacological properties (Changeux et al,1970:
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Miledi et al,1971). The solubilised receptor can then be purified 
further by affinity chromatography using immobilised neurotoxins, 
cholingeric ligands, lectins or specific monoclonal antibodies 
(Lennon et al,1980: Anholt et al,1984) followed by biospecific 
elution using a variety of quaternary ammonium salt analogues 
of ACh.
Isolation of nAChR from mammalian muscle poses serious 
problems created by proteolysis of the receptor during 
purification. An extensive array of anti-proteases are accordingly 
utilised (Lindstrom et al,1980: Schorr et al,1981: Einarson et al,
1982). In the case of mammalian skeletal muscle, denervation 
partly overcomes the problem of low density of receptor, causing 
them to proliferate over the entire muscle fibre membrane. The 
receptors that develop outside the NMJ are known as extra- 
junctional receptors, and behave slightly differently to 
junctional receptors. The purification procedures, themselves, 
are based on those successfully employed in the isolation of AchR 
from electric organs.
Throughout the purification of AChR from electric organs or 
skeletal muscle, various assay procedures are utilised. They are 
largely based on the separation of AChR-^5j_agQ-|- complexes from 
unbound receptors and free This has been achieved using
Sephadex $50 (Miledi et al,1971): ultrafiltration of the receptor
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toxin complex on sucrose density gradients (Lindstrom & Patrick, 
1974): ammonium sulphate precipitation (Meunier et al,1972): DEAE 
cellulose filtration assay (Schmidt & Raftery,1973: Dolly,1979): 
and more recently a polyethylenimine (PEI) filtration assay 
(Methods, section 1.5.2). AChR content is usually expressed in 
terms of ar-BGT binding sites per gram of protein or as a function 
of extract volume, if a crude extract is being used.
^5.2.4 Characterisation of the nAChR
The nAChR from electric organs and skeletal muscle is a 
transmembrane glycoprotein, exposed both intra and extra- 
cellularly, extending approximately 5nm into the extracellular 
space and 1.5nm into the intracellular space (Ross et al,1977) 
with an apparent MW of 250,000 (Conti-Tronconi & Raftery, 1984).
It contains 4-7?o carbohydrate, and is composed of 4 different
(
polypeptide chains arranged as a pentamer with a stoichiometry of 
. Their apparent M.Wts, from SDS/PAGE, are 40k, 50k, 60k, 
65k respectively (Reynolds & Karlin,1978: Lindstrom et al,1979a: 
Raftery et al,1980). The ar-subunits carry the ACh binding site, 
and, consequently, there are two sites per receptor, as determined 
by labelled or-BGT binding (Tzartos & Changeux, 1984: Wilson et al, 
1984). The AChR is also-a phosphoprotein (Vandlen et al,1979) 
with the phosphate groups attached to the cytoplasmic face of 
the receptor (Huganir et al,1984).
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The four receptor subunits show considerable sequence 
homology and immunological cross-reactivity (Numa et al,1983: 
Tzartos & Lindstrom,1980: Mehraban et al,1982). DNA cloning/ 
translation experiments (Mendez et al,1980: Anderson & Blobel, 
1981: Sumikawa et alj1981: Mishina et al>1984), coupled with amino 
acid sequence and nucleotide sequence analysis on the AChR of 
Torpedo marmorata (Sumikawa et al,1982a: Deillers-Thiery et al,
1983) and Torpedo californica (Ballvet et al.,1982: Noda et al» 
1982, 1983a,b), together with EM studies (Kumblek, 1987) have led 
to a model being proposed for the quaternary structure of the 
electric organ AChR.
Brisson & Unwin (1985) proposed that the five membrane 
spanning subunits lie in a pentamer of quasi-fivefold symmetry, 
around a central ion channel (see Fig. 18a). The ion channel 
is believed to be lined with alternating regions of positive and 
negative charges (Stevens,1985) and the extracellular portion 
of the receptor appears as a funnel. Amino acid sequence 
analysis and DNA cloning, had led to the proposal that each 
subunit has four transmembrane hydrophobic helical segments, one 
of which forms part of the ion channel, with a fifth hydrophilic 
helical segment found to lie on the intracellular side of 
subunit (see Fig. 18c: Noda et al,1982: Claudio et al*1983: 
Devillers-Thiery et alj1983: Stroud & Finer-Moore,1984: Guy &
Hucho 1987: Wonnacott,1990). However, this is only one of at
-  48 -
Fig,18: Diagrawatic Sunnary of Current Infopnation on the AChR
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least 3 models proposed. The precise tertiary structure and the 
location of the COOH terminal are somewhat controversial (Hucho,
1987). In its natural environment the receptor is associated 
with several small proteins, whose functions are not fully under­
stood but are believed to be involved in receptor stabilisation 
and synapse formation (Anholt et al,1984). DNA cloning, amino 
acid sequence analysis, site directed mutagenesis and monoclonal 
antibody studies, have indicated that the four subunits have 
evolved from a single ancestral gene (Conti-Tronconi et al,1983), 
and have assisted in the location of functional domains within 
each subunit (Wonnacott,1990). For example, the aBGT binding 
site has been specifically identified (Mulac-Jenicevic & Atassi, 
1987: Wilson & Lentz, 1988). Similarly, phosphorylation sites 
have been located in homologous positions in all 4 subunits 
(Huganir & Greengard, 1987), and it has been suggested that 
phosphorylation may regulate the rate of receptor desensitization 
(Huganir et alj1986: Hopfield et al,1988).
In Torpedo, the AChR has been found to exist in monomeric 
and dimeric forms with Sw2 q values of 9S and 13S respectively 
(Reynolds & Karlin, 1978). The dimer is believed to be the 
functional unit in vivo (Schindler et al,1984) and is formed by 
two monomers, covalently linked by a disulphide bond through the 
delta subunits (Sobel et al,1977).
The characterisation of the vertebrate skeletal muscle AChR
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has been somewhat slower, partly because it is less accessible, 
and partly due to the presence of two distinct forms of the 
receptor, juntional (J-AChR) and extrajunctional (EJ-AChR) 
(Famborough, 1981). EJ receptors differ from J-AChR's in several 
respects; namely they exhibit lateral mobility, have lower half- 
lives, longer channel opening times (Anholt et al*1984) and less 
glycosylation (Turnbull et al»1985). Another, significant 
difference, is that anti-AChR antibodies from Myasthenic sera, 
react preferentially with EJ receptors (Weinberg & Hall, 1979: 
Almon & Appel, 1975: Savage-Marengo et al3l980: Harrison et al,
1983). The same has been seen with rabbit anti-cat AChR anti-sera 
(Dolly et al,1983) and mouse anti-Torpedo AChR antibodies 
(Souroujon et al,1983). Similarly, a monoclonal anti-human AChR 
antibody has been shown to react preferentially with human 
denervated receptor. These studies and the demonstration that 
some Myasthenic sera block toxin binding to rat EJ-AChRs (Dwyer 
et al^1982a,b: Hall et al*1983) have led to the postulate that 
EJ-AChRs or foetal AChRs may be the autoimmunogen in Myasthenia 
gravis.
To date, most of the information has shown that the 
vertebrate receptor bears a remarkable resemblance to the electric 
organ AChR. Cloning experiments on calf AChR (Tanabe et al,1984) 
and human SChR (Shibahara et al»(1985) have confirmed this 
homology, and appear to suggest a common ancestral gene
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(Harrison & Behan,1986). Vertebrate AChR shows a 5w2q of 9S, 
which is a monomer, with no detection of a 13S dimer. A smaller 
4S toxin binding species has also been detected (Lo et al,1981), 
and this may be a degradation product. The subunit pattern also 
appears to be similar with all four subunits being detected. The. 
a-subunit also carries the ACh/a-BGT binding site.
Calf AChR does show an anomaly, however. It has been shown 
to contain an epsilon subunit, which is homologous with the gamma 
subunit (Takai et al,1985). It has been suggested that the 
embryonic form of the receptor possesses the gamma subunit which 




Myastenia gravis (MG) is a disease characterised by weakness 
and fatiguability of voluntary muscles. The first description of 
the disease was made by Thomas Willis (1672), and, since that 
time, various researchers and physicians have described patients 
with symptoms amounting to clinical MG (see Harrison & Behan,1986, 
for review). However, it was not until 1893 that the term 
'Myastenia gravis pseudoparalytica' was coined for the disease by 
Jolly (1893), the 'pseudoparalytica' being dropped a short while
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later. It was Campbell & Brambell (1900) who formally summarised 
the case histories of over 70 patients, all of whom were 
displaying symptoms of MG, and first suggested a possible 
aetiology for the disease involving a circulatory factor, possibly 
a microbial toxin.................................... ......
In 1934, Dr. Mary Walker made a connection between the 
symptoms of MG and those displayed by patients suffering from 
curare poisoning, which led her to use the antidote for curare 
poisoning, phytostigmine, as a treatment for MG. This drug blocks 
the action of anti-acetylcholine esterase (AChE), and was 
remarkably successful in treating MG patients. It also gave the 
first direct evidence that the primary lesion in MG was 
located at the NMJ. However, this was not confirmed until Engel 
& Santa (1971) described a simplified morphology at the NMJ in 
Myasthenic patients when compared to normals, and Famborough, 
(1973) demonstrated the reduction in the numbers of AChRs at the 
NMJ.
It was also during the early part of this century that a 
connection was made between MG patients and patients with thymic 
abnormalities, with the result that thymectomy was used to treat 
MG patients (Blalock, 1939; for review see Harrison & Behan,1986).
The first suggestions that MG was possibly an autoimmune 
disease, came from Smithers (1939), supported by reports from 
immunological abnormalities in MG patients from Nastuk et al* 
(1956,1960), and Straus et alj(1960), but it was Simpson*(1960)
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who made the most authoritative case for an autoimmune aetiology 
for MG. However, the identification of AChRs at the NMJ as the 
site of the autoimmune attack, was not made until Lindstrom & 
Patrick,(1973) demonstrated the appearance of MG like symptoms in 
rabbits immunised with purified fish electric organ AChR........
3.3.2 Clinical and Pathological Features of MG
MG is a rare disease affecting approximately 4-6 individuals 
per 100,000 (Kurtzke & Kurland, 1977). It can attack both males 
and females at any age, but 60% of patients are female with an 
onset age between 13-40 yrs (Osserman & Genkins, .1971). Males 
tend to develop the disease much later in life. This sex and age 
distribution appears to reflect, to some degree, the distribution 
of certain HLA antigens. Studies on Caucasian patients show that 
B8 and DRW3 appear to be associated with females suffering from 
early onset MG and thymic hyperplasia (Rule, 1973: McDevitt & 
Bodmer, 1974: Feltkamp et al,1975: Fritze et al,1976: Pirskanen, 
1976: Gross et al,1977), and A2 or A3 appear to be associated 
with late onset MG in males also suffering from thymomas 
(Feltkamp et al*1975: Fritze et al,1976).
The most characteristic clinical feature of MG is muscle 
weakness and fatigue. However, the clinical picture is varied, 
complicating diagnosis. In the mildest forms, extraocular
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muscles are affected, resulting in droopy eyelids (ptosis) and 
double vision (diplopia). Up to 90% of all patients show these 
symptoms. In more generalised cases, other muscle groups are 
affected, particularly in the extremeties and trunk. This general
weakness has been shown to increase with.exercise,, with.........  _
fluctuations in symptoms occuring daily, weekly or even over 
longer periods, and total remissions occuring in only 20% of 
patients. A large number of patients have also been shown to 
suffer from a variety of other diseases, a significant proportion 
of which are autoimmune (see Harrison & Behan, 1986).
Coupled with these clinical observations are pathological 
and morphological changes in the thymuses and at the NMJ of 
patients suffering from MG. About 10-15% of patients have 
thymoma with thymic hyperplasia or germinal centres observed in 
75-85% of patients (Castleman, .1966). Germinal centres .contain 
mainly B lymphocytes with a few T cells and macrophages. They 
are also found in patients suffering from a variety of other auto­
immune diseases.
The NMJ of MG patients have been shown through EM studies 
(Engel & Santa*(1971)), to have a simplified morphology compared 
to normal NMJ's. The post-synaptic membrane shows sparse shallow 
folds with reduced numbers of AChR's (Alberquerque et al,1976: 
Engel et al,1979b: Fambrough*1973). In contrast, the nerve 
terminals are slightly reduced in size, but contain normal
- 55 -
Fig,i9: DiagraMatic r e p r e s en ta t io n  of noraal J Myasthenic NMJ 's
rel ea s e  s it es
P M - s y n a p t i c  ft) Harwal N e u r o - Hu sc u la r
nerve terwinal j u n ct i on
00
p os t- s yn ap t ic  /  
MeH brane
A C h  v es i c l e s  
s y n a p t i c  cleft
j unct i on al  folds
A C h E
Muscle fibre
B) H ga st h en ic  N eu ro - nu sc u la r  
jun ct i on
i) Normal p re -s y na pt i c  terwinal 
s i n p l i f i e d  p o s t - s yn ap t ic 
n en br a ne
S pa rs e  s ha l l o w  f olds w i t h  
coM pl e ne nt  Mediated focal lysis 
M eM b r a n e  f ra gments in syn ap t ic  
cleft
A nt i g e n i c  M o d ul a ti on  - by cross 
linking of AChR with increased 
degradation 
widened s yn aptic space 
with loss of neMbrane
i
w is cl e  f ibre
- 56 -
numbers of synaptic vesicles with twice the concentration of ACh 
(Ito et al,1976: Cull-Candy et al,1978, 1980). Membrane fragments 
with complement components have been found in the synaptic cleft, 
which is also wider due to the loss of membrane (see Fig. 19).
These changes at the NMJ result in decreased.efficiency of .
synaptic transmission, which, if severe enough wili lead to the 
reduction of muscle power and hence weakness and fatigue.
Clinical diagnosis of MG purely on observations of symptoms 
is less than satisfactory, and makes the evaluation of therapies 
difficult. Consequently, various test conditions are applied.
The most regularly used clinical test is the ’Tensilon1 test, 
based on the administration of edrophonium chloride (an 
acetylcholinesterase inhibitor), followed by observation of 
improvement in weak muscles. If there is an improvement, then 
the test is positive.
A test carried out in conjunction with the Tensilon test, 
and one which specifically diagnoses MG, is the determination of 
anti-AChR antibodies in the sera (Methods, section 1.6 for details 
of assay). Although false positives do not occur, false negatives 
commonly do. Thus a minority, of MG patients have normal titres. 
These include patients presenting purely ocular symptoms (Vincent, 
1984), and some patients on corticosteroids or who have undergone 
thymectomy (Oosterhuis et al*1983). Even within those patients 
showing negative titres, correlation between antibody titre and
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clinical state is poor (Vincent & Newsom-DaviSj^BO: Limburg et 
31,1983).
Other tests include normal electromyographs, single fibre 
electromyographs, acoustic tests and eye tests. Kelly et al,(1982) 
compared results, over 3 years, from numerous MG patients, 
utilising ocular testing, routine EMG and antibody titres. They 
concluded that if patients with mild MG were tested by all 3 
methods, then positive diagnosis could be made in 95% of all cases.
3.3.3 Therapy
The most common form of therapy is treatment with AChE 
inhibitors, which act by increasing the effective concentration of 
ACh in the synaptic cleft. It has also been suggested that 
the effect of anti-AChE treatment is to produce greater numbers 
of activated AChRs.
Thymectomy is frequently used to treat patients who are not 
well controlled on antiesterase drugs along. As previously 
stated, many patients have thymic abnormalities (Thomas et al,
1982: Bofill et al,1985: Castleman,1966). Mulder et al,(1983) 
reported an overall benefit to 87% of 249 patients who had under­
gone thymectomy, with female patients faring better. Bartoccioni 
et al,(1980) showed significant reductions in anti-AChR antibody 
levels following thymectomy.
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Steroid therapy is also used and has been shown to be very 
effective in many cases (reviewed by Harrison & Behan,1986). 
Associated with this form of therapy, is the use of immuno­
suppressive drugs, such as azathioprine and 6-mercaptopurine 
(Mattell et al,1976: Aertel*1979). ...........
In patients with severe generalised MG, plasmapheresis 
(plasma exchange) coupled with immunosuppressive drug therapy 
(Pinching et al,1976: Dau et al,1977, 1979, 1980, 1981, 1982a,b: 
Newsom-Davis et al,1978, 1979a,b: Behan et al51979: Kornfeld et 
al,1979, 1981, 1982: Lisak et al,1979a: Perlo et al,1981: Orlarte 
et al,1981: Keesey et al,1981: Newson-Davis & Vincent,1982), and 
thoracic duct drainage (Mattell et al,1976: Bergstrom et al,1973) 
have been used with success in many cases. Following the use of 
this technique, an immediate and dramatic drop in anti-AChR 
antibody levels is often followed by a noted clinical improvement.
Gammaglobulin therapy has also been used (Gajdos et al,
1984) with claimed clinical improvement and reduction of antibody 
titres. Related to this form of therapy is the suggestion that 
anti-idiotypic therapy may be of benefit in autoimmune diseases 
(Fuchs, 1980), either by using polyclonal sera or monoclonal 
anti-idiotypic antibodies. There is increasing evidence of an 
operational idiotype-anti-idiotype network in MG (Schwartz et al, 
1978: Fuchs,1980: Dwyer et al>1983: Feingold et al,1980).
However, the benefit of such therapy may be of limited value.
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Heininger et al,(1983) demonstrated that remission phase patients 
do not contain measurable amounts of blocking anti-idiotypic 
antibodies, either in a free or immuno-complexed state, and 
suggested that such a mechanism does not induce remission. Such
a therapeutic strategy may also prove difficult, because.of. the....
demonstration of the heterogeneity within patients of anti-AChR 
antibodies (Newsom-Davis & Vincent,1980: Levfert,1981). Vincent 
(1981) did suggest the presence of a restricted idiotype, 
possibly corresponding to the main immunogenic region (MIR) of 
the AChR (Tzartos & Lindstrom>1980). However, Killen et al,
(1985) have demonstrated that the MIR does not generate anti­
bodies of a predominant idiotype.
3.3.4 Autoimmune Nature of MG
The possibility that MG might be an autoimmune disease was 
originally suspected on the basis of indirect evidence, consisting 
of a high incidence of thymic abnormalities in patients (Castleman, 
1966), the association of MG with other diseases of autoimmune 
aetiology (Simpson,1960), and reduced levels of complement 
proteins in some patients (Nastuk et al*1960). Two further 
discoveries also lent weight to this postulate. Firstly, a 
proportion of myasthenic patients were shown to have serum 
antibodies that reacted against skeletal muscle (Strauss et
al»1960), and secondly, the induction of an experimental animal model
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by Lindstrom & Patrick^(1973). The latter workers discovered 
that immunisation of rabbits with purified electric eel AChR, 
caused marked muscular weakness and respiratory difficulty, 
coupled with the production of anti-AChR antibodies. This model, 
termed 'experimental autoimmune myasthenia gravis1 (EAMG), has 
been extensively used to investigate the pathology and immunology 
of MG (for reviews see Harrison & Behan, 1986: Vincent, 1980: 
Fuchs, 1979: Lindstrom, 1979).
The autoimmune origin of MG was finally confirmed by several 
lines of evidence. It was shown that the binding of a-BGT to 
human J/EJ-receptors in frozen sections (Bender et al 1976), and 
of radiolabelled a-BGT to rat EJ-receptors (Almon et alj1974) 
could be blocked by anti-AChR antibodies found in myasthenic sera 
This, coupled with the determination by radioimmunoassay (RIA) 
of these antibodies in some 90?o of MG patients (Lindstrom et al, 
1976a,b, 1977, 1981: Lindstrom^1979) indicated that the anti-AChR 
antibodies were involved in the pathogenesis of MG.
It was further shown that anti-AChR antibodies were observed 
in transient neonatal MG, the titres declining as the patient 
improved (Lindstrom et al,1976b: Keesey et al,1977), showing that 
trans-placental transfer of anti-AChR antibodies were responsible. 
Ultrastructural studies of myasthenic NMJ's also showed the 
presence of IgG, C9 and C3 (Engel et al,1977a,b,c). Lindstrom & 
Lambert (1978) were able to show that receptor numbers were
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reduced at the NMJ in MG patients, and that the AChR’s were 1 
complexed with anti-AChR antibodies. They also demonstrated that 
patients with severe MG had lower numbers of receptors and more 
of them were complexed with anti-AChR antibodies.
These results gave direct evidence that the primary defect 
in MG is the reduction in AChR numbers at the NMJ, and is the 
result of an autoimmune attack involving humoral mechanisms.
3.3.5 Oriqih Of The Autoimmune Response In MG
A major question arises as to how tolerance to self AChR 
breaks down. Much attention has been paid to the thymus, 
especially because of the association between MG and thymic 
abnormalities (Castleman,1966: Thomas et al,1982: Bofill et al*
1985) and the beneficial effects of thymectomy in some patients 
(Simpson,1958: Buckingham et al,1976: Oosterhuis, 1981: Hankins 
et al,1985). Certain thymic cells, known as myoid cells, display 
characteristics of striated muscle, and cross react with anti- 
skeletal muscle antibodies (Van der Geld#1966). Cells cultured 
from the thymuses of rats (Kao & Drachman,1977: Wekerle et al» 
1973), mice (Wekerle et al,1981) and humans (Kao & Drachman,1977) 
appear to be typical of skeletal muscle cells in culture and 
display surface AChR's. Specific mab's have been used to detect 
AChR's on thymic cells from both normal and myasthenic patients
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(Kirchner et al,1987). AChR’s have also been detected in extracts 
of thymuses from a variety of sources (Lindstrom et al,1976c:
i
Ueno et al,1980: Raimond et al,1984), and anti-AChR antibodies 
have been shown to interact with a particular constituent of
thymuses (Aharanov et al,1975). The strategic location.of........
receptor bearing cells, T cells and B cells in the thymus, has 
accordingly led to the suggestion that the thymus is the site 
where the Autoimmune response develops, possibly through 
alteration in the AChR resulting in an interaction leading to a 
breakdown in tolerance.
It has also been suggested that the auto-immunogen may be 
located on lymphocytes. It has long been established that 
lymphocytes bear mAChR (see Harrison & Behan, 1986 for references) 
but it has only recently been suggested that they also bear nAChR 
(Richman & Arnason31979: Richman et al*1981: Menard & Rola- 
Pleszozynski, 1983: Walsh et alj1986).
Stefansson et al (1985) proposed that a viral or bacterial 
infection may result in the autoimmune response through cross- 
reactivity with microbial antigens. However, the spectrum of 
antibodies produced in an MG patient suggests the immunogen to be 
intact receptor, rather than a single cross-reacting determinant 
of microbial origin.
An anti-idiotypic cause has also been suggested especially 
where there is defective immuno-regulation. At least some
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autoimmune diseases develop as a result of an anti-idiotypic 
response towards antibodies produced against a biologically 
active molecule, such as insulin or thyrotropin (Wasserman et al, 
1982: Shechter et alt1982), and it is possible that this may be 
the case in MG (Cleveland et al41983: Erlanger et al51984).
3*3*6 Humoral Immunity In MG
The role of anti-AChR antibodies in the pathogenesis of MG 
has been inferred from indirect evidence (Introduction, section 
3.3.7). However, most of the work with anti-AChR antibodies in 
myasthenic patients, has been as a direct result of the develop­
ment of sensitive assays for their detection.
Almon et al (1974) first demonstrated that serum immuno­
globulin from approximately one third of a group of myasthenic 
patients was capable of blocking ar-BGT binding to rat AChR. This 
was followed by Bender et al (1975) who showed that 68% of 
myasthenic sera inhibited ar-BGT binding to frozen human muscle 
sections. However, it was not until the development of sensitive 
RIA procedures, based on the complexing of ^ 5 i-a-BGT labelled 
AChR by antibody, that it was possible to show that nearly 90% of 
all MG patients had anti-AChR antibodies in their sera (Appel et 
al,1975: Lindstrom et al,1976, 1981a: Mittag et al,1976, 1984: 
Lindstrom et ala1977: Monnier & Fulpuis,1977: Levfert et al,1978:
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Toyka et al,1979: Bartoccioni et al,1980: Walker et 81*1980: 
Cerrato et al,1981: Morel et al,1982). This assay has become 
a standard for the clinical diagnosis of MG (Methods, section 1.6) 
Precise methodical details vary between groups but with little 
effect on results and data obtained (Carter et alf1981). It has- 
been established that human AChR or primate (McAdams & Roses,1980: 
Mickle et al,1983) is most useful, with cross-species AChR giving 
lower titres (Oda et al>1980: Savage-Marengo et al»1979, 1980: 
McAdams & fioses^^SIc: Appel et al^1975: Brenner et al*1978: 
Konishi et al,1981: Kornfeld et al,1981b: Mittag et al,1981a,b, 
1984: Buot et al,1982: Zielinski et al,1982).
Enzyme linked immuno-sorbent assays (ELISA) have been used 
(Norcross et al,1980: Kawanami et al,1984) with varying degrees 
of success, but these, in contrast to RIA usually require purified 
human AChR, which is difficult to obtain (Stephenson et al,1981: 
Momoi & Lennon,1982: Turnbull et al,1985). A modification, 
using crude receptor preparations and based on the adsorption of 
monoclonal antibodies onto a microtitre plate has been described 
(Dwyer et al,1983a). Two further ELISA's have been described in 
which crude human receptor extracts were used (Kobayashi et als 
1984: Jailkhani et al,1986) while Hinman et al (1983) described 
and ELISA in which the plates were coated with ar-BGT and then 
incubated with Torpedo AChR, but unfortunately, this assay 
relied on cross-reactivity. Other assays include an EIA in which
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radiolabelled aBGT is replaced with horseradish peroxidase 
labelled ar-BGT (Furakawa et al>1984), and a haemagglutination 
assay (Muir & Jehanli,1985).
Even though several ELISA’s and EIA's have been described, 
none has been popular for either clinical or experimental use. .
3.3.7 Pathogenic Role of Anti-AChR Antibodies in MG
The concentration of anti-AChR antibodies in MG patients 
varies from 0.6 - 1000 nM, with an average of 50 nM (Lindstrom et 
al,1976d: Ito et alj1978: Levfert et al»1978). Although titres 
do not correlate closely with disease severity (Lindstrom,1979: 
Cerrato et al,1981), it is clear that anti-AChR antibodies are 
important in the pathogenesis of MG.
The lack of correlation may arise from a number of reasons. 
There is good evidence showing that myasthenic anti-AChR anti­
bodies are polyclonal, comprising various immunoglobulin classes 
and subclasses (Vincent & Newsom-Davis,1980: Lefvert*1981), with 
many sera containing ar-BGT binding site antibodies (Vincent & 
Newsom-Davis>1982: Mittag et al*1981: Vernet-der-Garabedian et al,
1986). The standard RIA is unable to detect anti-site antibodies, 
unless modified (Zielinski et al,1982). Sera from different 
donors also vary in their cross-reactivity with AChR preparations
from different species (Lindstrom et ald1978a: Savage-Marengo
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et al,1980: Harrison et al,1981), and to different AChR 
preparations from the same species (Vincent & Newsom-Davis*1979: 
Almon & Appel,1975: Weinberg & Hall,1979).
There is increasing evidence to suggest that a small anti­
body sub-population may be the primary pathogenic_agen.t in MG.
The main immunogenic region (MIR) of the AChR (Tzartos & Lindstom, 
1980) is located on the extracellular side of the a-subunit, and 
is distinct from the ACh/ a-BGT binding site. Myasthenic sera 
can be prevented from binding to the MIR by anti-MIR mab's, 
suggesting that the majority of anti-AChR antibodies in MG are 
directed towards the MIR, although, Tzartos et al,(1982,1983) 
have shown that. £ minority of antibodies of other specificities 
exist. The fact that these antibodies are pathogenic was 
demonstrated by their ability to modulate AChR by cross linking, 
and to fix complement (Tzartos & Lindstrom,1980). Certain anti- 
MIR mab's were shown to be able to transfer acute EAMG (Lindstrom,
1984).
As previously stated, the primary defect in MG is the 
reduction in numbers of AChR's at the NMJ. The exact mechanism 
of how anti-AChR antibodies are involved in this, is not known 
but several suggestions have been made.
A) Direct' Block of AChR
Blocking antibodies have been detected in a large number of 
sera (Mittag et al,1981: Drachman et al,1982,1977: Lennon et al*
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1983: Fulpuis et al,1981). Although in most cases these anti­
bodies account for only a minor fraction of the total antibodies 
found (Tzartos et al,1982: Vincent et al,1983) their effect could 
be significant (Gomez & Richamn,1983).
B) Antigenic Modulation
This is believed to be an important mechanism in receptor 
loss. Cross-linking of the receptors at the post-synaptic 
membrane by anti-AChR antibodies, accelerates AChR internalisation 
and degradation (Reiness et al*1978: Stanley & Drachman*1978: 
Merlie et al,1979: Fumagalli et al, 1982a,h) as receptor cross- 
linking causes changes in the membrane mobility and receptor 
distribution resulting in endocytosis and lysosomal destruction 
of receptors. The increase in the rate of receptor degradation 
is triggered by antibody alone and is dependent upon the ability 
of the antibodies to cross link receptors (Drachman et al*1978: 
Conti-Troconi et al,1981b) ie. upon their divalent nature. (See 
Fig 20).
C) Complment Mediated Lysis
The evidence for this mechanism is largely indirect, and 
results from the localisation of antibodies, C9, and C 3 on the 
post-synaptic membrane of NMJ from myasthenic patients, together 
with the visualisation of membrane fragments in the synaptic 
cleft (Sahashi et al*1978, 1980: Engel et al>1979, 1981b: Engel & 
Fumagalli,1982). Complement mediated lysis has been demonstrated
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on cultured rat myotubes mediated by myasthenic sera (Childs et al3 
1985, 1987: Ashizawa & Appelj1985). Ashizawa & Appel,(1985) 
demonstrated that the ability of myasthenic sera to cause lysis 
was correlated with disease severity.
Neither complement mediated lysis nor accelerated ..internal­
isation and degradation could deplete the numbers of AChR's, if
<
the loss was balanced by replacement. It is therefore believed 
(Engel, 1987) that antigenic modulation and complement mediated 
lysis operate together. In addition, destruction of the 
junctional folds by compl^hent reduces available membrane sites 
left for the insertion of new AChR's, and in turn amplifies the 
subsequent AChR depleting effect of either modulation or 
complement.
Other mechanisms may also be involved, for example, anti- 
idiotypic antibodies have been found in some myasthenic sera 
(Dwyer et alj1983) and their titres have been shown to be 
inversely related to the idiotypic titre.
3.3.8 Cellular Immunity in MG
The production of anti-AChR antibodies is the final stage 
in a complex immune reaction. The demonstration that PBL's and 
thymic cells from myasthenic patients (Lisal et al>1983a,b, 1984: 
Vincent*1979), when cultured in vitro produce anti-AChR anti­
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bodies, and the occurence of other autoimmune diseases in MG 
patients, have led to the idea of a defect in immuno-regulatory 
mechanisms in MG (Drachman et al,1982: Penn,1979: Shore et al, 
1979).
Numerous workers have attempted to gain evidence of 
abnormalities in the cellular immune responses of lymphocytes 
from MG patients. In particular, most work has concentrated on 
comparisons of B cells, T cells, and T cell subsets, in MG 
patients compared with normal individuals (extensively reviewed 
by Lisak et al,1985: Harrison & Behan,1986). However, the results 
so far obtained do not present a clear picture, and are somewhat 
conflicting, but, in general, show an increase in B cell and a 
decrease in T cell populations, in both thymuses and peripheral 
blood of MG patients.
It is conceivable that the proliferation of B cells, could 
result from either a decrease in the number of suppressor T cells 
and/or a defect in suppressor T cell function, or an increase in 
the numbers and/or function of autologous helper T cells.
Indirect evidence supporting changes in regulatory T cells, comes 
from the fact that susceptibility to MG appears to be MHC linked 
(Introduction, section 3.3.2, Oosterhuis et al,1981: Harrison & 
Behan,1986), and that PBL's from MG patients undergo proliferation 
when incubated with purified AChR from electric eel (Abramsky et 
al,1975: Richman et al,1976, 1979), Torpedo electric organ
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(Conti-Troconi,1977, 1979, 1982: Hohlfeld et al,1984) and human 
AChR peptides (Harcourt et al,1987: Hohlfeld et al,1987), 
supporting the concept that AChR specific T cells are important 
in the aetiology and regulation of MG. This has been further 
supported by Greenberg et al,(1984)j and Richards et al,(1986), both 
of whom investigated the proliferative responses of purified T 
cells from MG patients, when co-cultured with autologous non-T 
cells, in a reaction known as the Autologous Mixed Lymphocyte 
Reaction (AMLR). Greenberg found an increased AMLR which was 
abolished by thymectomy, whereas, Richardsdiscovered a decreased 
AMLR in MG patients. Even though the two results are different, 
they do indicate a defect in immune cell function in MG. In 
general, stimulation of lymphocytes in response to a specific 
antigen, indicates that the cells have previously been sensitised 
to that antigen. Suppressor T cell numbers have been shown to be 
decreased in various other autoimmune diseases (Berrih et al,1981 
Raeman et al,198l).
There is also increasing evidence of a T cell immuno­
dominant recognition site on the AChR, which appears to be on the 
ar-subunit but is distinct from the MIR and ACh/ ar-BGT binding 
site (Hohlfeld et al,1987). Recent studies have shown that there 
is no single immunodominant T-cell epitope on the AChR alpha— 
subunit, but that there are a number of distinct antigenic 
'hotspots' on which the T-cell response is focused. These
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'hotspots' being distinct from the anti-AChR antibody binding 
site (Hohlfeldf1989: Hohlfeld et al,1988: Zang et al>1988: Fujii 
et al,1988: Yokoi et al,1987: Melms et al,1989: Harcourt et al,
1988). However, the exact role of cellular mechanisms in the 
pathogenesis of MG is as yet unclear. . .....
3.3.9 Monoclonal Antibodies and MG
The development of murine monoclonal antibody technology 
(Kohler & Milstein,1975, 1976: Introduction section 4) has vastly 
increased the structural and functional knowledge of the nAChR. 
Thus:
1) Investigation of the structural homologies between 
subunits indicate that they were probably derived from a 
common ancestral gene (Tzartos & Lindstrom,1980: Tzartos et 
al,1981: Fracher et al,1983: Gullick & Lindstrom et alf1985,
1983). This has been confirmed through amino acid sequence 
and DNA sequence analysis (Raftery et al,1980: Noda et 
al,1983).
2) Structural homologies have been shown between receptors 
from different species (Tzartos & Lindstrom,1980: Tzartos 
et al,1981, 1983: Gomez et al,1981: Mochly-Rosen & Fuchs, 
1981: Lindstrom et al,1980).
3) The transmitter binding site and conformational changes
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in the receptor during activation and desensitisation have 
been analysed (Gomez et al,1979: James et al,1980: Mochly- 
Rosen & Fuchs,1981: Lindstrom et al,1981).
4) The role of glycosylation in the AChR subunit assembly 
has been studied suggesting that it is important for 
receptor assembly (Merlie et al,1982).
5) Affinity purification of AChR’s has been effected from 
a variety of sources (Momoi & Lennon*1982, 1984: Lennon et 
al,1980).
6) The antigenic specificities of myasthenic antibodies 
have been studied and show that the majority of them are 
directed towards the MIR on the ar-subunit (Tzartos & 
Lindstrom,1980: Tzartos et al>1981, 1982, 1983). Mab's 
have also been used to map antigenic determinants on 
receptors, as model auto-antibodies and as probes for 
determining the specificities of auto-antibodies in MG 
patients (Lindstrom,1985).
7) Mab's have been used to passively transfer EAMG into 
rats, mice and guinea pigs, with subsequent development of 
myasthenic like characteristics (Tzartos & Lindstrom,1980: 
Lennon & Lambert,1981: Gomez et al*1981: Gomez & Richman> 
1983: Merlie et alj1982: Dwyer et al,1981) with antigenic 
modulation being detected in some cases (Conti-Tronconi et 
al,1981: Tzartos & Stazinski-Powitz,1986). Antigenic
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modulation by myasthenic sera could be blocked by the use 
of monoclonal anti-AChR Fab fragments (Tzartos et al,1985).
8) The topography and transmembrane nature of the AChR has 
also been studied by using specific mab's (Froehner et al, 
1983: Lindstrom et al31984, 1985, 1986: Sargent et al,1984: 
Young et al^1985: Ratnam et al^1986a,b).
Murine mabs have clearly been widely used to investigate 
AChR's and MG/EAMG. There are, however, several areas where it 
would be advantageous to develop human mabs. Firstly, they may 
allow the development of high specificity antibodies, which could 
be used to map antigenic determinants on the human AChR which 
are active during the disease state, and delineate the 
specificities of pathogenic antibodies in MG and EAMG. Secondly, 
they may allow the development of human gammaglobulin therapy for 
MG, either through the administration of large doses of 
neutralising anti-idiotypic antibodies, manipulation of the 
idiotype network or possibly by targeting and elimination of self- 
reactive autologous lymphocytes active in the disease state. 
Thirdly, human mabs may prove useful in the identification of 
the immune mechanisms responsible for the development of MG.
At present there have been only two reports of human 
monoclonal anti-AChR antibodies having been produced from 
patients suffering from MG. Kawo et al,(1982) described the
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production of such antibodies through EBV transformation of PBL's 
(Introduction section 4.2.3 (2)), and Blair et al,(1985) briefly 
described the production of monoclonal anti-AChR antibodies 
through a human x human fusion technique (Introduction, section 
4.2.3 (i)A)). .......
4. MONOCLONAL ANTIBODIES
4.1 Murine Monoclonal Antibodies
In 1984 G. Kohler & C. Milstein were awarded the Nobel Prize 
for Physiology & Medicine for their work in the field of somatic 
cell hybridization which allowed the production of monoclonal 
antibodies of predetermined specificity.
The technique described by Kohler & Milstein (1973, 1976: 
fig. 21), revolutionised the study of the immune system and 
protein chemistry.
Antibody producing rodent hybridomas are prepared iri vitro 
by the fusion of antibody producing B cells with rodent myeloma 
cell lines. In the original technique Sendai virus was used to 
fuse the cells (Kohler & Milstein ,1975: 1976) but has largely been 
replaced by Polyethylene glycol (PEG). A further technique 
involving electrofusion of cells (Zimmerman and Vienken ,1982: 
Biscoff et al>1982) is also used, and is claimed to be 100,000 
times more effective than PEG fusing small numbers of cells
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MOPC-21 myeloma IgG1 2.5
MPC-11 myeloma IgG2b 2.5
P3/X63-Ag8 myeloma IgG1 1.3
P3/NS1/1-Ag4-1 
(NS-1)
myeloma kappa light 
chains
1.4
X63-Ag 8.653 myeloma none 6




FOX-NY myeloma none 9
Rat






References: 1) ATCC (1985)
2) Cotton & Milstein (1973)
3) Kohler & Milstein (1975)
4) Kohler & Milstein (1976)
5) Melchers et al (1978)
6) Kearney et al (1979)
7) Galfre & Milstein (1981)
8) Shulman et al (1978)
9) Taggart & Samloff (1982)
10) Galfre et al (1979)
11) Lane (1985)
12) Kilmartin et al (1982)
TABLE 3: Available Rodent Fusion Partners
(adapted from Galfre & Milstein (1981): Kozbor & Roder (1983): 
and Samoilovich et al (1987))
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(Dorfmann ,1985). The hybridomas inherit some characteristics of 
both parental cells, and lose others eg. they inherit immortality 
from the myeloma cells and the ability to form antibody from the 
B cells. Monospecific antibodies of monoclonal origin are 
maintained by clonal selection of the specific antibody producing 
clones (see Fig. 21).
The success of this technique since its introduction has 
been in the main due to the development of a number of very good 
rodent fusion partners of murine and rat myeloma origin, which do 
not secrete antibody, undergo fusion readily, and allow the 
selection of antibody producing hybridomas. Of these the 
preferred choice is often the murine cell line X63-Ag 8.633 
(Kearney et al51979).
Table 3 gives a summary of the most common murine and rat 
fusion partners.
4.2 Human Monoclonal Antibodies
Even though rodent mabs are of great use, both to the 
scientist and clinician, there are a number of problems associated 
with their use, which makes the construction of human mabs 
advantageous.
In particular it could be possible to produce abs for: 
targetting of drugs to specific cells eg. malignant cells,
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pathogens, and lymphocytes which are responsible for autoimmune 
disease or allergic reactions (Blair & Ghose,1983: Levey & Miller, 
1983); diagnostic uses in the imageing and localisation of 
damaged tissues, malignant cells etc (Emanuel et al41986: Rosen .... 
et al,1983: Glassey et al *1983':" Cole et al>1984: Olsson et al * 
1984: Haspel et 81,19858,6: Matsushita et al,1985: Andreason et 
al,1986: Kan-Mitchell et al,1986: Smith et al,1987: Strelkaushas, 
1987a: Sikora,1983: Sikora et al,1987: Glassey et al,1985:
Burnett et al,1987); immunisation procedures, both passive (e.g 
to prevent heamolytic disease of the newborn, to neutralise 
toxins, drugs and opsonise bacteria and viruses) and active (e.g 
immunisation with anti-idiotypic mabs to stimulate abs against 
pathogens for which there are currently no vaccines) (Atlaw et 
al,1985: Matsushita et al,1986: Schmidt-Ullrich et al,1986:
Hunter et al*1982: Emmanuel et al*1984: Crawford et al*1983: Bron 
et al,1984); they can also be used in the therapy of autoimmune 
diseases (Groce et al%1980: Sasaki et al,1984: Chiorazzi,1986), 
and for tissue typing (Steinitz et al,1977: Hulette et al,1985: 
Effros et al,1986). In addition to these uses they can also be 
used to investigate the immune system in both health and disease 
e.g characterisation of antigens (Smith & Teng*1987: Satoh et al, 
1983: Bron et al,1984: Carroll et al,1986) and B cell activity 
(Glassey et al,1983: Winger et al,1983: Cote et al,1985, 1986: 
Watson et al,1983). Human mabs are particularly useful in
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immunisations and gamma globulin therapy, where the use of 
xenogenic abs or sera results in the sensitization of the patient, 
anaphylatic shock, or serum sickness. Almost half of all patients 
treated with murine mabs developed a response to them, preventing . 
effective therapy (Miller et al,1982: Dillman et al,1982: Sears 
et al,1982). Naturally, administration of human mabs would 
circumvent this problem, even though it may result in the 
development of an anti-idiotypic response. Such a response could 
be the basis of therapy in auto-immune diseases, where the anti­
idiotype could neutralise the effect of auto-antibodies.
4.2.1 Human Monoclonal Antibodies - Production Strategies
The generation of human mabs has been hindered to some 
degree by the absence of an appropriate human fusion partner 
which grows well, produces stable hybrids, does not secrete 
antibodies of its own, and yet secretes high levels of antibody 
when fused to an immune lymphocyte (Samoilovich et al,1987). 
Obtaining sufficient numbers of immune human lymphocytes for 
fusion is also a problem (James & Bell*1987). It is also 
believed that lack of knowledge of the ideal state of cell 
differentiation for successful fusion has also contributed to the 
slow progress in human mab technology (Schwaber et al,1984).
Nevertheless, human mabs to a wide range of antigens have
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been produced (see Fig. 22 for summary of production techniques). 
The practical techniques can be subdivided into 3 areas, each of 
which will be considered separately. Before this the-source of 
lymphocytes for fusion will be considered.. . ......
4.2.2 Lymphocyte Sources
The successful development of murine mabs has not been 
limited by the availability of immune lymphocytes, for provided 
that the antigen is available in sufficient amounts, is non­
toxic and immunogenic, then appropriate immunisation procedures 
can be used to ensure sufficient immune cells for fusion. This, 
however, is not the case with human mab production, where the 
range of immunogens which can be injected is limited by ethical 
and other considerations. Furthermore, the source of immune 
lymphocytes is usually restricted to peripheral blood (PBL’s) 
which is not an ideal choice. James & Bell (1987) compared the 
results of numerous workers who produced human mabs to a variety 
of antigens utilizing immune lymphocytes from different sources. 
They were able to show that lymphocytes derived from spleens and 
tonsils provided better results than PBL’s. However, spleens and 
tonsils, are not in general, readily available from immune
t
subjects.
The poor performance of PBL's has been attributed to various
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reasons, including, insufficient B cells (Cote & Houghton,1985:
Ho et al,1986); insufficient memory cells or antigen specific B 
cells (Seigneurin et al,1983: Olsson et al,1983:.Ho et al,1986); 
transient appearance of antigen specific B cells in blood 
following immunisation (Burnett et al,1985); inappropriate state 
of B cell differentiation (Schwaber et al*1984); low mitotic 
activity of B cells (Burnett et al,1985); lack of la positive 
macrophages (Teng et al,1985); excess of cytotoxic T cells (Cote 
& Houghton*1985); presence of suppressor T cells (Cote & Houghton, 
1985).
Several techniques have been used to increase the number of 
specific B cell clones either in or derived from peripheral blood. 
Where ethics allow, in vivo immunisation is used. Peripheral 
blood is collected from donors who have been immunised following 
approved schedules or as a result of disease processes or 
accidental exposure to immunogens. While most described mabs are 
directed against viruses or bacteria or autoantigens in patients, 
others have been deliberately induced (see Table 4). Numbers of 
specific B cells may also be increased by in vitro immunisation 
(see Table 5).
In addition to these approaches, various lymphocyte 
manipulations have been used to increase the numbers of B cells 
and deplete the numbers of suppressor/cytotoxic T cells in order 
to provide a more favourable ratio of B cells to helper T cells
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Table 4 : Human Monoclonal Antibodies Produced By In Vivo 
Immunisation Procedures 








exposure Influenza virus Hunter et al (1982) 
Crawford & Callard (1983)
PPC Yoshie et al (1980)
P. aeruginosa Siadek & Lostrom (1983)
Tuberculin Garzelli et al (1986)
Chlamydia Rosen et al (1983)
Cytomegalovirus Emanuel et al (1984) 
Redmund et al (1986)
EBV. Rabies & 
Rubella
Koizumi et al (1986)
Hepatitis A Van Meel et al (1985)
Hepatitis B Strieker et al (1985)
HTLV-1 Matsushita et al (1986)
P. falciparum Schmidt-Ullrich (1986) 
Udomasangpetch et al (1986)
Blood group A Raubitschek et al (1985)
Rhesus D Bron et al (1984)
Rhesus G Foung et al (1986)
HDNPA Steinitz et al (1977/79)
Active Diptheria Gigliotti et al (1984)
immunisation toxoid
Gram neg. Bogard et al (1985)
endotoxin Teng et al (1985a)
Influenza virus Gigliotti et al (1984)
Pneumococcal
polysaccharide









Tetanus toxoid Zurawski et al (1978) 
Kozbor & Roder (1981) 
Chiorozzi et al (1982) 
Gigliotti & Insel (1982) 
Larrick et al (1983) 
Gigliotti et al (1984) 
Boyd et al (1984b) 
Tiebout et al (1984/85) 
Burnett et al (1985)
Hepatitis B Burnett et al (1985)
Colorectal
cancer
Haspel et al (1985a,b)
Rhesus D Boylston et al (1980) 
Crawford et al (1983) 
Doyle et al (1985) 
Paire et al (1986) 
Thompson et al (1986)
HLA Hulette et al (1985) 
Effros et al (1986)
DNCB Ollson & Kaplan (1980)
KLH Lane et al (1982)
Active
disease
M. leprae Atlaw et al (1985)
EBV Koizumi et al (1986)
Rubella Croce et al (1980)
Bladder tumour Paulie et al (1984)
Brain glioma Sikora et al (1982/83)
Breast tumour Wunderlich et al (1981) 
Cote et al (1983/84/85/86) 
Campbell et al (1986) 
Strelkauskas et al (1987a)
Colorectal
cancer
Hirohashi et al (1982b) 












Hirohashi et al (1982b)
Hirohashi et al (1982a) 
Cote et al (1983/84/85/86) 
Murakami et al (1985)
Lymphoid system 
tumours
Abrams et al (1984) 
Andreason & Olsson (1986) 
Carroll et al (1986)
Melanoma Trie et al (1982)
Warenius et al (1983) 
Watson et al (1983) 
Kan-Mitchell et al (1986)
Renal cancer Cote et al (1983/84/85/86)
Autoantigeris
Astrocytes Simpson et al (1986)
Cytoskeletal Cote et al (1986)
ss/ds DNA Shoenfield et al (1982) 
Massicotte et al (1984) 
Sasaki et al (1984)
Erythrocytes
Platelets
Shoenfield et al (1982)
Golgi Cote et al (1986)
Islet cells Eisenbarth et al (1982)
Neurofibrillary
plaques/tangles
Simpson et al (1986)
Nucleus & 
Nucleolus
Simpson et al (1986) 
Cote et al (1986) 
Someya et al (1986)
Sperm Kyurchiev et al (1986)
Table 4 (cont)
Immunization Antigens Refs







Simpson et al (1986)
Cytoskeletal
Golgi
Cote et al (1983/86)
ss/ds DNA 
Erythrocytes
Winger et al (1983)
Multiple organs Garzelli et al (1986)
Nucleus & 
Nucleolus
Simpson et al (1986) 
















- Human T cell Lymphotrophic Virus 1
- Plasmodium falciparum
- 4-hydroxy-3,5-dinitro-phenacetic acid
- Human Leucocyte Antigens
- 2,4-dinitrochlorobenzene
- Keyhold Limpet Haemocyanin
- Mycobacterium leprae
- single and double stranded DNA
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Table 5 : Human Monoclonal Antibodies Produced By In Vitro 
Immunization Procedures
(adapted from James & Bell 1987)
Immunogen Antigen Refs
Bacterial Tetanus toxoid Kozbor & Roder (1984) - 
Ho et al (1985/87) 
Ichimori et al (1985)
H.influenzae 
N.meningitides
Brodeur et al (1987)
Streptococcus Wasserman et al (1986)
Viral Influenza Crawford & Callard (1983)
Rubella Ritts et al (1983) 
Hilfenhaus et al (1986)
Hepatitis B Ichimori et al (1985)
Herpes simplex Masuho et al (1986)
Cytomegalovirus Matsumoto et al (1986)
Erythrocytes Sheep Strike et al (1984)
Blood group A Larrick et al (1985)
Forssman antigen Nowinski et al (1980)
Rhesus D Astaldi et al (1982)
Other DNP Teng et al (1985b)
DNP,KLH & sperm 
whale myoglobin
Bieber et al (1987)
PAP Vamaura et al (1985)
Bombesin Ho et al (1985/87)
klh Wasserman et al (1986)
Abbreviations:
H.influenzae - Haemophilus influenzae
N.meningitides - Neisseria meningtides
DNP - Dinitrophenol
KLH - Keyhold Limpet Haemocyanin
PAP - Prostatic Acid Phosphatase
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for fusion. These include, SRBC rosetting (Teng et al*1985a); 
separation on nylon wool (Gazzelli et al,1984: Ho et al,1985: 
Yamoura et alf 1.985) or Sephadex G-10 columns (Hoffman Heist, 
1985a,b) specific lysis with anti-suppressor T cells mabs (Lagrace 
et al/1985: Brodeur et al*1987); reconstitution of non-adherent - 
and adherent cells (Ho et al#1985) and polyclonal activation of 
lymphocytes with PWM, PHA, LPS, Staphylocus aureas Cowan I (B 
cell stimulant) or cyclosporin A.
4.2.3 Immortalisation Procedures
1) Fusions
In general, antibody producing B cells are fused, using PEG, 
to an immortal cell line which is sensitive to a selecting agent 
[usually hypoxanthine-aminopterin-thymidine (HAT)], and which is 
capable of supporting antibody secretion in culture.
The mechanism by which PEG brings about fusion is not fully 
understood, but it appears that close contact between the cells 
being fused is necessary (Knutton & Pasternak,1979). PEG appears 
to promote the close apposition of cell membranes while additives 
actually stimulate the fusion process (Wocjcieszym et alf1983).
The use of DMSO has also been shown to modify the cell membranes 
and enhance fusion (Fazekas de StGroth & Scheidegger ,1980).
All fusion protocols used can be further subdivided
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depending on the nature of the immortal cell line used.
A) Human x Murine Fusions
Production of heterohybridomas by fusion was the first 
technique used in attempts to produce human mabs (Schwaber 
& Cohen,1973: Levy & Dilley,1978) and was the direct result 
of applying murine hybridoma technology to human cells. To 
date this method has been used with considerable success, 
with mabs being produced to a wide variety of antigens (see 
Table 6).
The advantage of this system is the wide availability of 
non-secreting rodent cell lines, which grow well and 
support antibody production (see Table 3) eg. X63 (Kearney 
et 31,1979). Unfortunately the main disadvantage of the 
system is the inherent genetic instability of interspecies 
hybrids, with preferential loss of human chromosomes, in 
particular chromosome 2, which carries the kappa light 
chain locus. Surprisingly, chromosomes 14 and 22 appear to 
be retained, coding for the human heavy chain locus and the 
lambda light chain locus respectively (Croce et al,1980: 
Koskimies et al,1979). However, Thompson et al,(1986) were 
able to show that genetic instability was no worse than 
with murine hybrids, and could be minimised by early 
cloning.
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Table 6: Human Monoclonal Antibodies Produced By Fusion
Of Lymphocytes To A Murine Cell Line 
(adapted from James & Bell 1987)
Antigen Cell Line Refs
Tetanus toxoid X63 x PBL Giolotti et al (1982)
«« it NS-1 x SP/TON Ho et al (1985)
ii ii NS-1 x PBL Tiebout et al (1985)
ii it SP1 x PBL Butler et al (1983)
i i  ii Kozbor et al (1982)
Bombesin NS-1 x SP/TON Ho et al (1985)
Forssman ag NS-1 x SP Nowinski et al (1980=
Influenza virus X63 x PBL Gigliotti et al (1984)
Keyhold limpet 
haemocyanin





Sawada et al (1985)
Hepatitis B 
surface ag
NS-1 x PBL Tiebout et al (1985)
II ff P3/HT x PBL Burnett et al (1985)
Cytomegalovirus P3/X63-AgU1 x 
SP





Masuho et al (1986)
Phesus D ag SP2/0 x PBL Astaldi et al (1982)
DNA X63 x PBL Thompson (1986) Ph.D 
Thesis




NS-1 x PBL Haspel et al 1983a,b)
Mammary
carcinoma
NS-1 x All poss Wunderlich et al (T981) 
Cote et al (1983;1984; 
1985;1986)
Schlom et aL (1980)
Lung adeno­
carcinoma
X63 x LN Hirohashi et al (1986)
Lymphocytic
leukaemia
NS-1 x PBL Abrams et al (1984)
Melanoma NS-1 x LN Kan-Mitchell et al (1987)
Sperm coating X63 x PBL Kyurkchiev et al (1986)
Abbreviations:
PBL - peripheral blood lymphocytes
SP - splenic lymphocytes
TON - tonsular lymphocytes




B) Human x Human Fusions
The first report came from Ollson & Kaplan (1980) who 
obtained an anti-2,4-dinitrophenyl mab by fusing splenic 
lymphocytes with a human myeloma cell line. This report 
was followed by that of Croce et al*(1980a) who fused 
PBL's with a human myeloma, to give hybridomas which 
secreted anti-measles virus mabs. But, since 1980, progress 
has been slow, largely because of the lack of any really 
satisfactory human cell line. Many laboratories have 
developed their own, but, as yet, none has become routinely 
used. Table 7 lists some of the human cell lines currently 
available. Of these lines, very few are myelomas and the 
rest are human lymphoblastoid cell lines (LCL), derived 
from EBV transformation of human lymphocytes. LCL’s are 
easier to handle in culture than myelomas, but, like 
myelomas, have low fusion frequencies, support only low mab 
secretion, and secrete antibody themselves.
No completely satisfactory line is currently available, but 
a number of useful human mabs have nevertheless been 
produced by this technique (see Table 8).
C) Human x Human Heterohybridoma Fusions
In order to improve the fusion rates and growth character­
istics of the existing LCL's, several groups fused them
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Table 7 : Human Cell Lines Available For Fusion 
(adapted from James & Bell 1987; Samoilovich et al 1987)
Cell Line Cell Type Ig Secreted Refs
SK0-007 myeloma IgE- ' Olsson & Kaplan (1980 )-
RPMI 8226 myeloma lambda light 
chains
Abrams et al_(1983)
HFB 1 myeloma none Hunter et al (1982)..
KMMI myeloma IgG Togawa et al (1982)
RH-L4 lymphoma none Olsson et al (1983)
NAT-30 lymphoma N/K Murakami et al (1985)
GM 1500- 
6TG-AL
LCL IgG2 Croce et al (1980)
GM 1500- 
6TG-0A
LCL N/K Hulette et al (1985)
KR4 LCL IgG2 Kozbor et al (1982)
GM 467 LCL IgG2 Sato et al (1972)
GM 4672 LCL IgG Croce et al (1980)
ARH-yy LCL IgG Burk et al (1978)
LICR-LON-
Hmy2
LCL IgG1 Edwards et al (1982)
W1-L2 LCL N/K Emanuel et'al (1984)
H35-1-1 LCL IgM Chiorazzi et al (1982)
W1-L2-729
HF2
LCL IgM Strike et al (1984)
W1-L2-727 LCL IgG Emanuel et al (1984)
UC 729-6 LCL IgM Glassy et al (1983)
MC/CAR LCL none Ritts et al (1983)
MC/MNS-2 LCL IgG1 Ritts et al (1983)
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Table 7 : (cont)
LTR 288 LCL IgM Larrick et al (1983)
LSM 2-7 LCL N/K Schwaber et al (1984)
HS Sultan LCL none Lazarus et al (1982)
GK-5 LCL kappa light 
chains
Satoh et al (1983)
HO-323 LCL N/K Ohashi et al (1986)
KR-12 h/h hybrid 
myeloma
IgG2 Kozbor et al (1984)
3 HL m/h/h hybrid 
myeloma
IgM Teng et al (1985a)
HuNS1 LCL - Blair et al (1985)
Abbreviations:
LCL - Lymphoblastoid Cell Ine




Table 8 : Human Monoclonal Antibodies Produced By Fusion 
With A Human Fusion Partner 




H.FB-1 SP Influenza Hunter et al (1982)
virus . • ; .
LSM2-7 PBL & SP Pneumococcal
polysaccharide









Rauch et al (1986)
PBL & SP ds/ss DNA
Platelets,
Erythrocytes






All Breast tumour Cote et al (1986)
ITL Glioma Sikora et al (1982; 
1983)
SP & TON Streptococcus
KLH
Wasserman et al 
(1986)
HF-2 SP & TON Streptococcus
KLH
Wasserman et al 
(1986)
PBL & TON Sheep
Erythrocytes
Strike et al (1984)
UC729-6 All Breast tumour Cote et al (1984)
LN,SP & PBL Misc tumours Glassy et al (1985)
SK0-007 All Breast tumour Cote et al (1985)
PBL Blood group B Brodin et al (1983)
RH-L4 PBL Leukaemia Olsson et al (1984)
FU266 SP DNCB Olsson et al (1980)
GM1500 PBL Measles virus Croce et al (1980)
KR4 PBL TT Kozbor & roder (1984)
HuNS1 PBL AChR Blair et al (1985)
Abbreviations:
TON - tonsular lymphocytes
PBL - peripheral blood lymphocytes
SP - splenic lymphocytes
LN - lymph node lymphocytes
TT - Tetanus toxoid
ds/ss DNA - double stranded & single stranded DNA 
KLH - Keyhold limpet haemocyanin 
DNCB- Dinitro-chlorobenzene 
ITL - Intra-tumoural lymphocytes
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Table 9 : Human/Murine Heteromyelomas Available For Fusion 
(adapted from James & Bell 1987)
Cell Line Parental Cell Lines Refs
Murine Human
PSV2.Neo X63 FU266 Teng et al (1983)
SHM-D33 X63 FU266 Bron et al (1984) 
Yamaura et al (1983) 
Carroll et al (1986) 
Teng et al (1985b)
HM/5 X63 Hmy2 Ichimori et al (1985)
OrgM HH1 X63 normal 
B cell
Van Meel et al (1985)
SBC/H20 SP2/0 FU266 Carroll et al (1986) 
Foung et al (1985)
SP2/SP SP2/0 Spleen
cells
Brodeur et al (1987)
SP2/HPT SP2/0 normal 
PBL & TON
Brodeur et al (1987)
K6H6/B5 NS-1 B cell 
lymphoma
Carroll et al (1986)
K6H9/G12 NS-1 B cell 
lymphoma
Carroll et al (1986)
Abbreviations:
PBL - peripheral blood lymphocytes 
TON - tonsular lymphocytes
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Table 10 : Human Monoclonal Antibodies Produced Using 
Heteromyeloma Fusion Partners 









SHM-D33 PBL RhD Bron et al (1984)
SP PAP Yamaura et al (1985)
LN Lymphoma Carroll et al (1986)
SP J5 endotoxin Teng et al (1985b)
HM-5 PBL Hepatitis B 
surface ag, 
TT
Tchimori et al (1985)




Van Meel et al (1985)
SBC/H20 LN Lymphoma Carrol et al (1986)
PBL & SP Varicella 
zoster, 
blood group 
A, EBV, early 
ag, M.leprae
Foung et al (1985b)
SP2/SP TON Influenza
virus
Brodeur et al (1987)
K6H6/B3 LN Lymphoma Carrol et al (1986)













- peripheral blood lymphocytes
- tonsular lymphocytes
- lymph node lymphocytes
- splenic lymphocytes
- Mycobacterium leprae
- Epstein Barr Virus
- Tetanus Toxoid
- Prostatic acid phosphatase
- double stranded & single stranded 
Deoxyribonucleic acid
- 2,4-dinitrophenol
- ribosomal Ribonucleic acid
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with a murine myeloma (or occasionally a human myeloma) 
thereby obtaining a heteromyeloma which could then be used 
as a fusion partner. It has been claimed that these 
heteromyelomas perform better than their original parent 
cell lines in fusion experiments, as they tend to be a 
compromise between the two systems. Several useful cell 
lines (see Table 9) and human mabs (see Table 10) have been 
produced by this approach (Teng et al,1983, 1985a: Foung et 
al,1985a: Kozbor et al,1984).
2) Transformation
Viral cell transformation is potentially an extremely 
valuable aid to the production of human mabs, but, at the present 
time, it is limited to the use of viruses known to transform B 
cells, in particular the Epstein-Barr Virus (EBV) which,is the 
most commonly used, and preferentially infects human B cells 
(Johdal & Klein,1973). Table 11 lists some of the human mabs 
produced by this technique.
EBV is obtained by culturing a marmoset cell line B95-8, 
which secretes live virus into the surrounding culture medium 
(Miller & Lipman,1973). The virus transforms B cells by binding 
to their C3D(CR2) complement receptor (Frade et al,1985).
However, only a small proportion of the infected cells become 
transformed, and there is some debate as to the identity
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Table 11 : Human Monoclonal A ntibodies Produced By EBV C e ll
T ransformation 




































SP & PBL 
SP





Zurawski et al (1978) 
Tiebout et al (1984) 
Boyd et al (1984a,b) 
Kozbor et al (1981)
Voshie & Ono (1980)
Rosen et al (1983)
Evans et al (1984) 
Seigneurin et al (1983)
Furuya et al (1982)
Crawford & Callard (1983)
Emanuel et al (1984) 
Redmond et al (1986)
Koizumi et al (1986)
Udomsangpetch et a'l (1986)
Boylston et al (1980) 
Crawford et al (1983)
Doyle et al (1983)
Melamed et al (1985)
Paire et al (1986) 
Koskimies et al (1979) 
Goossens et al (1987)
Raubitschek et al (1985) 
Steinitz et al (1979) 
Goossens et al (1987)
Watson et al (1983)
Paulie et al (1985)
Hirobashi et al (1982a) 
Hirobashi et al (1982b)
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DNA PBL Sasaki et al (1984) 
Sasaki et al (1983)
DNA, Sperm, 
Erythrocytes
PBL Winger et al (1983)




PBL Simpson et al (1986)
NNP PBL Steinitz et al (1979)
Rheumatoid PBL Steinitz et al (1982)
factor 5teinitz et al (T980)
Human IgG/M/A PBL Brown et al (1982)
Steinitz et al (1980)
Trinitrophenol PBL Kozbor et al (1979)
T cell leukaemia LN Matsushita et al (1986)
AChR TH Kamo et al (1982)
Abbreviations:
PBL - peripheral blood lymphocytes 
TON - tonsular lymphocytes 
SP - splenic lymphocytes 
LN - lymph node lymphocytes 
BM - bone marrow cells
NNP - 4-hydroxy-3,5-dinitrophenacetic acid
ITL - intra tumoural lymphocytes
EBV - Epstein Barr virus
RhD - Rhesus D antigen
TH - Thymic lymphocytes
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of this specific population of B cells (Aman et al,1985: Chan et 
al*1986).
The advantage of this system is the ability to immortalise , 
a large proportion of B cells. However, in a mixed lymphocyte 
population, as found with PBL ’ s , the presence of viral coat 
proteins on the cell surface of infected B cells does result in 
the sensitization of T cells with subsequent formation ofcytotoxic 
T cells, which will kill the infected B cells (Tsoukas et al,1981). 
It is therefore necessary either to preselect the B cells by 
removal of the T cells prior to transformation, or to incorporate 
PHA or cyclosporine A into the system, which polyclonally 
activates all the T cells before they become sensitized (Bird 
et al,1981).
Apart from the above disadvantage, there are others, not 
least of which is the handling of EBV. This virus is a herpes 
type virus, first isolated by Epstein et al,(1964), and is known 
to be involved in the development of Burkitts Lymphoma.inparts of 
Africa, and nasopharyngeal carcinoma in Southern China (Keiff et 
al*1984). In the majority of populations of both developed and 
underdeveloped countries, it is usually found as a subclinical 
infection known as infectious mononucleosis (glandular fever)
(Henle & Henle,1966, 1969). As can be seen, precautions must be 
taken when handling the virus.
Coupled with these problems are those associated with the
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transformed cell lines themselves. It is not uncommon for the 
cell lines to grow well for 1-2 months, before antibody titre 
suddenly declines. This titre, even before decline, tends to be 
only a fraction of that seen when using hybridomas (Boylston et 
al,1980: Melamed et al»1985). Although early cloning has, in 
some cases, rescued antibody secretion, many cell lines have been 
lost because of the extremely poor cloning efficiency of LCL's 
(Zurawski et al,1978: Kozbor & Roder,1981, 1983).
3) Transformation Followed By Back Fusion 
(EBV/Hybridoma Technique)
This technique combines those of fusion and transformation. 
In essence it involves the EBV transformation of B cells from a 
donor, followed by either vigorous cloning to obtain a LCL which 
is then fused to a fusion partner, or direct fusion of the 
transformed B cells following a period of growth and partial 
cloning (this has the effect of expanding the B cell population 
to provide sufficient numbers of cells for fusion).
Kozbor et al,(1982) first successfully combined the two 
techniques. It has been reported that transformation prior to 
fusion actually increases the fusion frequencies (Kozbor & 
Roder,1984). This has been explained by Burnett et al,(1985), 
who reasoned that EBV transformation activates B cells, allowing
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them to fuse more efficiently.
The hybrids produced by this method have the same 
instability problems as any other hybrid, but this can be over­
come by early cloning. It has. also been shown to increase 
antibody production over the original LCL, and in some cases, 
actually rescue antibody production (Kozbor et alj1982: Foung et 
al,1984: Levy & Dilley,1978).
Disadvantages of this system include the requirement to 
carry out two immortalization steps, with an increased risk of 
contaminantion and infection. Secondly, as the procedure involves 
the fusion of two immortal cell lines, then a second selection 
step is required to select non-fused LCL's, so ouabain is 
usually incorporated to kill non-fused LCL’s.
As the original fusion technique was subdivided according 
to the nature of the fusion partner (Introduction, section 4.2.3. 
(i)), then so can the EBV/hybridoma method.
A) LCL x Murine Fusions
This was the obvious choice, due to the ready availability 
and ease of handling of non-secretor murine myeloma cell lines 
(see Table 3). However, as with the human/murine fusions, inter- 
species hybrids are inherently unstable (Introduction, section 
4.2.3.(i)A), even though some groups state they can be stabilised 
through early cloning, and are easier and safer to handle than 
human/human fusions (Cote et al,1983: Thompson et al,1986).
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A further advantage of this system, is the natural resistance of 
murine cells to ouabain, 10,000 times more resistant than human 
cells. As a consequence of this, the double selection procedure 
is very effective, (see Table 12 which lists some of the mabs 
raised by this technique).
B) LCL x Human Fusions
Due to the reported instability of interspecies hybrids, 
several groups fused their antibody secreting LCL to a human 
partner (Table 7 lists some available partners).
Kozber et alf(1982), designed their own human fusion 
partner, KR4, which is ouabain resistant, and derived from a 
6-thioguanine resistant LCL (GM1500-6TG-A-11). But unfortunately 
KR4, like its parent secretes IgG. However, they were able to 
obtain IgM anti-TT mabs. Yet, again, the main disadvantage of 
this technique is the non-availability of a fusion partner with 
the required characteristics (Introduction, section 4.2.3 (i)B). 
(See Table 12 which lists some of the mabs raised by this method)
C) LCL x Heterohybridoma Fusions
Heterohybridomas represent a compromise between human and 
murine fusion partners, and have been used successfully as fusion 
partners in this technique (see Table 12 which lists some of the 
mabs raised by this method). This procedure is not widely used 
even though it may prove very useful.
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Table 12 : Human Monoclonal Antibodies Produced By The 
EBV/Hybridoma Technique 






TT KR4 Kozbor et al (1982)
TT KR-12 Kozbor et al (1984)
P.aeruginosa LTR228 Siadek & Lostrom (1985)
M.leprae KR4 Atlaw et al (1985)




OrgMHHI Van Meel et al (1985)
HLA GM 1500 Hulette et al (1985)
Lung carcinoma KR4 Cole et al (1984)
Breast
carcinoma
KR4 Campbell et al (1985)
Rheumatoid
factor
KR4 Haskard et al (1984)





SP2/0 Larrick et al (1985)
Rhesus D X63 Thompson et al (1986) 
Goossens et al (1987)
PAP SP2/0 Yamaura et al (1985)
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Table 12 : (co n t)




















Teng et al (1985a) 
Brom et al (1984) 
Foung et al (1985) 
Foung et al (1985a) 
Yamaura et al (1985)
Abbreviations:
P.aeruginosa - Pseudomonas aeruginosa
M.leprae - Mycobacterium leprae
TT - Tetanus toxoid
CMV - Cytomegalovirus
PAP - Prostatic acid phosphatase
HLA - Human leucocyte antigens
LCL - Lymphoblastoid cell line
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As can be seen all these methods have had some success, 
some more than others, but an essential ingredient to all of 
them is the incorporation of feeder cells or conditioned media,.... 
when cloning or expanding cells at low densities, in order to try 
and improve growth characteristics (James & Bell>1987).
The feeder cells generally used are of murine origin, 
either peritoneal macrophages (Fazekas de StGroth & Scheidegger, 
1980), splenocytes (Goding*1986) or thymocytes (Oi & Herzenberg, 
1980). They all provide factors which enhance the growth of 
hybrids and LCL’s, but their use does have certain disadvantages, 
namely the possibility of infections, competition for metabolites 
and increased accumulation of waste products which may be 
inhibitory (Samoilovich et al,1987). An alternative to feeder 
cells, is the use of conditioned media which has been shown to 
support the growth of cell lines and hybridomas (Nordah & Potter* 
1986: Rathjen & Greczy^1986: Van Snick et al*1986).
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PROJECT AIMS
Polyclonal myasthenic sera and murine monoclonal antibodies 
have been invaluable tools in delineating the autoimmune response 
and in studying the structure of the nAChR in relation to the 
autoimmune disease, Myasthenia gravis. However, future 
understanding of specific antigenic sites on the human NMJ nAChR, 
which are active in the disease state, coupled with prospective 
new therapies, have led various research groups into the field of 
human monoclonal antibodies.
The development of human anti-AChR monoclonal antibodies 
from myasthenic patients will allow characterisation of the 
active antigenic sites on the nAChR and the origin of the 
autoimmune response in Myasthenia gravis, and may lead to the use 
of human anti-idiotypic monoclonal antibodies or manipulation of 
the immune system regulatory mechanisms, as possible new 
therapies for patients.
Thus, this study, is the first attempt by this group to 
develop human monoclonal antibodies directed against human nAChR 
from patients suffering from Myasthenia gravis. In addition to 
this aim, work was also undertaken to develop a suitable 




JO Sources of AChR
Torpedo marmorata electric organs were purchased from 
Institut de Biologie Marine, Arcachon, France and stored at -80°C
Bovine fetal calves were obtained fresh from a local 
slaughter house. Muscle from the fore and hind limbs was removed 
and frozen in liquid nitrogen before being stored at -80°C for up 
to 3 months.
Adult human muscle was supplied by local hospitals and was 
obtained by dissecting calf muscle from lower limb amputations, 
where the amputation was carried out as a result of severe 
vascular disorders. The muscle so obtained, free from fat, 
tendons and skin, was frozen immediately in liquid nitrogen and 
stored at -80°C for up to 2 months.
2) Immunoreaqents & ELISA Reagents
Myasthenic blood samples were obtained from local hospitals, 
in particular from the Bristol Eye Hospital, under a collaboration 
with consultant eye specialist Dr Campbell.
Normal blood samples were obtained from volunteers within 
the Biochemistry Department.
All blood samples were collected with 10IU heparin per ml 
of blood, and the myasthenic blood was collected in sterile 
evacuated tubes to minimise contaminations.
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Goat anti-(human IgG) and anti-(mouselgG) antiseras were 
gifts from colleagues, as were murine monoclonal anti- 
neurofilament protein antibodies and murine monoclonal anti-AChR 
antibodies (C7, C11, B11, E8).
Normal mouse and goat antisera were obtained from normal 
animals kept at the University of Bath animal house.
Freund's complete and incomplete adjuvants were from 
Miles Laborataries, Stoke Poges, Slough, UK.
Enzyme conjugated second antibodies and substrates for 
ELISA studies were obtained from Sigma Chemical Co., Poole, 
Dorset, UK, as were avidin and streptavidin HRP conjugates, and 
biotin-N-hydroxy-succinimide in dimethylformamide.
ELISA microtitre plates were obtained from NUNC, Uxbridge,
UK.
3) Tissue Culture Reagents
RPMI-1640, fetal calf serum, antibiotics, selection media 
for mab production and Ficoll-Hypaque seperation medium were 
obtained from Flow Laboratories, Irvine, UK.
Tissue culture flasks, plates, wells and other disposable 
apparatus was obtained from NUNC, Uxbridge, UK.
Mouse myeloma cell line, X63 and EBV producing marmoset 
cell line, B93-8, were both gifts from Dr A Jehanli.




All radiochemicals were obtained from Radiochemical Centre, 
Amersham International, Amersham, Bucks, UK. This included 
Na^^I and [^H]-biotin-N-hydroxy-succinimide.
5) Ligands
a-BGT from Bungarus multicinctus was obtained from 
Boehringer Corp., Mannheim, W. Germany, as a lyphilised powder.
Benzoquinonium chloride was a gift from Stirling Winthrop 
Inc., Rensselaer, N.Y., U.S.A.
Decamethonium chloride and nicotine were gifts from 
colleagues.
6) Chemicals
All standard laboratory chemicals were obtained from Sigma 
Co., Poole, Dorset, UK. BDH Chemicals, -Poole* Dorset > UK,
or Aldrich Chemical Co. Ltd., Gillingham, UK.
Gel filtration/ion exchange equipment was supplied by 
Pharmacia Ltd., Hounslow, UK.
Ion exchange resins, DEAE cellulose filters, GFB & GFC 
glass fibre filters were all obtained from Whatman Laboratories 
Ltd., Maidstone, Kent.
Polyethyleneimine was obtained from Sigma Co., Poole, 
Dorset, UK. As was fish skin gruatin.
7) Instrumentation
was counted using an LKB Ultragamma counter.
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C 3 h ]  was counted using a Packard Tri-carb scintillation 
counter (model 3255).





1.1 Iodination Of Alpha-BGT
aBGT was labelled to a high specific activity with ^25j by 
the Chloramine-T method (Hunter, 1967) as modified by Urbaniak et 
at,(1973).
Carrier free Na 125j (lOOmCi/ml, 20/ul)in dilute sodium 
hydroxide was added to aBGT (2.5nmols) in 50mM potassium phosphate 
buffer, pH 7.5 (20/il). The reaction was started by the addition 
of Chloramine-T (10^1 5mg/ml ) in 50mM potassium phosphate 
buffer, pH 7.5, and the mixture was stirred for 1 min at room 
temperature. The reaction was then terminated by the addition of 
sodium metabisulphite (750/ul, 0.16mg/ml) in 50mM potassium 
phosphate buffer, pH 7.5, followed by the addition of carrier 
potassium iodide (200^1,10mg/ml) in 50mM potassium phosphate 
buffer, pH 7.5.
Labelled arBGT was then separated from unreacted 125j by 
passage through a Sephadex G25 column (25 x 1cm) which had been 
previously equilibrated with 10mM potassium phosphate buffer, 
pH 7.5, containing 1?o (w/v) BSA. The^^IarBGT was then eluted by 
using the same buffer.
Fractions (1ml) were collected from the column, and 
aliquots (5/xl) from each fraction were counted for radioactivity.
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The peak fractions, containing 123I-aBGT were pooled and stored 
for no longer than 3 weeks at 4°C. The specific radioactivity 
of the 123I-o BGT was calculated assuming 100% recovery of the 
protein.
1.2 Biological Activity Of ^23I-aBGT
The biological activity of radiolabelled aBGT was determined 
by measuring the proportion of ^23I-aBGT bound by a large molar 
excess of purified Torpedo AChR by using a DEAE filtration assay.
Triplicate samples of Torpedo AChR (20 pmol, 100^1) were 
incubated with radiolabelled aBGT (0.2 pmol, 50^1) for 90 mins 
at room temperature in the presence and absence of 2.5mM (final 
concentration) Benzoquinonium chloride.
Bound and free ^23I-aBGT were then separated by ion- 
exchange chromatography on DEAE cellulose filters, by filtering 
the reaction mixture through two DE81 cellulose filters' in a 
millipore scintered glass filtration system. The filters before 
being counted, were washed with assay buffer ( 3 x 1ml). The 
biological activity of the radiolabelled aBGT was then expressed 
as a percentage of the total radioactivity added.
The buffer used throughout this procedure was the toxin 
binding assay buffer which consisted of 10mM potassium phosphate 
buffer, pH 7.4, 0.1% (w/v) BSA, and 1% (v/v) Triton X-100.
^23I Bound
Biological Activity = x 100%
Total ^23I added
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1.3 Preparation Of AChR Extracts From Various Sources
Crude AChR extracts were prepared from Torpedo marmorata 
electric organ; foetal calf muscle and human skeletal muscle.
The procedure used was essentially the same for all tissues and 
was based on the methods described by Wonnacott et 81,(1980): 
Sinigaglia & Gotti,(1983): Stephenson et al,(198l) and Turnbull 
et al,(1985). A schematic representation of the basic method 
is shown in Fig. 23.
Frozen tissue (200-300g) was coarsely chopped, and 
homogenised in a Waring blender at full speed for 2 min in 10mM 
potassium phosphate buffer, pH 7.4 (4 vol), containing various 
protease inhibitors (1mM EDTA, 0.1mM PMSF, 0.1mM Benzethonium 
chloride and 500 g/ml Bacitracin). The resultant homogenate was 
centrifuged (10,000g, 1h, 4°C) and the supernatant was discarded. 
The pellet was then homogenised as before, in one volume of the 
same buffer, but this time containing 2% (w/v) Triton X-100. 
Following homogenisation the mixture was extracted by paddle 
stirring for 2-4h, over ice, at 4°C. The resulting extract was 
then centrifuged (100,000g, 1h, 4°C), and the supernatant (crude 
extract) filtered through glass wool before assaying for AChR 
activity (Methods, section 1.5).
1.3.1 Variation Of Procedures Depending On Tissue Type
i) Torpedo marmorata Electric Organ
Electric organs were readily available, having been freshly
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Fig,23 - Diagrawatic SuHwary Of nAChR Extraction 
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dissected and frozen immediately. The tissue could be stored at 
-80°C for periods of up to a year without appreciable loss in 
receptor yield. The AChR appears to be relatively resistant to 
intrinsic proteolytic degradation during purification procedures, 
and so tissue solubilisation and AChR purification, by affinity 
chromatography, were carried out at 23°C.
ii) Foetal Calf Muscle
Foetal calves are inexpensive and easily obtainable from 
local slaughterhouses. Muscle was removed by dissection from 
freshly slaughtered calves, frozen immediately and stored at 
-80°C for up to 3 months. Foetal calf AChR is known to be 
susceptible to proteolytic degradation (Einarson et 81,(1982).
For this reason, the preparation of the crude extract was
completed within as short a time as possible, and all steps were
carried out on ice or at 4°C.
iii) Human Skeletal Muscle
Adult human leg muscle was obtained from patients undergoing 
amputations necessitated by either vascular abnormalities, or 
diabetic gangrene. The muscle (normally gastronemius) was 
coarsely dissected and frozen immediately in liquid nitrogen. It 
was then stored for periods of up to 6 months at -80°C. Due to 
the fibrous nature of human skeletal muscle, and the relative 
stability of the adult AChR (Turnbull et al,(1985), solubilisation 
times were increased.
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1.4 Purification Of Torpedo marmorata AChR by Affinity
Chromatography
The crude AChR extract obtained from the electric organs of 
Torpedo marmorata, was processed further to obtain a pure 
preparation of Torpedo AChR. This procedure involved separating 
the AChR from the other constituents of the crude extract by the 
use of an affinity column. The affinity resin consisted of 
Sepharose 4B beads that had been activated by cyanogen bromide 
(March et al^  1974), to which aBGT purified from Na.ja na.ja 
siamensis, had been coupled according to the method of Lindstrom 
et al,(1981). The resin was stored at 4°C, and has been shown to 
remain active for over one year, without appreciable loss of 
efficiency (Nickless, PhD Thesis, 1985).
A crude preparation of Torpedo AChR (Methods, section 1.3) 
was filtered through glass wool and stirred for 2-4 h at room 
temperature with the Sepharose 4B resin (25ml packed volume).
The affinity beads were then filter-washed with 10mM potassium 
phosphate buffer, pH 7.4, containing 0.1% (v/v) Triton X-100, 
protease inhibitors, and 0.5M sodium chloride (500ml), and then 
with the same buffer without sodium chloride (500ml).
Following washing, the affinity beads were packed into a 
column (2cm x 8cm) and the AChR was eluted from the beads, by 
passing 25mM benzoquinonium chloride (BZQ) in 10mM potassium 
phosphate buffer, pH 7.4, containing 0.1% (v/v) Triton X-100,
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and protease inhibitors, through the column, and then directly 
onto a DE 52 ion exchange column (1cm x 5cm). The BZQ was 
recirculated through the two columns overnight at 4°C, following 
which the DE 52 column was washed free of BZQ using 10mM potassium 
phosphate buffer, pH 7.4, containing 0.1% (v/v) Triton X-100, and 
proteae inhibitors. The AChR was then eluted off the DE 52 
column by using 0.5M sodium chloride in 10mM potassium phosphate 
buffer, pH 7.4, containing 0.1% (v/v) Triton X-100 and protease 
inhibitors. 1-2 ml fractions were usually collected, and 
the fractions were assayed for [^^I]-aBGT binding activity 
(Methods, section 1.5). The peak fractions containing the AChR 
were pooled and assayed again for [^^1] -arBGT binding activity 
(Methods, section 1.5). The purified AChR preparation was then 
usually dialysed to remove the sodium chloride, against 10mM 
potassium phosphate buffer, pH 7.4, containing 0.1% (v/v) Triton 
X-100, and protease inhibitors, and the purified preparation 
stored at 4°C. The affinity beads were regenerated after use by 
washing, firstly, with 10mM potassium phosphate buffer, pH 7.4, 
containing 0.1% (v/v) Triton X-100, and 0.5M sodium chloride 
(500ml) followed by the same buffer without sodium chloride 
(500ml). The beads were then stored in 10mM potassium phosphate 
buffer, pH 7.4 containing 0.1% (v/v) Triton X-100, and 0.02%
(w/v) sodium azide as an anti-bacterial agent.
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1.5 Assay Of AChR Activity In Crude And Purified Extracts
The assays involved the addition of an excess of 
to a preparation containing AChR. Non-specific binding was 
measured by carrying out parallel incubations in the presence of 
a large excess of the competitive antagonist benzoquinonium 
chloride (BZQ).
1.5.1 Ammonium Sulphate Precipitation Assay
The AChR content of crude receptor preparations was 
measured by using a method adapted from that of Meunier et al# 
(1972)-
Triplicate samples of serially diluted receptor extracts 
(100^1) were incubated with an excess of (2.5 - 5 nM
final concentration) diluted in 10mM potassium phosphate buffer, 
pH 7.4, containing 2% (v/v) Triton X-100, for 45 min at room 
temperature, before the addition of saturated ammonium sulphate 
solution (133/ul) to give a final concentration of 40?o (v/v).
The mixtures were then incubated overnight at 4°C, and the 
resulting precipitates were collected on Whatman GF/C glass fibre 
filters. The filters were washed with 40?o (v/v) saturated 
ammonium sulphate ( 3 x 1  ml) by vacuum filtration on a Millipore 
filter unit, and counted for radioactivity.
Specific binding of [ ^ ^51 ]—arBGT was blocked in parallel 
incubations performed as above, but containing, additionally, 
2.5mM BZQ (50/xl, 10mM). A value for the specifically bound
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radioactivity in the sample was obtained by subtraction. One 
picomole of AChR was defined as the amount of receptor that binds 
one picamole of [^^IJ-aBGT under saturating conditions. Thus:
cpm (sample)-cpm(+BZQ) pmol dilution
[AChR] =   x toxin x of x 10
(pmol/ml) cpm (total) added sample
1.5.2 Polyethylenimine (PEI) Filtration Assay
In this assay, triplicate samples of serially diluted crude 
receptor extracts (100^1) were incubated with an excess of 
[125I]-aBGT (Methods, section 1.5.1) diluted in 10mM potassium 
phosphate buffer, pH 7.4, containing 2% (v/v) Triton X-100, for 
45 min at room temperature before the addition of PBS (1ml). The 
samples were then filtered through a GF/B glass fibre filter, 
which had previously been soaked for either 3h at room temperature 
or overnight at 4°C, in PBS containing 0.33?£ (v/v) 
polyethylenimine. The filters were washed (2 x 1ml) with PBS 
under vacuum on a Millipore filter unit, and allowed to dry 
before being counted for radioactivity.
Specific binding of [^^Ij-arBGT was blocked by carrying out 
parallel incubations, performed as above, but containing 2.5mM BZQ 
(50|ul, 10mM). The specifically bound radioactivity in the 
sample was then calculated as before.
1.5.3 DEAE-Cellulose Filtration Method For Purified AChR
The content of AChR in the purified extract was measured by
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using a DEAE-cellulose filtration assay similar to that described
by Schmidt and Raftery, (1973).
Triplicate dilutions of receptor samples (100jul), in 10mM 
potassium phosphate buffer, pH 7.4, containing 1% (v/v) Triton 
X-100 and 0.15o (w/v) BSA, were incubated with [ ^ 5 i]_q;bgj 
(1/100 dilution of stock solution, equivalent to 1.0-2.5 nM, 50/ul) 
for 90 min at room temperature. The samples were then filtered 
through 2xDE-81 cellulose filter discs, pre-moistened with the 
potassium phosphate buffer. The discs were washed (3 x 1ml) by 
vacuum filtration of a Millipore filter unit, using the potassium 
phosphate buffer. Following washing, the discs were then counted 
for radioactivity. Non-specific binding was measured in parallel 
incubations performed as above, but containing in addition 
2.5mM (final concentration) BZQ (50/ul, 10mM). Determination of 
the specifically bound [^23j]_aBGT gives a value for the AChR 
content in the purified extract in pmol/ml as described 
previously.
1.6 Assay Of Anti-AChR Antibodies In Myasthenic Sera
A conventional radioimmuno-assay (RIA) procedure, similar 
to that described by Lindstrom et alj(1981), was used to detect 
anti-AChR antibodies in Myasthenic sera. The procedure involved 
the immunoprecipitation of the ^25j_ a BGT/AChR-antibody complexes 
by using a second anti-globulin antiserum.
AChR (0.5nM) was incubated (45min. 23°C) with an excess of
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125i_aBGT (5.0nM) in the presence and absence of BZQ (2.5mM).
The toxin-AChR complex (100/ul) was incubated (overnight, 4°C) 
with the antiserum (5^ ul), appropriately diluted in normal human 
serum. The complex was then precipitated by the addition of the 
second antibody, goat anti-human IgG antiserum, and incubated for 
2h at room temperature, or overnight at 4°C. The precipitate so 
formed, was pelleted by centrifugation (15000rpm, 10 min, 4°C), 
washed ( 3 x 1  ml) with RIA buffer (10mM potassium phosphate 
buffer, pH 7.4; 0.15M sodium chloride; 1?o(v/v) Triton X-100; and 
0.01?£(w/v) sodium azide), and then counted for radioactivity.
All tests were carried out in triplicate at differing dilutions, 
and subtraction of the counts obtained in the presence of BZQ - ■ 
from the counts obtained in its absence, gave specifically bound 
radioactivity in the test sample, with the antibody titre being 
expressed as moles of specific a-BGT binding sites precipitated 
per litre of serum.
2. PROCEDURES RELATING TO CELL CULTURE
2.1 Maintenance Of EBV Marmoset Cell Lines And Production Of
EB Virus
Epstein-Barr virus (EBV) containing culture supernatant was 
prepared from a B958 Marmoset cell line, which actively secretes 
the live virus into the culture medium (Miller et al>1973). The 
Marmoset cells are normally stored frozen in liquid nitrogen. On
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being thawed for use, the cells (10 x 10^ cells/ml, 2 ml) were 
transferred to complete tissue culture medium (20ml), in order to 
dilute out the freezing mixture, and then washed by centrifugation 
(2300 rpm, 10 min) using culture medium (20mls). The cells were 
then resuspended in a small volume of tissue culture medium and a 
viability count was carried out. They were then seeded at 1 x 10^ 
viable cells/ml in complete tissue culture medium in tissue 
culture flasks (25ml), and maintained in an atmosphere of 95?£ 
relative humidity containing 3% carbon dioxide at 37°C. When the 
culture medium was depleted (approx. 10 days), as indicated by a 
colour change in the medium from pink to yellow, (added pH 
indicator), the supernatant was collected by centrifugation 
(2500 rpm, 10 min) in an MSE bench centrifuge, and either filtered 
by positive pressure through a 0.45/um Millipore membrane and 
stored in 20ml aliquots at -20°C, or stored immediately, at -20°C 
in 100ml aliquots and filtered just prior to use. The cells at 
this stage could either be frozen down and stored, resuspended to 
produce more EBV containing supernatant, or discarded totally.
If they were being stored, the pelleted cells were suspended in 
freezing media (RPMI containing 2mM Glutamine, 50?o(v/v) FCS, and 
10?o(v/v) DMS0) at a cell density of 10 x 10^ cells/ml. The 
cells were then transferred to freezing ampoules and placed in a 
slow freezer, suspended in the vapour phase of liquid nitrogen 
overnight, before transferring the ampoules to liquid nitrogen 
containers.
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2.2 Separation Of Peripheral Blood Lymphocytes
Peripheral blood lymphocytes (PBL's) were separated from 
whole blood, using a modification of the procedures described by 
Boyum (1968).
Blood samples (15-20ml) were obtained from patients 
suffering from Myasthenia gravis. The blood samples were usually 
collected and processed the same day with all manipulations 
being carried out under strictly sterile conditions.
The blood samples were first diluted (1:1) with PBS 
containing heparin (10 units/ml), and mixed thoroughly. Aliquots 
of the diluted blood (7ml) were then layered carefully onto the 
top of Ficol lymphocyte preparation medium (3ml) in sterile 
siliconised polycarbonate centrifuge tubes (12ml). The Ficol/ 
blood gradients were then centrifuged (2000 rpm, 25 min) in an 
MSE bench centrifuge.
The separated lymphocytes, located at the Ficol/serum 
interface (see Fig. 24, which gives a diagramatic summary of the 
separation of lymphocytes and their transformation) were removed 
by using a sterile disposable plastic pipette, with circular/ 
criss-cross movements, being careful not to disturb the pelleted 
red cells, and placed in a sterile tube. The cells were then 
washed twice with fresh sterile PBS (20ml), by centrifugation 
(2300 rpm, 10 mins) in a bench centrifuge, in order to remove any 
traces of the Ficol. After the final wash, the PBS was decanted
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off, and the cells resuspended in PBS (20ml), by gentle agitation 
using a sterile pipette. A small sample of the suspension was 
taken for counting (Methods, section 2.6), prior to transformation.
Occasionally, a leucocyte enriched plasma fraction (approx. 
50-100ml) was available from plasmapheresis. In this case a 
crude cell separation was initially carried out prior to Ficol 
fractionation.
To the lymphocyte rich plasma (75ml), a solution of sterile 
Dextran in PBS was added [25ml, 2% sol.(w/v)] in sterile tissue 
culture bottle. Following thorough mixing, the cell suspension 
was left to stand for 1-2 h at 37°C, until most of the 
contaminating red cells had settled, leaving a turbid white 
supernatant containing lymphocytes. This layer was removed by 
pipette and washed twice with PBS by centrifugation (2300 rpm,
10 min) in order to remove the Dextran. The pelleted cells were 
then suspended in PBS and applied to Fical gradients as described 
above.
2.3 Transformation Of PBL's Using EB Virus
PBL's separated on Ficol gradients, were resuspended in EBV 
containing culture supernatant (Methods, section2.1) at a density 
of 1-2 x 10^ cells/ml. The cells were incubated with the EBV 
containing supernatant, for 2—3 hr at 37°C, before being 
pelleted by centrifugation (2300 rpm, 10 min). The EBV containing 
supernatant was decanted off, and the cells resuspended in
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complete tissue culture medium, at a density of 1 x 10^ cells/ml . 
They were then plated out into 96 well flatbottomed tissue 
culture plates (100/zl/well, 1 x 10^ cells/well) which already 
contained 100^1/well complete tissue culture medium with added 
phytohaemagglutinin [1?o(v/v) final concentration, final well 
volume 200/ul]. The cells were grown in the presence of PHA for 
between 3-5 days, in a carbon dioxide/humidified incubator at 
37°C, after which time the supernatant was removed by way of 
gentle aspiration using a sterile glass pipette attached to a 
vacuum line. The medium was then replaced with fresh complete 
tissue culture medium not containing PHA, and this medium changed 
every seven days, or when the old media changed colour from 
orange to yellow, whichever was the sooner.
The cells were grown in this way until they were near 
confluency, at which time the supernatant from individual wells 
was collected and assayed for anti-AChR activity (Methods, 
section 3).
2.4 Pokeweed Mitogen Stimulated PBL's
PBL's separated by Ficol gradient centrifugation were 
resuspended in complete tissue culture medium at a density of 
2 x 10^ cells/ml. The medium contained, in addition to the 
normal supplements, Pokeweed mitogen (25/ug/10^ cells). The cells 
were then incubated in a tissue culture flask (25ml) for five 
days at 37°C in a carbon dioxide/humidified incubator. The
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enhanced B cell population was harvested by centrifugation 
(2300 rpm, 10 min), and washed twice with PBS by centrifugation 
(2300 rpm, 10 min) in order to remove the Pokeweed mitogen. The 
pelleted cells were resuspended in EBV containing supernatant 
(Methods, section 2.1) at a density of 1-2 x -10^ cells/ml. After 
2-3 h at 37°C, the cells were harvested by centrifugation 
(2300 rpm, 10 min) and the EBV containing supernatant decanted 
off. The cells were resuspended in complete tissue culture 
medium at a density of 1 x 10^ cells/ml, and plated out into 96 
well flatbottomed tissue culture plates (100/EL/well, 1 x 10^ 
cells/well) which already contained irradiated murine thymocyte 
feeder cells (Methods, section 2.3.1). The final well volume 
was made up to 200/EL with complete tissue culture medium and the 
cells were grown at 37°C in a carbon dioxide/humidified incubator. 
The medium was replaced every seven days with fresh, or when it 
changed colour from orange to yellow, whichever was the sooner.
2.5 Fusion Of Lymphoblastoid Cell Lines
2.5.1 Preparation Of Feeder Cells
The day prior to the fusion, feeder cells were prepared 
from one of three sources, and plated out into 96 well flat 
bottomed tissue culture plates.
Preferred feeder cells were isolated human mononuclear 
lymphocytes. These were isolated from either normal blood 
samples (40ml) or lymphocyte enriched plasma fractions (obtained
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from volunteers from a local hospital), by the Ficol density 
gradient centrifugation technique (Methods, section 2.2). Once 
isolated, the cells were washed twice with PBS, by centrifugation 
(2300 rpm, 10 min), resuspended in PBS (20ml), and a small 
fraction was retained for counting (Methods, section 2.6). The 
cells were then irradiated for 250 sec by using a gamma source 
(Co^O isotope). Following irradiation, the cells were pelleted 
(2300 rpm, 10 min), and resuspended in complete tissue culture 
medium at a density of 1 x 10^ cells/ml. They were then plated 
out at 1 x 10^ cells/well, into 96 well flatbottomed tissue 
culture plates, and incubated, until use, in a carbon dioxide/ 
humidified incubator at 37°C.
If human mononuclear lymphocytes were not available, which 
was usually the case, then murine macrophages or thymocytes were 
used as alternatives. These were prepared from either adult 
balb/C mice, in the case of macrophages, or 6 week old balb/C 
mice, in the case of thymocytes. In the preparation of 
macrophages, the adult mice were killed by way of cervical 
dislocation, whereas in the preparation of thymocytes, the mice 
were killed by asphyxiation, as cervical dislocation normally 
contaminated the thymus with blood.
The macrophages were obtained from the abdomens of freshly 
killed mice, by injecting PBS (5-10ml) into the abdominal cavity 
with a syringe. The mice were then gently massaged, sprayed with
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alcohol, and a small incision was made in the side of the 
abdominal wall. Through this incision the PBS, containing the 
macrophages, could be extracted with a sterile disposable pipette. 
After collection, the cells were washed with PBS, by 
centrifugation (2300 rpm, 10 min), resuspended in PBS (20ml), and 
counted (Methods, section 2.6). They were then irradiated for 
230 sec using a gamma source, harvested by centrifugation (2300 
rpm, 10 min), resuspended in complete tissue culture medium at a 
density of 1 x 10^ cells/ml, and plated out into 96 well flat- 
bottomed tissue culture plates at 1 x 10^ cells/well. The cells 
were then incubated at 37°C in a carbon dioxide/humidified 
incubator until use.
Thymocyte feeder cells were prepared from the dissected 
thymuses of 6 week old mice. The thymuses were placed into 
sterile PBS, so that they could be washed, and the larger blood 
vessels were dissected from them. After this, they were 
transferred to fresh PBS and crushed by using blunt forceps to 
release the cells. A single cell suspension was obtained by 
passing crushed organs repeatedly through a syringe needle. The 
cells were then washed twice with PBS, by centrifugation, before 
being counted and irradiated. They were then treated in exactly 
the same way as the macrophages.
2.5.2 Maintenance of X63 Murine Myeloma Cell Line
The murine myeloma cell line, X63, was normally stored
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frozen in freezing ampoules (2ml), in liquid nitrogen, at a 
density of 3-10 x 10^ cells/ml in freezing mixture (Methods, 
section 2.1 for details of cryopreservation).
On thawing, the cells were transferred immediately to 
complete tissue culture medium (10ml), followed by washing, 
with the same medium, by centrifugation (2300 rpm, 10 min) so as 
to remove most of the DMS0. The cells were then resuspended in 
complete tissue culture medium and counted for viability (Methods 
section 2.6). The cells were then resuspended in complete tissue 
culture medium at a density of 1 x 10^ viable cells/ml, in a 
tissue culture flask (23ml), and grown in a carbon dioxide/ 
humidified incubator at 37°C. They were grown under these 
conditions until the medium changed colour from orange to yellow. 
At this time, the cells were gently dislodged from the bottom of 
the flask, using a sterile plastic pipette, and a further 
viability count was carried out. They were then reseeded in 
fresh medium in a tissue culture flask (25ml), at a density of 
1 x 10^ viable cells/ml, and grown as before. This procedure was 
repeated several times until the viability of the cells reached 
95?o, at which time they were ready for fusion.
2.5.3 Ouabain Sensitivity Of X63 Cells
X63 cells grown up to 95?o viability, were harvested by 
centrifugation (2300 rpm, 10 min) and resuspended at a density of 
4 x 10^ cells/ml, in complete tissue culture medium. The cells
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were then plated out into 24 well flatbottomed tissue culture 
plates (0.5ml suspension/well, 2 x 10^ viable cells/well). To 
each well was added further complete tissue culture medium (0.5ml) 
which contained appropriate dilutions of Ouabain (ranging from 
5mM to 1/uM final concentrations). The cells were grown for 6 
days at 37°C in a carbon dioxide/humidified incubator, after 
which time the cells from individual wells were harvested and 
counted by using a Trypan blue exclusion assay (Methods, section 
2.6). Triplicate test wells were used for each Ouabain 
concentration.
2.5.4 Fusion of Lymphoblastoid Cells with X63
Lymphoblastoid cells, previously shown to produce anti-AChR 
antibodies, growing in 24 well expansion plates, were harvested 
and pooled. A cell count (Methods, section 2.6), showed between 
5-10 x 10^ cells. These cells were then mixed with an equal 
number of X63 cells, and the resulting mixed cell population was 
centrifuged to a common pellet (2300 rpm, 10 min). The cells 
were washed in Mg^+/Ca^+-free PBS, by centrifugation (2000 rpm,
10 min), and the PBS was carefully aspirated off from the pellet, 
which was loosened from the bottom of the tube by gentle 
agitation. Sterile PEG 1500/DMS0 (1ml, 45?o sol) was added drop- 
wise to the cells, over 1 min at toom temperature with constant 
agitation. The fusion mixture was then incubated for 90 secs in 
a waterbath at 37°C, again with constant agitation. PBS was
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added at room temperature, with agitation over the first 2 mins, 
at a steadily increasing rate (1ml over 1 min, 3ml over next 
min, up to 20ml total volume). The cells were pelleted by 
centrifugation (1200 rpm, 10 min), and resuspended, by gentle 
agitation, in complete tissue culture medium, over a period of 
5-10 mins. The cell density of the suspension was then adjusted 
to 1 x 10^ cells/ml, and the cells were plated out into 96 well 
flat bottomed tissue culture plates (100/il/well, 1 x 10^ cells/ 
well) already containing feeder cells (Methods, section 2.5.1). 
The plates were incubated overnight at 37°C in a carbon dioxide/ 
humidified incubator, and on the following day, complete tissue 
culture medium containing 4?o(v/v) HAT and 2/uM Ouabain was added 
to the wells (100/ul/well, final HAT conc. 2%(v/v), final Ouabain 
conc. 1/uM). The Ouabain was kept as a stock solution of 200/xM in 
distilled water, and was filter-sterilised by passage through a 
0.2/um Millipore filter. Following the addition of HAT/Ouabain 
medium, the cells were grown at 37°C in a carbon dioxide/ 
humidified incubator, and were fed every 7 days with fresh medium 
containing HAT/Ouabain. The hybridomas so produced, were grown 
in this way for approximately 5-6 weeks, when supernatants were 
removed from the wells and assayed for anti-AchR activity 
(Methods, section 3). Fig. 25 gives a diagramatic summary of 
fusion procedures.
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2.6 Cell Counting And Cell Viability
Cell counting was carried out by using a haemocytometer 
counting chamber (improved Neubauer ruling).
Both the cell chamber and the coverslip were cleaned with 
water and alcohol, before the coverslip was placed over the 
counting area.
A sample of the cell suspension (100/ul) was mixed with an 
equal volume of 0.01?o methylene blue in 1?o acetic acid. The 
sample was then introduced into the counting area by capillary 
action,-and the cells were allowed to settle for 1 min before 
counting. Only the blue-stained cells are counted, and in order 
to obtain an accurate count, over 200 cells were counted in 
either one or more large squares.
cells/ml = 2 x N x 10^ N = Nos. Cells Counted
X X = Nos. Squares
Cell viability was determined by using the Trypan blue dye 
exclusion test.
A sample of the cell suspension under study (1 00 /il) was 
removed and mixed with an equal volume of Trypan Blue solution 
(0.2?o (v/v) in PBS) prior to counting. Counting was carried 
out within 10 min of the addition of the dye, as cell viability 
decreases with time owing to the toxic nature of the dye. This 
also avoids inaccuracies which may arise because of non-specific 
adsorption of the dye by membrane proteins (Kruse et al 1973).
Viability = Nos. Viable Cells x 100 
Total Nos. Cells
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3^ ASSAY OF CULTURE SUPERNATANTS FOR ANTI-AChR ANTIBODIES
3.1 Direct Enzyme-Linked-Immunosorbent Assay
A direct ELISA was used to assay culture supernatants 
obtained from EBV-transformed cells, and from heterohybridomas.
A 96 well microtitre ELISA plate was incubated overnight 
with a diluted solution of purified Torpedo AChR (Methods, 
section 1.4; 5/ug/ml, lOO^ul/well, diluted in 50 mM sodium 
carbonate/bicarbonate buffer, pH 9.6), at 4°C. Following coating, 
the plate was washed (3 x 10 min) with PBS containing 1% casein, 
and 0.05% Tween-20, and blocked by using the same buffer (200/ul/ 
well) by incubation at room temperature for 30-40 min.-
The wells were then incubated overnight at 4°C with culture 
supernatant from the test plates (100^tl/well), before being 
washed (3 x 10 min) with the PBS/casein buffer, and incubated 
with goat anti-human (gamma & mu specific) IgG horseradish 
peroxidase conjugate in PBS/casein buffer (100/uJ/well, 1/500 dil. 
of each specific conjugate) for 3 h at room temperature. The 
wells were then washed (3 x 10 min) with buffer and incubated 
with 100^1 of substrate solution [tetramethyl benzidine (lOO^g/ml) 
in 1M acetate/citrate buffer, pH 6.0 (10ml), and hydrogen 
peroxide (1.5 /u 1/10 ml )] for 45-60 min at room temperature. The 
reaction was quenched by the addition of 2M sulphuric acid 
(25/il/well). The optical density of the wells was then measured 
in an ELISA reader at 450nm.
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3.2 Modified Radio Immuno Assay
A modified RIA procedure was used to assay culture 
supernatant from expanded EBV transformed cells and from 
expanded heterohybridomas.
Culture supernatants (25^1) were incubated with human AChR 
(200/ul), which had previously been radiolabelled with ^ S j.^bgT 
(Methods, sections 1.1, 1.3), overnight at 4°C. In order to 
increase pellet size, pooled normal human serum (3/ul) was also 
added.
Following incubation, precipitating antibody was added 
(25 - 100/ul goat anti-human IgG, depending on batch), and 
precipitation was allowed to occur overnight at 4°C, following 
which, the precipitate was pelleted by centrifugation (2500 rpm, 
10 min, 4°C), washed ( 2 x 1  ml) by centrifugation (2500 rpm,
10 min, 4°C) with radioimmunoassay buffer (10mM potassium 
phosphate buffer, pH 7.4, containing 1% (v/v) Triton X-100,
0.1SS (w/v) sodium azide and 0.1?o (w/v) BSA). The supernatant was 
then discarded and the pellets were counted for radioactivity.
Specific binding was measured by carrying out all assays in 
the presence and absence of BZQ, and all assays were carried out 
in triplicate.
Antibody titre was then expressed as the amount of 
radiolabelled receptor bound in the pellet.
Titre (nmols/ml) = Specific cpms. x 1000/25
Spec. Act. Toxin
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3.3 Antibody Capture ELISA For The Detection Of Anti-AChR 
Antibodies Using Biotinylated Alpha-BGT (BaBGT)
3.3.1 Biotinylation Of Alpha-BGT
Alpha-BGT was dialysed against 0.1M sodium hydrogen
carbonate (2L, overnight at 4°C), and its concentration was
adjusted to 5mg.ml. To this solution (1ml) a freshly prepared
u
solution of biotin-N-hydro>^succinimide in dimethylformamide 
(0.1ml, 40mg/ml) was added dropwise with gentle stirring at room 
temperature, before either dialysis or desalting on a G23 
Sephadex column.
If dialysis was used, then it was carried out for 48h at 
4°C, against phosphate-buffered saline, pH 7.3 (2L). The 
concentration of the BaBGT was then adjusted to 0.5mg/ml in PBS 
containing BSA (10mg/ml). To this, an equal volume of glycerol 
was added [50?o (v/v) final concentration], and aliquots (300/ul) 
were stored at -20°C.
If desalting was used then BSA in PBS (10mg/ml, 100/ul) was 
added to the reaction mixture, and the whole was applied to a 
Sephadex G23 column (5ml), that had been previously equilibrated 
with PBS containing sodium azide (0.01% (w/v). The BaBGT was 
eluted by using the same buffer, with 0.5ml fractions being 
collected. The optical density of the fractions was then measured 
at 280nm. The BaBGT peak was pooled and aliquots (300/ul) were 
stored at -20°C in the absence of glycerol.
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3.3.2 Characterisation of BaBGT
i) Sensitivity Of BaBGT Binding To Purified AChR
The binding of BaBGT to AChR was characterised by means of
a solid phase enzyme assay.
Microwell module strips were coated by incubation with
purified Torpedo AChR (Methods, section 1.3) in 50mM sodium
carbonate/bicarbonate buffer, pH 9.6 (lOO^l/ml) overnight at 4°C.
The strips were then washed ( 3 x 3  min) with PBS containing 0.05%
(v/v) Tween-20 and 1% (w/v) casein (Assay Buffer), and blocked by
incubation with the same buffer (2G0jul/well) for 30 min at room
temperature. At this stage the strips can be used immediately or
stored at 4°C for at least two weeks without loss of activity.
After coating and blocking, the wells were incubated with
serial fold dilutions of BaBGT, diluted in assay buffer (100/ul/
well) for 2-3h at room temperature, or overnight at 4°C. The
wells were then washed ( 3 x 5  min) with Assay Buffer, and then
incubated with appropriate dilutions of Avidin-horseradish
peroxidase conjugate (HRP-Avidin) in Assay Buffer (100/xl/well) 
for 3h at room temperature. After washing with assay buffer
(3 x 5min), the wells were incubated with enzyme substrate
solution (Bos et al,1981). This comprises 0.1M sodium acetate/
acetic acid buffer, pH 6.0 (10ml), containing tetramethylbenzidine
in dimethylsulphoxide (100/il, 10mg/ml), 0.05% (v/v) Tween-20, and
hydrogen peroxide (30% solution, 1.5^1). Incubation was continued
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at room temperature, until a colour reaction was observed (between 
45min and 2h). The colour reaction was terminated by the 
addition of 2M sulphuric acid (25/il/well), and the optical 
density of the wells was read at 450nm.
The sensitivity of BaBGT binding to purified AChR was 
further shown by the comparison of BarBGT binding, and ^^1-aBGJ 
binding to AChR coated wells.
Polyvinyl 96 well EIA plates were coated with serial fold 
dilution of purified Torpedo AChR (5000 - 39 ng/ml), diluted in 
50mM sodium carbonate/bicarbonate buffer, pH 9.6 (100/xl/well) 
overnight at 4°C. After washing with Assay Buffer ( 3 x 5  min) 
and blocking with the same buffer (200^1/well, 30min at room 
temperature), the wells were incubated with either BaBGT (1/500 
dilution, 100/xl/well) diluted in assay buffer, or with an 
equivalent amount of 125j_aBGT (0.56pmol//ul) also diluted in 
Assay Buffer, for 3h at room temperature.
The wells that had been incubated with BaBGT were then 
washed (3 x 5min) and incubated with HRP-avidin (1/500 dilution,
3h at room temperature) followed by washing and incubation with 
substrate solution (1h, room temperature). The reaction was 
terminated by the addition of 2M sulphuric acid (25^1/well) and 
the optical density of the wells was read at 450nm. The wells 
that had been incubated with ^^1-aBGJ were washed (3 x 5min), 
dried and individually counted in an LKB ultrogamma counter.
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ii) Specificity Of BaBGT Binding To Purified AChR
The specificity of BaBGT binding for AChR was assessed by 
the ability of unlabelled aBGT, and the cholinergic ligands, 
benzoquinonium chloride, decamethonium bromide, and nicotine, to 
inhibit the binding.
AChR coated wells (Methods, section 3.1) were preincubated 
with the inhibitor solution ^O^l/well) for 2h at room temperature 
before the addition of the BaBGT (1/500 dilution, 50^1/well), 
diluted in assay buffer. The wells were then incubated overnight 
at 4°C, washed (3 x 5min) with assay buffer, and incubated with 
HRP-avidin (1/500 dilution, lOO^l/well), diluted in Assay Buffer, 
for 3h at room temperature. After the final wash (3 x 5min) with 
assay buffer, the wells were incubated with the enzyme substrate 
solution (100^1/well) for 1h at room temperature, before the 
reaction was terminated by the addition of 2M sulphuric acid 
(25/ul/well). The optical density of the wells were then measured 
at 450nm.
iii) Determination Of Number Of Biotin Molecules Bound Per aBGT
Molecule
The number of biotin molecules bound per aBGT molecule was 
determined by employing a colourimetric assay developed by 
Green (1965).
The procedure involved the setting up a standard curve, 
using a known standard biotin solution.
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The spectrophotometer was zeroed at 500nm by using Avidin 
in 20mM potassium phosphate buffer, pH 7.0 (0.9ml, 0.65mg/ml,
5 M). To this solution, 5mM 4-hydroxyazobenzene benzoic acid 
(20/ul) in 20mM potassium phosphate buffer, pH 7.0, was added and 
mixed thoroughly. The new optical density (falling between 0.6 
and 1.0 optical density units) at 500nm, was noted before 
continuing. Sequential additions of a standard biotin solution 
(VI, 0.2mg/ml in 1mM sodium hydroxide) were made to the same 
curvette, and the decrease in the optical density was noted, 
this gave rise to a standard curve from which unknowns could be 
determined.
Unknown biotin solutions were assayed in a similar way.
Cuvettes were set up with the Avidin solution and the
4-hydroxyazobenzene benzoic acid, as before, but this time,
additions of the BaBGT solutions (10/ul) were made up to a maximum
of 40^1. Again the decrease in the optical density was noted.
From this decrease, by using the standard curve, a measure
of the number of biotin molecules per aBGT molecule was made.
3.3.3 Antibody Capture Enzyme Linked Immunosorbent Assay (ELISA) 
For Detection Of Anti-AChR Antibodies In Culture 
Supernatants From Murine Hybridomas
i) Binding Of The Monoclonal Anti-AChR Antibodies to 
Purified AChR
This was investigated by a direct ELISA system, so as to 
determine which monoclonal antibodies would be of use for further 
study.
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Microtitre module strips were coated with purified Torpedo 
AChR (5/ug/ml, 100/ul/well, (Methods, section 1.4) in 50mM sodium 
carbonate/bicarbonate buffer, pH 9.6, overnight at 4°C. The 
wells were then washed (3 x 5min) and blocked (30 min, 200/ul/well, 
room temperature) with Assay Buffer. They were then incubated 
with increasing dilutions of the several monoclonal antibodies 
available for study (an anti-neurofilament monoclonal antibody 
was also included as a control), for 2h at room temperature, the 
antibodies being diluted in assay buffer.
After washing (3 x 5min), the wells were incubated with 
horseradish peroxidase-goat anti-mouse IgG (gamma specific) 
conjugate (1/500 dilution, lOOyul/well) for 3h at room 
temperature. After washing (3 x 5min) the wells were finally 
incubated with enzyme substrate solution (Methods, section 3.1, 
100^ul/well) for 45min at room temperature, before the reaction 
was terminated by the addition of 2M sulphuric acid (25yul/well). 
The optical density of the wells were then measured at 450nm.
ii) Antibody Capture ELISA
Having determined which monoclonal antibodies were to be 
used for further study, the antibody capture ELISA was 
investigated.
Microtitre module strips were coated with goat anti-mouse 
IgG (5/xg/ml, 100/xl/well) in 50mM sodium carbonate/bicarbonate 
buffer, pH 9.6 overnight at 4°C. After washing (3 x 5min) and
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blocking (30min, 200/ul/well, room temperature) with Assay Buffer, 
the wells were incubated with serial fold dilutions of the 
antibody-containing culture supernatant (100/il/well) for 2-3hrs 
at room temperature, the supernatants being diluted in assay 
buffer.
After washing (3 x 5min), the wells were incubated with 
either crude Torpedo receptor preparation (2pmol), or crude 
foetal calf receptor preparation (0.2pmol), the former 
appropriately diluted, overnight at 4°C (100/il/well, Methods, 
section 1.3). Following receptor incubation, the wells were 
incubated with BaBGT (1/300 dilution, 100^ul/well), HRP-Avidin 
(1/500 dilution, 100^1/well), and finally, with enzyme substrate 
solution (100/ul/well, 1h, at room temperature), as described 
previously (Methods, section 3.3). Between each step the wells 
were washed (3 x 5min) with Assay Buffer.
After incubation with substrate (Methods, section 3.1), the 
reaction was terminated by the addition of 2M sulphuric acid 
(25|xl/well), and the optical density of the wells was measured 
at 450nm.
3.3.4 Antibody Capture ELISA to Detect Anti-AChR Antibodies In
Myasthenic Sera
Microtitre module strips were coated with either goat 
anti-human IgG (gamma specific) or goat anti-human IgG (mu 
specific) antibodies (5 g/ml, 100/xl/well) in 50mM sodium
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carbonate/bicarbonate buffer, pH 9.6, overnight at 4°C.
Wells were washed (3 x 5min) and blocked (30min, at room 
temperature) with Assay Buffer (PBS, pH 7.3, containing 0.05?o(v/v) 
Tween-20, and 0.2%(v/v) Fish Skin Gelatin, as blocking agent), 
before being incubated with serial fold dilutions of various 
Myasthenic sera (neat - 1/3120 dilution), including pooled 
normal human sera, for 3 hrs at room temperature.
Sera chosen for study, covered a wide range of antibody 
titres (high, medium and low) as indicated by conventional 
radioimmunoassay (Methods, section 1.6).
After washing (3 x 5min), wells were incubated with 
undiluted crude human muscle receptor preparation (1pmol/ml, 
100/ul/well) overnight at 4°C. This was then followed by washing 
(3 x 5min), incubation with BaBGT (1/500 dilution, 100/ul/well) 
for 2h at room temperature; washing (3 x 5min); incubation with 
Streptavidin peroxidase (1/200 dilution, 100/ul/well) for 2h at 
room temperature; washing (3 x 5min); and finally, incubation 
with enzyme substrate solution (100/ul/well) for 20 min at room 
temperature. The reaction was terminated by the addition of 2M 
sulphuric acid (25/ul/well) and the optical density of the wells 
was read at 450nm.
4. PRODUCTION OF ANTI-IDIOTYPIC ANTIBODIES DIRECTED TOWARDS
ANTI-AChR ANTIBODIES
The basic procedure for the production of anti-idiotypic 
antibodies involved the immunization of a laboratory bred rabbit
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with an F(ab) 2  fraction prepared from IgG purified from a 
Myasthenic patient. After immunization and subsequent boosting, 
blood samples were taken from the rabbit and processed to give an 
anti-idiotypic fraction. This was then tested for anti-idiotypic 
activity.
4.1 Purification of Human IgG from a Myasthenic Patient (P.)
Myasthenic serum (5 ml) was dialysed overnight against 30mM 
potassium p'hosphate buffer (7.3 pH, 300 ml) and applied to a DE52 
cellulose ion exchange column (1 x 30cm) which had been 
equilibrated in 30mM potassium phosphate buffer, pH 7.3. The 
serum was eluted by using the same buffer with a flow rate of 
36ml/h, and fractions (4ml) were collected. The optical density 
(A2Qq ) eacb fraction was measured and the fractions containing 
IgG were pooled.
The column was washed with 30mM ipotassium phosphate buffer, 
pH 7.3, containing 0.3M sodium chloride, re-equilibrated with 
30mM potassium phosphate buffer, pH 7.3 and stored at 4°C.
4.2 Pepsin Digestion Of Purified IgG And Purification Of
F(ab)7 Fragments
The Myasthenic IgG was concentrated (x10) in a Minicon 
Concentration Unit (B15), to give an IgG concentration of 
approximately 6mg/ml.
The concentrated IgG fraction was then dialysed against 
0.1M sodium acetate buffer, pH 4.5 for 3h at room temperature,
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with constant stirring. The pH of the fraction was monitored 
until it had dropped to 4.5 at which point a solution of pepsin 
(20yul, 30mg/ml) was added and the digestion mixture was incubated 
overnight at 37°C.
The digest was then centrifuged (4000rpm, 15min), and the 
pellet was discarded. The pH of the supernatant was adjusted to
7.4 by dropwise addition of 2M Tris-(hydroxymethyl)-methylamine, 
in order to inhibit the action of the pepsin.
The digest was then applied to a DE52 cellulose ion exchange 
column (1cm x 5cm), that had been previously equilibrated in 10mM 
potassium phosphate buffer, pH 8.0. The F(ab)2 fragments were 
eluted in the void volume with 10mM potassium phosphate buffer, 
pH 8.0. Fractions (2ml) were collected, their optical density 
(A2 8 0 ) was monitored. Fractions containing F(ab) 2  fragments were 
pooled.
4.3 Identification Of F(ab^Fragments In Purified Fraction
4.3.1 Determination of Anti-AChR Binding Sites
A standard radioimmunoassay was carried out, similar to 
that described for the assay of culture supernatants (Methods, 
section 3.2).
Samples of the F(ab) 2 fraction were diluted 1:1 to 1:64) in 
radioimmunoassay buffer (RIA buffer). Triplicate samples of 
the diluted F(ab) 2 fraction (25yul) were then incubated with 
radiolabeled AChR (100^1) with or without added benzoquinonium, 
for 2hrs at room temperature. The assay was then carried out as 
previously described (Methods, section 3.2).
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4.3.2 Immunodiffusion
Immunodiffusion gel (4.4ml) comprising Agar (0.5g), 
distilled water (25ml), PBS (25ml), 0.1%(w/v) sodium azide, and 
3%(w/v) polyethylene glycol 6000, was poured on to a level plastic 
microscope slide, and allowed to solidify for 15min at 4°C.
Following solidification, a symmetrical arrangement of 
wells was cut into the agar gel. This arrangement consisted of 
one central well with six wells arranged equidistant from the 
central well in a hexagonal array (see Fig. 48). Two such 
arrangements can be placed on the same slide.
In the central well of the first array was placed anti-human 
gamma chain IgG (20yul), and in the other one was placed anti­
human light chain IgG (20yul). The remaining wells contained 
samples (20/ul) of the F(ab) 2  fractions (as obtained from the 
column), samples of wash fractions from the column and a sample 
of Fc gamma.
The plate was then incubated at 4°C for 24hr, after which 
it was washed overnight in PBS and distilled water. It was then 
stained in 0.5% (v/v) Ponceau-S / 5% (v/v) TCA for 15min. 
Destaining was carried out using 5% (v/v) acetic acid. The plate 
could then be dried completely at 37°C.
4.3.3 SDS PAGE of F(ab)g Fragments
A 7.5% acrylamide gel was prepared by mixing 25% stock 
acrylamide (12ml), 1M Tris/1M Bicine (4ml) and distilled water 
(22.7ml). The acrylamide solution was degassed for 5min prior
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to the addition of 10% (w/v) SDS (0.4ml), TEMED (0.025mls) and 
ammonium persulphate (0.9mls, 1.5% (w/v)) were added just prior 
to pouring. The gel was poured with the comb in position, 
allowed to polymerize, and then clamped into the electijjphoresis 
tank.
Samples were prepared in reduced and non-reduced forms. 
Reduced samples were prepared by boiling protein (10/ug) with 
SDS/mercaptoethanol (10/ul, 10%/10%) and bromophenol blue (2.5/ul, 
1mg/ml BPB in 50% (v/v) glycerol) for 5min. The non-reduced 
samples were prepared in exactly the same manner but without the 
added mercaptoethanol. Sample volumes were increased to 20yul 
with elution buffer, which contained 10% (w/v) SDS (20ml) and 1M 
Tris/1M Bicine (40ml) in distilled water (21).
The samples were then loaded onto the gel and a loading 
voltage of 50 volts applied. After loading is complete, which 
can be seen visually, the voltage was increased to 150 volts 
(or 10-15 v/cm). The gel was allowed to run until the 
bromophenol blue had reached the bottom of the gel. The gel 
was then removed from the apparatus and stained overnight, with 
constant shaking, in 10% (v/v) TCA containing 1% (v/v) Coomasie 
Blue R250 (10% solution in methanol). The gel was then destained 
in 10% (v/v) TCA.
Standard proteins were phosphorylase B (3/ig);
Galactosidase (3/ug); human IgM (2^ ug); human IgG (2/ug); BSA (2/zg); 
Aldolase (4/xg) and Carbonic Anhydrase (4/ig).
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4.4 Immunization of Rabbit
A mature laboratory bred rabbit was immunized with a 
cocktail consisting of F(ab) 2  fragments (100^ ug in 250/ul distilled 
water), and complete Freunds adjuvant (750/ul). This was split 
into two equal fractions and injected intramuscularly into two 
sites on the rabbit.
After six weeks the rabbit received a booster injection of 
the same cocktail. After five days a bleed was taken from an ear 
vein (20mls). A further bleed was taken after another four days. 
All bleeds were taken in non-heparinised tubes. Any further 
boosts were carried out using the same quantity of protein but in 
non-complete Freunds adjuvant.
4.5 Preparation of Anti-Idiotypic Fraction From Rabbit Serum
The basic procedure involves absorbing the rabbit anti­
human light chain antibodies from the rabbit serum on a 
Sepharose 4B / Human IgG column, followed by sodium sulphate 
precipitation of the remaining immunoglobulins. The concentrated 
immunoglobulin fraction was then tested for the presence of anti- 
idiotypic antibodies directed against anti-AChR antibodies.
4.5.1 Linkage of Human IgG to Sepharose 4B Beads Using
Cyanogen Bromide
Human IgG from normal human serum (NHS) was prepared as 
previously described (Methods, section 4.1).
The IgG fraction obtained from NHS (10ml) was concentrated
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by ammonium sulphate precipitation. An equal volume of a 
saturated ammonium sulphate solution was added dropwise, and the 
whole stirred for 1h at room temperature. After stirring the 
precipitate was separated out by centrifugation in a bench . 
centrifuge (6000rpm, 15min). The precipitate was dissolved in 
distilled water (10ml) and dialysed overnight against 50mM sodium 
carbonate/bicarbonate buffer, pH 9.5.
Packed Sepharose 4B (10ml) was washed (3 x 40ml) with 
distilled water, by centrifugation, before being suspended in 
distilled water (10ml) and 2M sodium carbonate solution (20ml).. 
The slurry was cooled to 4°C with constant stirring. With 
increased stirring, cyanogen bromide in acetonitrile (2.12ml,
0.94 g/ml) was added dropwise over 15 sec. followed by vigorous 
stirring (3min) on ice. The slurry was then filtered through a 
scintered glass filter and washed immediately with 0.1M sodium 
carbonate/bicarbonate buffer, pH 9.5 (50ml), distilled water 
(50ml), and 0.2M sodium carbonate/bicarbonate buffer, pH 9.5 
(50ml). All the washing buffers had been previously cooled on 
ice. The gel was resuspended in the antibody containing solution 
and stirred continuously overnight at 4°C.
The gel was then washed by filtration, using 0.1M sodium 
acetate buffer, pH 4.5 (160ml), containing 0.5M sodium chloride, 
and 0.1M sodium carbonate/bicarbonate buffer, pH 9.5 (160ml), 
containing 0.5M sodium chloride. It was at this stage that the
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degree of coupling was calculated based on the amount of protein 
added to the gel and that which was calculated to be still 
remaining in the first filtrate.
Unbound groups on the Sepharose beads were blocked by 
stirring the gel with 1M ethanolamine/HC1 buffer, pH 9.5 for 1 hr 
at room temperature. The beads were then washed with PBS and 
then packed into a column.
4.5.2 Preparation of Anti-Idiotypic Fraction from Rabbit Serum
Blood (20ml) collected from the rabbit was allowed to 
coagulate by incubation at 37°C for 30min, followed by an 
overnight incubation at 4°C. The serum was then separated by 
centrifugation (4000rpm, 20min).
The serum was then applied to the Sepharose 4B/human IgG 
column in order to absorb out the rabbit anti-human light chain 
antibodies. The column was eluted with PBS (20ml/hr) and 
fractions (2ml) were collected. The optical density of the 
fractions was measured at 280nm, and the void volume peak was 
pooled to give the anti-idiotypic fraction. The column was 
cleaned by using a solution of 0.5M ammonium hydroxide. The 
anti-human light chain antibodies so produced were dialysed 
against PBS (4°C overnight), and stored at -20°C.
The anti-idiotypic antibody fraction was concentrated by 
ammonium sulphate precipitation, involving the dropwise addition 
of a saturated ammonium sulphate solution to the antibody
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fraction until a ratio of 10:6 (antibody : ammonium sulphate) 
was achieved. The whole was stirred for 1h at room temperature 
to maximise precipitation. The precipitate was separated by 
centrifugation (4000rpm, 20min), following which it was dissolved 
in distilled water (1ml), and dialysed against PBS (overnight 
at 4°C).
A similar concentration procedure was carried out on 
normal rabbit serum, which was then used as a control in the 
assay for anti-idiotypic antibody activity.
4.6 Assay of Immune Rabbit Serum for Anti-Idiotypic Activity
4.6.1 Competitive RadioImmunoAssay
Samples of Myasthenic serum (5yul, 1/10 dilution in NHS) 
were incubated with varying dilutions of the anti-idiotypic 
fraction, or dilutions of the concentrated NRS Ig fraction (1/1; 
3/4; 1/2; 1/4; 0) for 2h at 37°C, prior to the addition of 
radiolabelled AChR (200/ul, as previously described. Methods, 
section 1.6) with or without added benzoquinonium. The samples 
were left to react overnight at 4°C, before the addition of the 
second precipitating antibody (35/xl). Precipitation was allowed 
to occur overnight at 4°C, before centrifugation and washing.
The pellets were then counted for radioactivity and the results 
calculated as before.
4.6.2 ELISA For Anti-Idiotypic Antibodies
A 96 well microtitre plate was coated with either myasthenic
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F(ab) 2 fragments (100/il/well, 5/ig/ml) or normal human F(ab) 2  
fragments (100|itl/well, 5jug/ml) in 50mM carbonate buffer, pH 9.5
overnight at 4°C. The wells were then washed (3 x 10min) with
PBS containing 0.05?o (v/v) Tween-20, and 1?o (w/v) casein, and 
then blocked for 40min by using the same buffer, at room 
temperature. The wells were then incubated with increasing 
dilutions of the anti-idiotypic fraction or normal rabbit IgG 
preparation (2h, 37°C, or overnight at 4°C). The wells were 
then washed (3 x 10min) with the PBS/casein buffer, and incubated 
with goat anti-rabbit gamma chain horseradish peroxidase
conjugate (lOO^l/well, 1/500 dil. 2h, room temperature).
Following washing substrate solution was added (Methods, section 
3.1) and incubated for 40min at room temperature. The reaction 
was quenched by the addition of 2M sulphuric acid (25/ul/well).
The optical density of the wells was measured at 450nm.'
4.6.3 Adsorption of Anti-AChr Antibodies onto a Sepharose
4B / Anti-Idiotypic Column
i) Purification of IgG from Anti-Idiotypic Serum
A sodium sulphate precipitation was carried out on the 
anti-idiotypic fraction as prepared previously (Methods, 
section 4.5).
Solid anhydrous sodium sulphate was added slowly to the 
anti-idiotypic fraction, until a concentration of 18?o (w/v) was 
reached. The whole was stirred slowly at room temperature for
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1h, before the precipitate was separated out by centrifugation 
(4000rpm, 15min). The pellet was then washed in 0.1M sodium 
bicarbonate containing 18% (w/v) sodium sulphate, and dissolved 
in PBS (10ml). The solution was dialysed against PBS (overnight 
4°C), and then against 50mM sodium carbonate/bicarbonate buffer,- 
pH 9.5 (3h, room temperature).
ii) Cyanogen Bromide Coupling of Anti-Idiotypic IgG to
Sepharose 4B
The anti-idiotypic IgG prepared by sodium sulphate 
precipitation (Methods, section 4.6.3.i) was attached to 
Sepharose 4B affinity chromatography gel beads by means of 
cyanogen bromide coupling (Methods, section 4.5.1) and packed 
into an affinity column (1cm x 10cm).
iii) Adsorption of Myasthenic Serum onto Affinity Column
The Sepharose 4B/anti-idiotypic IgG affinity column was 
equilibrated with PBS containing 0.5M sodium chloride.
Following this, Myasthenic serum (100/ul, containing added 
myoglobin and Dextran blue) was applied to the column. The 
column was eluted with the PBS/sodium chloride buffer, and 
fractions collected (0.5ml). The optical density of the fractions 
was measured at 280nm, and the void volume peak pooled.
The column was washed with 0.5M ammonium hydroxide and 
re-equilibrated with PBS containing 0.2% (w/v) sodium azide.
The column was then stored at 4°C.
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The adsorbed serum was then examined by radioimmunoassay 
(Methods, sections 3.2 & 4.3.1) against an equivalent dilution of 




1.1 Iodination of Alpha-BGT With
The iodination of commercially available BGT was routinely 
carried out by using Na[^^I] and the Chloramine-T method 
(Methods, section 1.1).
In general, this procedure iodinated the toxin to a very 
high specific activity, ranging from 745-767 Ci/mmol [751^7.8 (6)] 
with incorporations of 89- 97% [94£1.8% (6)] [meant SEM(n) ].
A typical elution profile obtained from the Sephadex G25
column from one of these preparations is shown in Fig. 26. This
particular preparation had a specific activity of 763 Ci/mmol,
96% incorporation, 0.55 pmol toxin//ul, and a biological activity 
of 51%.
1.2 Determination Of The Biological Activity of [.^^1 - BGT]
The biological activity of the iodinated BGT was assessed
by its ability to bind large molar excesses of Torpedo AChR.
Toxin receptor complexes were separated from unbound species by 
ion-exchange chromatography on DEAE-cellulose filters. The 
biological activities of the [^5j_ BGT] species prepared ranged 
from 48 - 52% [51 ±1.3% (6)] as defined by:
[^2 5 j ] 5ounc|
Biological Activity =   x 100%
Total [^^1] added
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1.3 Preparation Of AChR Extracts From Various Sources
Receptor extracts were prepared from three sources, human 
gastronemious muscle, foetal calf muscle, and Torpedo marmorata 
electric organs. In addition to the crude extracts prepared from 
all three, a purified extract was obtained from the Torpedo 
marmorata electric organs (see Fig. 27, for elution profile).
A difficulty inherent in the purification of AChR from 
mammalian, particularly human, sources, is the susceptibility of 
the receptor to proteolytic degradation. For this reason, the 
procedures are largely carried out at 4°C in the presence of 
protease inhibitors.
The purified Torpedo AChR was stored at 4°C in the presence 
of 0.02?o (w/v) sodium azide, and was used for periods of longer 
than 3 months without appreciable losses in [^5j]_a3Qj binding 
activity. The purified Torpedo AChR extract was assayed by the 
DF-81 cellulose filtration assay, shortly after initial 
preparation, and then at regular intervals, until it was either 
discarded or completely used. Upon initial assay, the purified 
receptor extract contained 291 pmol/ml of AChR as determined by 
the DEAE-cellulose filtration assay, this dropped to 263 pmol/ml 
after 3 months.
The foetal calf and the human muscle crude extracts were 
stored at 4°C in the presence of 0.02?o (w/v) sodium azide.
Initially all the crude receptor extracts were assayed by
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the ammonium sulphate precipitation assay (Methods, section 1.3.1)
but this tended to give variable results with high non-specific
binding. The PEI assay (Methods, section 1.5.2) on the other
hand, gave more consistent results with low non-specific binding,
and was preferred for assaying crude receptor extracts.
From six human muscle AChR preparations the AChR content of
*
the crude extracts ranged between 0.5 pmol/ml and 1.5 pmol/ml.
Of two foetal calf muscle extracts, the AChR contents were 2.4 
/ *and 2.7 pmol/ml. Both the human and the foetal calf extracts
were assayed immediately after preparation, and later after
storage for approximately 1 month.^ It was found that there was
a slight but not significant drop in the AChR content of the
extracts. It was usual for the human extract to have been
completely used within the month following its preparation.
The crude Torpedo AChR extract prepared was also stored at
4°C in the presence of 0.02% (w/v) sodium azide. Upon initial
/ *assay, using the PEI assay, the AChR content was 1446 pmol/ml.
This value, again, decreased slightly upon storage but not to any 
significant degree.
2. CELL MANIPULATIONS AND TRANSFORMATIONS
2.1 Ouabain Sensitivity Of X63 Myeloma Cell Line
X63 cells were grown for 6 days in complete tissue culture 
medium with added ouabain, in a carbon dioxide/humidified 
incubator at 37°C (Methods, section 2.5.3). After this period
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Fig.28 • Ouabain Sensitivity Of E M o m  Cells
Growth is expressed as a percentage of the growth 
of control yells, as determined by the counting of 
viable cells.





the number of viable cells per well were counted, together with 
the total number of cells per well, using the Trypan blue dye 
exclusion assay (Methods, section 2.6).
For each concentration of ouabain, ranging from 1^ uM to 5mM, 
triplicate test wells had been seeded. The number of viable 
cells per well was then expressed as a percentage of the total 
number of viable cells in the control wells (i.e. wells with no 
added ouabain).
Fig. 28 shows that the X63 myeloma cells are capable of 
withstanding concentrations of ouabain up to 10jtM without loss of 
viability, 50?o inhibition of growth was shown at a final ouabain 
concentration of approximately lOO^M. Consequently, when 
carrying out fusions, a concentration of 2/uM Ouabain was used.
2.2 PBL Transformations/Fusions
Blood samples from patients suffering from Myasthenia 
gravis, were used to obtain human peripheral blood lymphocytes 
for transformation/fusion experiments. Approximately 76 
heparinised blood samples (15-A0ml) were processed. The number 
of cells obtained from a sample varied greatly, but was 
approximately 1.6 x 10^ cells/ml of blood.
In addition to blood samples obtained by this method, 
lymphocytes were also prepared from lymphocyte-enriched plasma 
obtained from patients who were undergoing plasmapharesis therapy.
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However, there were only 6 of these. They gave approx. 16 x 10^ 
cells/ml of lymphocyte enriched plasma [18 x 10^£ 0.6 x 10^ (n=6)].
For separation techniques, see Methods, section 2.2.
Of the samples transformed, only 3 gave rise to plates that 
were assayable. Of these only one plate of cells wereused in a 
fusion experiment from one patient.
In the case of this patient (code BB) used for the fusion, 
venous blood (13ml) was collected, and contained 13 x 10^ cells 
(0.8 x 10^ cells/ml blood). The cells were transformed on day 0 
(Methods, section 2.3), and plated into a 96 well flatbottomed 
tissue culture plate, where they were grown for 13 days in 
complete tissue culture medium. They were then tested for anti- 
AChR antibody production by direct ELISA with Torpedo AChR 
(Methods, section 3.1; Table 13).
By this method, it was determined that wells C7, F8, G5,
G10, and H7 contained antibodies against Torpedo AChR (see 
Table 15), and these cells were subsequently expanded into 3ml 
tissue culture plates. The cells were grown almost to confluence 
for the next 9 days in the 3ml plates. At this time, the cells 
were harvested and pooled (total cell count 16 x 10^ cells) and 
fused with an equal number of X63 cells (Methods, section 2.5.4). 
The fused cell products were plated out onto thymocyte feeder 
cells (Methods, section 2.5.1) at a cell density of 1.6 x 10^ 
cells/well, and grown in selection media containing HAT and
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Table 15
Assay Results Of Direct Torpedo ELISA Performed On Culture 
Supernatants Obtained From EBV Transformed Lymphocytes
1 2 3 4 5 6 7 8 9 10 11 12.:.
A 0.14 0.11 0.13 0.12 0.17 0.13 0.18 0*12 0.13 0.16 0.19 0.12
B 0.13 0.15 0.18 0.16 0.15 0.19 0.13 0.14 0.17 0.16 0.15 0.15
C 0.16 0.17 0.15 0.15 0.17 0.13 0.27 0.13 0.15 0.19 0.14 0.18
D 0.18 0.15 0.18 0.16 0.19 0.17 0.20 0.24 0.16 0.17 0.15 0.21
E 0.13 0.23 0.14 0.16 0.17 0.17 0.20 0.19 0.14 0.16 0.14 0.19
F 0.17 0.16 0.16 0.14 0.16 0.13 0.20 0.49 0.16 0.14 0.16 0.16
G 0.18 0.21 0.18 0.21 0.35 0.16 0.23 0.19 0.21 0.28 0.16 0.16
H 0.16 0.17 0.23 0.20 0.19 0.14 0.25 0.18 0.18 0.17 0.15 0.14
All marked wells were pooled and the pooled cells fused with an 
equal number X63 murine myeloma cells using PEG.
Table 16
Results Of Direct Torpedo ELISA On Culture Supernatants 
From Heterohybridomas
1 2 3 4 5 6 7 8 9 10 11 12
A 0.08 0.06 0 c 06 0.07 0.07 0.06 0.07 0.20 0.07 0.06 0.07 0.06
B 0.21 0.08 0.07 0.07 0.30 0.34 0.07 0.08 0.06 0.07 0.06 0.07
C 0.63 0.17 0.08 0.30 2.07 0.44 0.06 0.33 0.07 0.19 0.30 0.07
D 0.13 0.47 0.48 0.41 0.44 0.07 0.07 0.06 0.25 0.07 0.80 0.09
E 0.40 0.06 0.07 0.07 0.07 0.36 0.07 0.41 0.75 0.33 0.65 0.06
F 0.30 0.07 0.06 0.06 0.07 0.07 0.09 0.45 0.56 0.63 0.91 0.07
G 0.07 0.07 1.35 0.58 0.08 0.08 0.49 0.47 0.31 0.66 0.61 0.07
H 0.10 0.08 0.08 0.07 0.06 0.07 0.08 0.85 0.09 0.08 0.06 0.07
All marked wells were expanded into larger wells (1ml x 24) and 
re-tested after 9 days of growth.
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Table 17
Assay Of Heterohybridoma Culture Supernatants Using The Direct 
Torpedo ELISA Following Expansion Into 1ml Wells
0.02 C60.28 C1 0.640.03 0.04
0.21 05D40.07 030.06 C11 0.060.07
0.42 E90.06 09 0.50 011 0.20 0.120.02
0.20 F1°0.05 E1° 0.08 E11 0.20 0.190.19
1' 2' 3’
A' 0.52 F11 0.22 G8 0.11 H8
B' 0.11 G3 0.03 G9
C' 0.25 G4 0.32 G10
D' 0.10 G7 0.02 G11
All marked wells were expanded into 3ml tissue culture dishes 
prior to cloning. However, all dishes became infected.
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Ouabain (Methods, sections 2.5.3 & 2.5.4) for 34 days. At this 
time, the supernatants from the wells were collected and assayed 
for anti-AChR antibody production, using the direct ELISA with 
Torpedo AChR (Methods, section 3.1). Of the 96 wells tested, 33 
were positive (see Table 16) all of which were expanded into 24 
well tissue culture plates. The hybridomas were grown for 9 days 
in these plates before being re-assayed both by the direct ELISA 
(Methods, section 3.1), using Torpedo AChR, and by RIA using 
human AChR (Methods, section 3.2). Of the original 33 positive 
wells assayed prior to expansion, only 12 of them reassayed as 
positive (see Table 17). When tested for reaction against human 
AChR, by RIA, none of the wells were positive. Of the 12 positive 
wells assayed 6 of them were expanded into 3ml tissue culture 
plates (A3, A5, B2, B6, C1, and BB1). At this stage, all of 
the expanded plates were lost to infection.
3. ANTIBODY CAPTURE ELISA FOR THE DETECTION OF ANTI-AChR
ANTIBODIES USING BIOTINYLATEP ALPHA-BGT
3.1 Biotinylation of AIpha-BGT
The B BGT prepared was stable at -20°C for at least 11 
months, without loss of activity.
Six lots of conjugate were prepared (Methods, section 3.3.1) 
two by using dialysis, and four by using a Sephadex G25 column.
The optical density profile, at 280nm, of the fractions 
obtained from a typical G25 column (Fig. 29), shows two distinct 
peaks. In order to determine which peak contained BarBGT, ^H-aBGT 
(50/ul, 0.05 Ci/jul) was added to the biotinylation mixture before
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application to the G25 column. Fractions obtained from the 
column were then counted for radioactivity and tested for BaBGT 
activity by ELISA, using purified Torpedo AChR (Methods, section 
3.3.2). The profiles obtained are shown in Fig. 29, in which it 
can be seen that the BaBGT is located entirely in the first of 
the two peaks. Fractions corresponding to this peak were 
accordingly collected in subsequent preparations.
3.2 Characterisation of BaBGT Species And Its Binding To
Purified AChR
3.2.1 Sensitivity Of BaBGT Binding To Purified AChR
The binding of BaBGT to purified Torpedo AChR was examined 
by a solid phase assay as described in the Methods, section 
3.3.2.i).
Concentrations of BaBGT as low as 0.6pmol/ml (1/31,200 
dilution) can readily be detected by this assay, a feature of 
which is the low background (0D K 0.05) observed in the absence 
of BaBGT (Fig. 30). For subsequent studies, dilutions of 1/500 
were chosen for both the BaBGT and the HRP-avidin, representing 
concentrations of O^^g/ml and 1/ug/ml respectively.
Comparison of BaBGT with ^^I-aBGT in a radioimmunometric 
AChR binding assay (Methods, section 3.3.2.1) shows that the 
BaBGT is more sensitive at detecting lower AChR concentrations 
than equivalent amounts of ^5j_agQ-|- (Fig. 31).
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Fig. 30 - Interaction Of B-alpha-BGT With Torpedo AChR Coated 
Mictrotitre Wells
Checkerboard titration of B-alpha-BGT concentration and HRP-avidin
concentration: 1:300 (•), 1:900 (■), 1 :2700 (^) and
1:8100 ( a ). Coating antigen concentration used 5/ug/ml.
Concentrations of stock solutions of HRI^-avidin and B-alpha-BGT 
were 500fx^/ml and 250^ / m l  respectively.
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3-2.2 Specificity Of BaBGT Binding To Purified AChR
Specificity of BaBGT binding was investigated by the use of
a solid phase assay, using purified Torpedo AChR, in the presence
of various inhibitor ligands (Methods, section 3.3.2.ii).
The binding of BaBGT to AChR was specific, as shown by its
inhibition with unlabelled aBGT and the cholinergic ligands,
nicotine, benzoquinonium and decamethonium (Fig. 32).
3-2.3 Determination Of The Number Of Biotin Molecules Per 
aBGT Molecule
The number of biotin molecules bound per aBGT molecule was 
determined by employing a colorimetric assay developed by Green 
(1965, Methods, section 3.3.2.iii). This involved using a 
standard biotin solution to obtain a standard curve from which 
unknowns could be determined (Fig.33).
All the conjugates produced in this study contained 4-5 
biotin molecules per molecule of aBGT as determined by this assay. 
The biological activity and affinity of the BaBGT for Torpedo 
AChR was not determined in this study but they were taken to be 
70% and 25% respectively, to that of the native toxin, as shown 
by Lukasiewicz et al (1978). This will be discussed in greater 
detail in the discussion.
3.3 Antibody Capture Enzyme Linked Immunosorbent Assay (ELISA)
3.3.1 Binding Of Murine Anti-AChR Monoclonal Antibodies To 
Purified Torpedo AChR
The binding of the various monoclonal antibodies available, 
was investigated by means of a direct ELISA, so as to determine
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Fig,32 - Inhibition Of B-ftlpha-BCI To AChR Bn Various Ligands
B-Alpha-BGI - 1:500 dil. HRP-avidin - 1:500 dil. 
unlabelled Alpha-BGT - ♦
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Fig,33 - Standard Curve Used For The Determination Of The Number 
Of Biotin Molecules Attached Per* ftlpha-BC! Molecule
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which monoclonal antibodies would be suitable for further study 
(Methods, section 3.3.3.i).
Six monoclonal antibodies (C7, C11, B11, E8, A3 and E11) 
were investigated, together with an anti-neurofilament monoclonal 
antibody, used as a control. From the ELISA results (Fig. 34) it 
was decided to use monoclonals C7, C11, B11, and E8, for further 
study. The properties of these monoclonals are also shown in 
Table 18, from which it can be seen that all four monoclonals are 
of the IgG-2b subclass, and have IgG concentrations, in the 
undiluted supernatant, ranging from 7.5 - 15^ ug/ml. They all 
reacted against Torpedo AChR, but only monoclonals C11, B11, and 
E8, reacted against fetal calf AChR.
3.3.2 Antibody Capture ELISA
The antibody capture assay for anti-AChR antibodies was 
assessed in terms of the detection of monoclonal antibodies in 
supernatants from the four murine hybridomas C7, C11, B11 and E8.
The ELISA procedure allowed reproducible detection of 
anti-AChR antibodies against Torpedo AChR (Fig. 35) and fetal 
calf AChR (Fig. 36), over a wide range of antibody dilutions from 
1/100 to 1/5120, for all four monoclonals. This represents 
detection of antibody levels from 15 - 0.2ng/ml IgG (Table 19 
gives an indication of the minimun detection levels).
Direct comparison of the antibody capture ELISA with the 
conventional double antibody radioimmunoassay, using the
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TABLE 18
PROPERTIES OF MOUSE MONOCLONAL ANTI-AChR ANTIBODIES
Antibody Subclass IgG concentration Anti-AChR antibody
(</q/ml) titre of supernatant
(nM)a
Torpedo AChR Fetal calf AhR
C7 1gG2b 10.0 110 NDb
C11 " 8.0 139 0.73
B11 " 7.5 180 4.50
E8 " 15.0 301 2.32
a) titre detected by immunoprecipitation radioimmunoassay (Carter 
et al, 1981) and expressed in terms of aBGT binding sites.
b) ND = not detected
F ig . 35 & 36 -  T it ra t io n  Of Anti-AChR A ntibod ies
Fig. 35 and 36 Antibody-capture ELISA for the detection of 
antibody binding to Torpedo AChR and Fetal Calf AChR, respectively. 
Monoclonal antibody culture supernatants used were C7 ( 4  )>
C11 (•), B11 (■), E8 (A), and anti-neurofilament (----).
Values are the average of triplicate samples. Percentage standard 
deviation for each reading was less than 20?o.
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TABLE 19
TITRATION OF MOUSE MONOCLONAL ANTI-AChR ANTIBODIES BY ELISA
Antibody Minimum detection levels
Torpedo AChR Fetal calf AChR
Supernatant IgG conc. Supernatant IgG conc.
dilution (nq/ml) dilution (nq/ml)
C7 1/5120 1.95 N.D. N.D.
C11 1/320 25.0 1/2560 3.1
B11 1/80 94.0 1/2560 2.9
E8 1/640 23.4 1/1280 11.7
(a) N.D. not detected
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monoclonal antibody C7, showed the ELISA to be considerab ly  more
sensitive, detecting minimum levels of IgG of 0.2 ng/ml compared
with 25 ng/ml for the radioimmunoassay (Fig. 37).
The ELISA also confirmed the lack of cross reactivity of
monoclonal antibody C7-against fetal calf AChR, which was
initially indicated by the radioimmunoassay (see Table 18).
The specificity of BaBGT binding to AChR was further
demonstrated by assaying a monoclonal anti-neurofilament antibody,
as a control, which showed no response against either type of
AChR, and was further shown, by the fact that responses in the
assay to anti-AChR antibodies were completely abolished in the
presence of 20mM decamethonium bromide, as in the inhibition
assay already described (see Methods, section 3.3.3.ii).
3.3.3 Optimisation Of Assay Conditions
In order to develop the antibody capture ELISA further for
use in detecting human anti-AChR antibodies produced either by
Epstein-Barr virus transformed human lymphocytes, or human/murine
heterohybridomas in culture, the various assay conditions were
optimised by using C7 monoclonal antibody.
i) Optimisation Of Coating Antibody Concentration And
Monoclonal Antibody Dilution
Concentration of coating antibody and monoclonal antibody 
dilution were both examined in a checkerboard assay.
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increasing amounts of goat anti-mouse IgG (gamma specific) 
antibodies, from 0 - 10/ug/ml, in coating buffer overnight at 4°C. 
The wells were then incubated with varying dilutions of C7 
monoclonal antibody for 2-3h at room temperature, and processed 
as before, except that the HRP-avidin was made up in PBS, 0.05% 
Tween-20 buffer without casein (see Discussion for explanation).
It was found that a coating antibody concentration of 
5^ ug/ml was sufficient to saturate the binding capacity of the 
wells (Fig. 38). From the same assay a monoclonal antibody 
dilution of 1/400 was adopted for use in successive assays.
It was observed whilst carrying out these assays that in 
certain wells set up as negative and positive controls that very 
high background optical densities were recorded. This was 
something not normally seen, as one of the main advantages of the 
assay is the low background levels (^0.05 O.D. units).' This 
observation was attributed to the presence of casein as a 
blocking agent (see Discussion)
These wells had been blocked with the casein buffer, but 
did not have any coating antibody attached, nor were they 
incubated with the monoclonal antibody, or Torpedo AChR. They 
were, however, incubated with BaBGT and/or HRP-avidin. Both 
these test wells gave equivalent O.D. values, a fact attributed 
to an interaction of the HRP-avidin with the casein bound to the 
wells (see Discussion).
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As it appeared that the casein used in the buffers was 
interfering with the assay, steps were taken to alter the assay/ 
blocking buffer. Various systems were investigated, all were PBS 
based, but differed in the nature of the component used to reduce 
the non-specific binding. These components included 1% (v/v) 
Tween-20, 1% BSA, 5% fetal calf serum, or 5% normal goat serum. 
However, they were all found to be ineffective blockers, again 
giving high background levels.
The final buffer system examined was PBS containing 0.05% 
(v/v) Tween-20, and 0 . 1  - 0.2% (v/v) fish skin gelatin as the non­
specific blocker. This was found to be a very effective blocker, 
especially when used in conjunction with Streptavidin horseradish 
peroxidase conjugate (see Discussion). A combination of both 
these changes resulted in a reduction of the background levels 
down to the levels previously seen ({ 0.05 O.D. units), and at 
the same time the sensitivity of the assay appeared to increase. 
These changes were therefore adopted for subsequent assays.
ii) Optimal Incubation Times And Temperatures For C7
Monoclonal Antibody
Incubation times and temperatures were altered in order to 
determine conditions for maximum binding of the C7 monoclonal 
antibody to the ELISA plates.
In the assay, wells were incubated with culture supernatant 
containing C7 monoclonal antibody (1/400 dilution) from between
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0 - 3h, at two different temperatures (room temperature (23°C 
and 4°C).
It was found that there was no significant difference 
between carrying the incubation out at toom temperature or at 
4°C (Fig. 39). Maximum binding of the monoclonal antibody to 
the coated wells was achieved after approximately 2 h incubation.
It was therefore decided to carry out the incubation for 
2-3h at room temperature, for subsequent assays,
iii) Optimal Binding Of Torpedo AChR
Receptor concentration was examined along with incubation 
times and temperatures.
In the first assay, after the wells had been incubated with 
the monoclonal antibody, they were incubated with increasing 
amounts of a crude Torpedo AChR (0-20pmol/ml, 100/ul/well) 
overnight at 4°C, before being processed as already described. A 
dilution profile was obtained (Fig. 40), which can be seen to be 
linear over the range of AChR concentrations, 0-5pmol/ml, with 
saturation occuring at a receptor concentration of 3 pmol/ml.
Of note from the profile, is that receptor levels as low 
as 0.1 pmol/ml give measurable O.D. values above background, 
and that a receptor concentration of 1 pmol/ml gives O.D. 
readings 1 . 0  optical density units, indicating that the assay 
has a high sensitivity at low receptor concentrations. This 
becomes important if mammalian/human receptor preparations are to
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be used in the assay, as they frequently only have receptor 
levels of approximately 1 . 0  pmol/ml.
In the second assay, receptor binding was examined with a 
view to optimising incubation times and temperatures.
After incubation of the wells with monoclonal antibody, 
they were incubated with a crude preparation of Torpedo AChR 
5 pmol/ml, 1 0 0/zl/well) at either room temperature over a time 
period of 0-3h, or at 4°C over a time period of 0-20h.
Figure 41 indicates that binding at room temperature is 
complete after approximately 3h, whereas at 4°C it is complete 
only after the overnight incubation. It would also appear that 
the incubation at 4°C results in a slightly higher final optical 
density than the incubation at room temperature.
From both these assays, it was decided to carry out the 
incubation with a receptor concentration of 3 pmol/ml, and 
overnight at 4°C.
iv) Optimal Concentrations Of BaBGT And Streptavidin Peroxidase
Several assays were carried out for both species, so as to 
determine optimal concentrations to use in the assay, and to 
determine incubation times and temperatures.
With regard to BaBGT, once the wells had been incubated 
with receptor, they were incubated with varying dilutions of 
BctBGT (1/30 - 1/1638400 dilution, 100//l/well) for 2h at room 
temperature. They were then incubated with Streptavidin 
peroxidase (1 / 2 0 0  dilution, 1 0 0/ul/well) for a further 2 h at room 
temperature, prior to development with substrate. From this, a 
dilution profile for BaBGT was obtained (Fig. 42), from which it
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Fig.42 - Dilution Profiles For Both B-‘V  -BGI And Streptavidin-H 














can be seen that the maximum response is obtained by using a 
BaBGT dilution of 1/800, but to ensure a slight excess when 
carrying out the assay, a 1/500 dilution was used in further 
assays.
A similar dilution profile (Fig. 42) was obtained for the 
use of Streptavidin peroxidase, but in this case, after the wells 
had been incubated with AChR, they were incubated with a 1/500 
dilution of BaBGT for 2h at room temperature, prior to the 
addition of varying dilutions of Streptavidin peroxidase (1/50 - 
1/102400, 100fd/well, 2h at room temperature). From this profile 
it was decided to continue to use a 1/200 dilution of Streptavidin 
peroxidase in conjunction with a 1/500 dilution of BaBGT.
Having determined optimum incubation concentrations for 
both species, assays were carried out to determine optimal 
incubation times and temperatures.
In both cases the assays were carried out at 37°C and at 
room temperature, over the time period of 0-3h, using the 
concentrations already mentioned above. With regard to the 
BaBGT (Fig. 43), there appears to be no difference between 
binding at 37°C and at room temperature. However, with 
Streptavidin peroxidase (Fig. 44) there does appear to be a 
temperature effect, in that the assay carried out at 37°C gives 
lower optical density values than those obtained in the assay 
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is obtained after a 2-3h incubation with either species.
From these assays it was decided to carry out further 
studies using an incubation time of 2-3h at room temperature for 
both species, and to use a 1/300 dilution of BaBGT, and a 1/200 
dilution of Streptavidin peroxidase.
3.3.4 Antibody Capture ELISA To Detect Anti-AChR Antibodies
In Myasthenic Sera
The antibody capture ELISA, developed to detect anti-AChR 
antibodies in culture supernatants, was used to detect human 
anti-AChR antibodies found in the sera of patients suffering from 
Myasthenia gravis. These antibodies are normally detected by the 
use of the conventional double antibody radioimmunoassay 
procedure (Table 20).
The sera from five Myasthenic patients were chosen for 
study, as they represented a typical cross section of antibody 
titres(Table 20), as detected by radioimmunoassay. Pooled normal 
human sera was also included as a control. Titres are normally 
compared to this serum which has a titre of 0 - 3.3 x 10”^M.
In assays for anti-AChR IgG antibodies, (i.e. plates 
coated with goat anti-human IgG (gamma specific antibodies) 
there was no detectable reaction from any of the sera tested, 
even from the high titre IgG sera.
However, this was not the case with the assays attempting 
to detect IgM anti-AChR antibodies (i.e. plates coated with
- 197 -
TABLE 20
COMPARISON OF ANTI-AChR ANTIBODY TITRES OF DIFFERENT PATIENTS 
AS DETERMINED BY CONVENTIONAL RADIOIMMUNOASSAY
Patient Titre x 10 Duration of Myotoxicity
Disease % lysis
N.H.S 0 - 3  N/A 10 - 20%
RATHBONE 33 3yrs ND
SHAW 22 - 25 8 yrs ND
HARWOOD 199 8 yrs 30%
ROSS 100-1000(713) 8 yrs 30%
PETLEY 100 (420) 8 yrs 50%
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goat anti-human IgG (mu specific) antibodies (Fig. 45)). It 
can be seen that there is a reaction with all the sera, including 
the normal human sera. With two of the sera (HN and RS), the 
reaction was comparable to that obtained with normal human sera. 
What is of note is that both these sera are high titre sera with 
the conventional radioimmunoassay. Of the other three sera, one 
is a high titre sera (PT), and the other two are low/medium 
titre sera (RA and SH).
4 PRODUCTION OF ANTI-IDIOTYPIC ANTIBODIES
4.1 Purification Of Anti-AChR Antibodies From Myasthenic Serum
4.1.1 Purification Of IgG Fraction
IgG was prepared by ion exchange chromatography (Methods, 
section 4.1) from a batch (50ml) of plasmapheresis serum that 
showed a high titre (100.7nmol/ml) in the conventional 
radioimmunoassay.
The purified IgG (36ml) contained 30mg total protein.
Fig. 46 gives the elution profile.
4.1.2 Pepsin Digestion Of Purified IgG
F(ab) 2 fragments were prepared from myasthenic IgG (30mg 
protein) by pepsin digestion (Methods, section 4.2), and purified 
by ion exchange chromatography when they were eluted in the void 
volume (see Fig. 47 for elution profile) to give pooled fractions 
containing 14.2mg total protein (10ml, 1.42mg protein/ml).
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4.1.3 Characterization of F(ab)? Fraction
i) RadioImmunoAssay
The purified F(ab) 2 fraction was assayed by the standard 
clinical radioimmunoassay (Methods, section 1.6) for its ability 
to bind to AChR. It was then compared to the anti-AChR antibody 
titre, seen in the serum donor patient (P). The radioactivity 
seen to bind in the pooled fraction was also compared to that 
which bound in each of the other two peaks obtained in ion- 
exchange chromatography (see Fig. 47).
The F(ab) 2 pooled fraction (10ml) had a titre of 19.01 
nmols AChR binding sites per ml. This represents a yield of W** 
of the binding sites present in the original batch of serum. In 
addition to the pooled fractions from peak 1 (see Fig. 47), 
fractions 10 and 21, from peaks 2 and 3 respectively, were 
assayed by RIA. Peak 2 (fraction 10) contained 1.0 nmols AChR 
binding sites per ml, and peak 3 (fraction 21) contained 0.78 
nmols AChR binding sites per ml, each fraction had a total volume 
of 2ml.
ii) Immunodiffusion
The three peak fractions from ion exchange chromatography, 
were further investigated by immunodiffusion (see Fig. 48 which 
gives a diagramatic representation of the result of the 
immunodiffusion). It can be seen that only the void volume 
fractions were precipitated by the goat anti-human light chain IgG.
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iii) SDS PAGE
The purity of the F(ab)2 fraction was investigated by SDS 
polyacrylamide electrophoresis, using reduced and non-reduced 
samples (see Fig. 49). This clearly demonstrates that the FCab)^ 
fragments were located in the void volume peak. The non-reduced. 
sample gave rise to one clearly defined band, whereas the reduced
sample gave rise to two bands.
4.2 Preparation Of Anti-Idiotypes Towards Anti-AChR Antibodies
The purified F(ab) 2 fragments were used to immunise a 
laboratory bred rabbit. Following the immunisation procedure 
(Methods, section 4.4), anti-idiotypic antibodies were prepared 
from whole rabbit blood. This involved the removal from the 
serum of rabbit anti-human light chain antibodies b$ affinity 
chromatography.
IgG prepared from pooled normal human serum by ion exchange 
chromatography (see Fig. 50 for elution profile, pooled fraction
32ml, 3.9mg protein/ml giving total IgG of 124.8mg) and ammonium
sulphate precipitation, was linked to Sepharose 4B by cyanogen 
bromide. Optical density measurements of the antibody solution 
before and after linkage showed that 89?o of the total NHS IgG 
used (approx. 25mg) bound to the beads. This column was then 
used to adsorb out the rabbit anti-human light chain antibodies 
in the immune rabbit serum (see Fig. 51 for elution profile). 
Anti-idiotypic antibodies were then eluted from the column with
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0.5M NH^OH. This elute was concentrated by ammonium sulphate 
precipitation, and the resultant pellet dissolved in PBS (10ml). 
Optical density measurements at 280nm, gave a protein 
concentration of 6.9 mg/ml. This gives a total yield of 69mg of 
protein from 20ml of immune rabbit serum. With 10-15mg of IgG/ml 
of serum there is a percentage recovery of between 23-34.5?o. A 
similar antibody preparation was made from norman rabbit serum.
4.2.1 Assay Of Anti-Idiotypic Activity
i) Competitive RadioImmunoAssay
The blocking effect of the anti-idiotypic antibodies was 
investigated by a modification of the standard radioimmunoassay, 
utilising two Myasthenic sera, and the concentrated NRS IgG as a 
control. No blockage of radiolabeled AChR binding to anti-AChR 
antibodies from patient J. was observed with any concentration of 
anti-idiotype. However, a certain amount of blockage was seen 
with patient P. against whom the anti-idiotypes were raised 
(see Fig. 32).
ii) Enzyme Linked Immunosorbent Assay
The ELISA used, investigated the ability of the anti­
idiotypes to bind to the myasthenic Ftab^ fragments, and normal 
human F(ab) 2 fragments, when compared to the control NRS IgG.
The results show that the anti-idiotypic antibodies bind to the 
myasthenic F(ab)^ fragments, but not to the normal human F(ab) 2  
fragments. However, the concentrated NRS IgG used as a control
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also binds to the myasthenic F(ab) 2  fragments but not to the same 
extent (see Fig. 53, shows the binding ability of anti-idiotypic 
antibodies).
iii) Adsorption Of Myasthenic Sera Onto An Anti-Idiotype
Affinity Column
A crude anti-idiotypic IgG preparation obtained by sodium 
sulphate precipitation of the immune rabbit serum, was linked to 
Sepharose 4B beads by cyanogen bromide treatment. Optical 
density measurements of the antibody solution before and after 
linkage, gave the extent of coupling as approximately 85% (65mg 
of protein was used, 1 0 .6 mg remained in the solution).
A sample of Myasthenic serum (patient P) was applied to the 
column and the void volume peak collected. The adsorbed fraction 
was then compared to a similarly undiluted serum sample, by the 
radioimmunoassay procedure already described (Methods, .section 
1.6). The results showed a 22% decrease in anti-AChR antibody 
titre in the adsorbed serum (unadsorbed, 116nmols AChR binding 
sites/ml: adsorbed, 90nmols AChR binding sites/ml).
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DISCUSSION
1. Preparation Of Radiolabelled Alpha-BGT & AChR Extracts
The nAChR is the most extensively characterised neuro- 
transmitter receptor in biochemical terms, with advances being 
largely attributed to the discovery of the a-neurotoxins, and a 
rich source of receptor seen in the electric organs of the 
electric fish and eels (Introduction, section 3.2.2).
In particular, aBGT has been used as an affinity ligand in 
the purification of nAChRs from a variety of sources, including 
mammalian, and when radiolabelled in a quantitative assay for 
nAChR. For a radiolabelled ligand to be of use in detecting 
small quantities of receptor, it must possess high specific 
radioactivity and biological activity. This is seen with 
iodinated derivatives of aBGT, namely ^^1-oQGl (Methods, section 
1.1; Results, section 1.1) prepared using the Chloramine-T method 
of Hunter et al (1967), as modified by Urbaniak et al (1973).
The procedure is relatively simple to carry out, as is the 
detection of the radioactive ligands, thus making it ideally 
suited for such studies. Thus, preparation of ^^I-aBGT with 
high specific radioactivity and biological activity, is carried 
out as a matter of routine.
The radiolabelled arBGT’s prepared during the course of this 
work had specific activities and biological activities (Results,
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section 1 .1 ) which compared favourably with similar preparations 
made by colleagues (Walsh, (1990); Nickless, (1985). The 
biological activities decrease notably after a period of 
approximately three weeks, and conseguently, each preparation 
was discarded after this time. The loss of activity has been 
attributed to the presence of Chloramine-T, a powerful oxidising 
agent, and/or by radiation damage caused by the decay products of 
[1 2 3 I] (Walsh, (1989)).
The solubilisation, isolation and purification of nAChR's 
from a whole range of tissues have been carried out in this 
department for a number of years (Stephenson et al, (1981); 
Turnbull et al, (1985); Lotwick, (1985); Nickless, (1985);
Walsh, (1990))consequently procedures for solubilisation and 
purification have been optimised and standardised, to such an 
extent, that it was considered that it was not necessary to 
undertake these studies again, especially as this was not the 
immediate aim of this work. Therefore, all procedures described 
(Methods, section 1.3 & 1.4) are those which are used as a matter 
of routine in the preparation of nAChR extracts. However, one or 
two points are worthy of note.
Firstly, Triton-X100 has been shown to be the most 
effective solubilising agent (Walsh, (1990); Nickless, (1985)) 
including the solubilisation of nAChR from human muscle 
(Stephenson et al, (1981). It is a non-ionic detergent which
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does not interfere with the biochemical and pharmacological 
characterisation of the receptor which occurs if ionic detergents 
are used (Sugujama & Changeax, (1975)), and keeps the receptor in 
solution by forming mixed micelles with the receptor.
Secondly, mammalian sources of AChR tend to have high 
levels of proteolytic enzymes present, which does not occur in 
the electric organs of the electric fish and eels. Consequently, 
in addition to the low levels of receptor, proteolytic degradation 
becomes a problem. In order to overcome this a series of 
additional modifications to the procedure are employed, namely, 
the introduction of protease inhibitors, shortened extraction/ 
purification times, and all procedures carried out at 4°C where 
possible (Lindstrom et al, (1979); Anholt et al, (1984); Schorr 
et al, (1981); Stephenson et al, (1981)).
All receptor preparations so prepared during the course of 
this study, were assayed at frequent intervals (Methods, section 
1.5; Results, section 1.3), to ensure the AChR content was known 
before use, and to ensure that it did not change appreciably. A 
slight drop in levels was seen but this was not appreciable and 
can be attributed to some proteolytic degradation occuring. It 
is also possible that some of the receptors present in the extract 
denature over time producing free subunits. This would not be 
reflected in the assays carried out using ^^5j —^ BGT as this ligand 
will still bind to free ar-subunits of the receptor. Lindstrom et 
al, (1980), and Einarson et al, (1982), have shown that, beta,
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gamma and delta subunits of the receptor are more sensitive to 
proteolytic degradation than the relatively protease resistant 
alpha subunit. AChR content of all extracts, Torpedo, human and 
fetal calf, compared favourably with similar extracts prepared by 
colleagues (Walsh, (1990); Nickless, (1985)) and with levels 
reported in current literature (Stephenson et al, (1981); Momoi & 
Lennon, (1982); Lotwick, (1985); Turnbull et al, (1985); Einarson 
et al , (1982); Gotti et al (1982)) Yields do vary between 
preparations, especially between human muscle extracts. This has 
largely been attributed to the quality of the material used for 
extraction. Most extracts are prepared from muscle obtained from 
lower leg amputations. The amputations are from patients who 
were suffering from diabetic gangrene, or other ischemic vascular 
diseases. Ischemia may result in partial denervation of the 
muscle which in turn may lead to proliferation of EJR 
(Introduction, section 3) thus providing a richer source of AChR. 
Alternatively, if the patient has been inactive for long periods 
because of vascular disease, then wasting of the muscle may occur 
thus reducing the overall quality of the tissue for extraction 
purposes. Only one crude fetal calf extract was prepared, along 
with only one crude Torpedo extract, consequently we can't discuss 
variability between preparations. In addition some of the crude 
Torpedo extract was used to obtain purified Torpedo AChR. Even 
though variability cannot be discussed with respect to these 
results, it is of interest to note, that in a much more detailed 
study by Walsh, (1990), fetal age plays an important part in the
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yield of nAChR obtained. In fact, the older the fetal calves 
used, the lower the nAChR content of the extract produced. This 
was reasoned to be due to the fact that in young fetal calves 
most of the nAChR is probably EJ in form (Introduction, section 3) 
on relatively small muscle fibres, consequently, extraction is 
that much easier compared to fetal calves which are older. In 
older fetal calves innervation occurs, with a consequent decrease 
in the AChR content of the muscle fibres, and concentration of 
the nAChR's at the NMJ. In addition, as the fetal calves become 
older, the muscle becomes more fibrous in nature, making 
extraction more difficult.
As previously stated, ^^I-arBGT is used in a variety of 
assays to determine AChR levels in extracts. Throughout this 
work, three assays were used for this purpose.
The first, was used to determine levels in purified AChR 
extracts, and involved the separation of the relatively acidic 
toxin-receptor complex from non-bound toxin by filtration through 
ion exchange filters (DE-81), the complex binding to the filters, 
whereas the free toxin washes through. The amount of radio­
activity bound to the filter disc was directly proportional to 
the amount of AChR in the test sample (Methods, section 1.3). In 
order to prevent the binding capacity of the discs from being 
exceeded, two discs are routinely used. This assay is more 
sensitive and reproducible than that normally used to assay crude
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receptor extracts, with low non-specific binding principally due 
to the purified nature of the extract with all other proteins 
having been removed. Consequently, it was this assay which was 
used to assay purified AChR preparations.
The second, was used to assay crude receptor preparations, 
and involves the precipitation of the total protein present in 
the extract, including the labelled AChR, by addition of ammonium 
sulphate. The ammonium sulphate assay was first described by 
Meunier et al, (1972). However, because of the precipitation of 
the total protein content, this assay tends to give very high 
non-specific binding with very poor replicates. Consequently, an 
alternative assay was looked at which is normally used to assay 
receptor content in crude rat brain homogenates (personal 
communication, Dr. S. Wonnacott). The PEI assay, as it is known, 
involves the separation of the receptor/toxin complex from free 
^25i_aBGT on glass fibre discs which have been preincubated in 
PEI. The discs so treated retain the acidic receptor/toxin 
complex because they are negatively charged. This assay when 
compared to the ammonium sulphate precipitation assay, gives 
results which are quantitatively comparable, but with greater 
reproducibility, lower non-specific binding, and is easier to 
carry out than the ammonium sulphate precipitation assay. A 
detailed comparison of the two assays was carried out by Walsh 
(1990). Details of the observations made during this study are
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not shown, however, they do confirm the conclusions made by 
Walsh (1990). Consequently, the PEI assay was used in preference 
to the ammonium sulphate precipitation assay for the assay of 
crude receptor extracts.
2* Human Monoclonal Antibodies
Since the development of murine monoclonal antibodies 
(Kohler & Milstein, 1975; 1976), their uses and applications have 
become extensive. In particular, they have been used in the 
immunological characterisation of the nAChR, with particular 
reference to the autoimmune disease, Myasthenia gravis 
(Introduction, section 3.3.9). However, even though their uses 
have been widespread, certain applications make it advantageous 
to develop human equivalents. For example, in the further 
characterisation of the immunological responses operative in 
Myasthenia gravis, and in the development of possible theraputic 
strategies for patients (Introduction, section 4.2).
The introduction of murine monoclonal antibodies have been 
in the main successful, however, the development of human 
equivalents have been somewhat less so. This has been attributed 
to a variety of reasons (Introduction, section 4) but in 
particular to the non-availability of a suitable human fusion 
partner which satisfies all of the desired criteria (Introduction 
section 4.2.1), and of sufficient numbers of immune lymphocytes 
for immortalisation. With regard to this latter point, the most 
readily available tissue is peripheral blood, however, PBL's tend 
to perform poorly (Introduction, section 4.2.2). Several
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procedures have been used to overcome this problem and to increase 
the relative numbers of specific immune lymphocytes present in 
peripheral blood. These largely consist of in vivo/in vitro 
immunisation procedures or preselection techniques (Introduction, 
section 4.2.2). The problem of a suitable fusion partner has been 
solved by various researchers, through the development of their 
own fusion partners for their own particular needs. This has led 
to a wide variety of techniques and fusion partners becoming 
available, with no particular one having any real advantage over 
any of the others (the techniques and fusion partners available 
are reviewed in the Introduction, section 4).
During this work, only one technique was used for the 
immortalisation of PBL's. This is the EBV/hybridoma technique 
(Introduction, section 4.2.3.iii) during which separated PBL's 
are transformed using EBV and the resultant lymphoblastoid cells 
fused with the mouse myeloma cell line, X63 (Kearney et al, (1979)).
This procedure has several advantages over the rest. The 
use of cell transformation, means that a relatively large number 
of lymphocytes can be transformed at the same time. However, not 
all of the cells will be transformed. For a cell to be 
transformed it must be at a particular stage of differentiation, 
even though there is some debate as to'the specific stage when 
B cells become susceptible to transformation (Introduction, 
section 4.2.3.ii). Consequently, if cellular differentiation is
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important for transformation then this partly explains the poor 
performance of PBL's, as a large number of cells present in 
peripheral blood are dormant awaiting activation, and are there­
fore not at a stage of differentiation for transformation to take 
place. In general it will be a mixed lymphocyte population.that 
will be transformed, with cells in various stages of cell 
differentiation. Prior to the separation of PBL's, in vivo/in 
vitro immunisation or preselection techniques would have been 
carried out in order to increase the numbers of specific 
lymphocytes present. A similar situation exists to in vivo 
immunisation in patients suffering from autoimmune diseases, where 
clonal expansion of specific immune lymphocytes has already 
occured. The association of transformation with the stage of 
cellular activation/differentiation also explains the failure 
during this work to transform B cells that have been stimulated 
with the polyclonal B cell activator PWM (Methods, section 2.4) 
which is used to enrich the B cell population of separated PBL's. 
The PWM stimulates the cells beyond the stage when they are able 
to be transformed through infection by EBV. Therefore, PWM was 
not used to polyclonally expand the B cell population prior to 
transformation. By not polyclonally expanding the B cell 
population before transformation another problem is caused, 
whereby cytotoxic T cells develop because they become sensitized 
to the presence of viral coat proteins on the cell surface of the
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transformed B cells. These would not normally be present if PWM 
stimulation was used prior to transformation, as the T cells would 
die in culture. This problem is circumvented by addition of the 
polyclonal T cell activator, PHA. Following transformation, PHA 
is included in the culture medium (Methods, section 2.3) where it 
polyclonally stimulates all of the T cells present before they 
become sensitized. As they are not immortal cells then they die 
within a few days of culture, leaving only the transformed cells.
PHA was, however, found to be cytotoxic to the transformed
cells if they were left in its presence for up to 7 days. This
was discovered through visual monitoring of the cultured cells
through an inverted microscope. If the culture cells were
examined around 7 days following transformation, it was noted that
there was a large amount of cell debris and dead cells in the
wells. This was initially attributed to the cell death'of the T
cells, and untransformed B cells, caused by the presence of the
PHA, but the debris appeared too excessive to be explained by
this reason alone. In addition, there were very few colonies 
of transformed cells and the ones which continued to grow did so
at a very slow rate, so much so that they could only be assayed
after approximately 3-4 weeks (Discussion, section 2). When they
were assayed, none were found to be secreting detectable amounts
of anti-AChR antibodies. This was in contrast to the situation
seen by Thompson et al, (1986, personal communication) in which
- 222 -
colonies grew well and were assayable after only 1 - 2  weeks, 
following transformation. It became clear that the only change 
to the system was the addition of PHA, but its presence was 
essential, as already described above, so the time period over 
which the cells were exposed to it was reduced from 7 to 3 days. 
This simple step alleviated the problem, with the result that the 
transformed cells grew well and in accordance with the growth 
seen by Thompson et al, (1986).
Having obtained a satisfactory system for transformation, 
and identified the culture wells containing the particular anti­
body of study, two lines can now be followed. The first involves 
expanding and cloning the lymphoblastoid cells, in order to 
obtain a cloned lymphoblastoid cell line (LCL), which secretes the 
antibody of interest. LCL, however, produce antibody titres which 
are lower than those seen in hybridomas, and have a tendancy to 
loose antibody production over a period of a few months 
(Introduction, section 4.2.3.ii). Antibody production can be 
rescued by back fusion of the LCL to a suitable fusion partner 
(Introduction, section 4.2.3.iii) and this is the basis of the 
second line which can be followed. However, it is not necessary 
to clone a LCL before fusion. In fact, as the cloning procedure 
is time consuming and labour intensive, to clone a LCL and then 
clone hybridomas is wasteful both of time and resources. The 
first cloning step can be eliminated. To do this, following assay
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of the transformants, all the positive wells are pooled. This 
pooled cell population, a large proportion of which are secreting 
the antibody of interest, are fused immediately with the selected 
fusion partner. In this study, the fusion technique used was the 
heterohybridoma fusion (Introduction, section 4.2.3.i) &
4.2.3 iii)) and the fusion partner chosen was the murine myeloma 
cell line, X63 (Kearney et al , (1979)).
This technique and cell line was chosen because the cell 
line was readily available, grows well in culture, fuses with 
high frequency and efficiency, even with human cells, is HAT 
sensitive and ouabain resistant (Introduction, section 4), in 
addition there were no suitable human fusion partners available. 
Ouabain resistance becomes an important factor where two immortal 
cell lines are being fused together. In the majority of hybridoma 
techniques, only one selection step is required, as only one 
immortal cell line is being produced. However, in the 
EBV/hybridoma technique, two such lines will be present, the 
unfused lymphoblastoid cells and the hybridomas. If both are 
left in culture, both will continue to grow, the lymphoblastoid 
cells contaminating the hybridomas. Therefore, it is necessary 
to select against the unfused lymphoblastoid cells. The advantage 
with using X63 cells, is that they are murine in origin and murine 
cells are 1 0 , 0 0 0  times more resistant to ouabain than human cells. 
Consequently, ouabain can be incorporated into the system to kill
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the unfused lymphoblastoid cells but leave the hybridoma cells 
intact. The X63 cells used in this work can withstand a ouabain 
concentration of 2 x 10"^ M (Results, section 2.1). Ouabain is 
therefore incorporated into the selection medium, along with HAT, 
at this concentration.
The fusion was carried out using PEG, and although it is 
very toxic to cells, it promotes the close apposition of cell 
membranes, by reducing membrane charges, while the presence of 
DMSO helps to modify the cell membranes to enhance fusion. By 
using a short fusion time ( 1 min) the toxicity to the cells was 
minimised. In addition, cell transformation prior to fusion, 
actually increases fusion frequencies by activating the B cells 
(Introduction, section 4.2.3.ii).
The major disadvantage of the heterohybridoma technique, is 
the inherant genetic instability of the heterohybridoma's 
(Introduction, section 4.2.3.i) with antibody producing hybridomas 
rapidly losing antibody production. Such non-producing cells tend 
to grow faster than antibody producing hybridomas and overgrow 
them, so clearly cloning is essential when trying to retain 
antibody production. Thompson et al, (1986), upon whose 
techniques this work was based, found no such instability in the 
heterohybridomas produced.
Extensive problems were encountered throughout this work in 
addition to those already described above. The primary problem
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with both the growth of lymphoblastoid cells and hybridomas, was 
chance infections, mainly bacterial in origin, even though some 
fungal contaminations did occur. As a consequence, the whole set 
of procedures used, and asceptic techniques, were re-evaluated on 
several occasions, especially where recurrent infections occured. 
However, even with the introduction of slightly different 
procedures, for example, installation of a sterile vacuum line 
into the flow cabinets, together with blood samples being 
collected directly into sterile evacuated tubes, infections 
continued to play a major role in the lack of success of this 
technique. With regards to this latter point, a change in the 
procedure was made as a result of noting that blood samples when 
taken normally, are done using a syringe and the blood is then 
transfered into sterile tubes. Unfortunately, this involves 
opening the tubes to the air, thereby increasing the possibility 
of infection. So it was requested that blood samples be taken by 
using evacuated tubes, equiped with a rubber self sealing cap.
In addition to this possible cause of infection, it is possible 
that some infection results from the blood directly, even though 
this will not be the major cause.
Freshly taken blood samples were not the only samples used 
in this study. A large number of samples were received by post 
from various parts of the country, however, these samples were 
anything from 7 to 14 days old before they were received. These
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samples, generally, gave a very poor lymphocyte preparation when 
separated on Ficol (Methods, section 2.2), with notable 
haemoglobin contamination of the lymphocytes, in addition to 
low viability. These lymphocytes tend to transform poorly, giving 
rise to very few lymphoblastoid cell lines. The poor performance 
of such lymphocytes can be explained with regard to their age. In 
general, the older the cells are the poorer they perform in such 
studies, consequently, fresh blood samples were used wherever 
possible.
Even considering all of these problems, some of which were 
overcome, partial success was achieved, in which one patient 
successfully gave rise to heterohybridomas following initial 
transformation of PBL’s with EBV. In this case, both the 
transformants and heterohybridomas were assayed utilising the 
direct Torpedo ELISA (Methods, section 3.1; Results, section 2.2). 
A decrease in the assayable antibody titres was noted (Results, 
section 2 .2 ) on assaying the transformants through to the 
heterohybridomas, which were finally lost through infection. Only 
6 positive wells were detected on initial transformation, however, 
these increased to 33 on back fusion, before finally decreasing 
to 6 on expansion before being lost. These results tend to 
support the view that back fusion can rescue antibody production 
even though the resultant heterohybridomas are genetically 
unstable with rapid loss of antibody production (Introduction, 
section 4.2.3). Assay of the expanded positive wells by modified
- 227 -
RIA (Methods, section 3.2), failed to detect any antibodies 
directed against human AChR. This result can be explained by a 
number of possible causes. Firstly, the RIA may not be sensitive 
enough to detect the small concentration of specific antibodies 
found in the culture supernatant obtained from transformants or 
heterohybridomas, whereas ELISA's are (Discussion, section 3). 
Secondly, the wells chosen for expansion and cloning were done so 
on the basis of their reaction with Torpedo AChR. Cross-reactivity 
is not the ideal method of detecting antibodies directed against 
a similar antigen found in another species, for example, in this 
case Torpedo AChR is used to detect antibodies directed against 
human AChR. For this to be successful, there must be some degree 
of similarity between the two antigens. This is seen in the 
nAChR's derived from different species (Introduction, section 3.2), 
however, it is more than probable that certain epitopes on the 
Torpedo AChR, which are not found on the human AChR, have greater 
antigenicity than others which are, thus the majority of 
antibodies produced will be directed against these particular 
determinants. So it is of no great surprise that the antibodies 
detected do not react with human AChR.
In addition, the lack of reactivity with human AChR in the 
RIA, can be further explained, by antigen orientation/presentation 
in the ELISA. Brennand et al (1986) has suggested that 
immobilisation of the antigen on ELISA plates in direct ELISA's,
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is in such a way that a variety of antigenic determinants are 
lost either through direct binding to the polyvinyl, or through 
steric hinderance. Thus if Torpedo AChR binds to the plates in
such a way that crossreactive determinants are masked or hidden,
then the antibodies detected will be specific for the Torpedo 
receptor and will not react with the human receptor. Consequently, 
antibodies detected by the direct Torpedo ELISA will not react 
with the human receptor.
Without the development of a suitable screening assay, the 
use of the phenomenon of cross-reactivity in this manner will 
always pose a problem, as will the inherant problems in the tissue 
culture techniques themselves (see above).
3. Assaying Anti-AChR Antibodies In Culture Supernatants
3.1 General Discussion
The success of any monoclonal antibody technique,-whether 
human or murine, is wholly dependant on the screening assay used 
to detect the particular antibody of interest. As can be seen 
from Figs. 24 & 25, assay steps are crucial in the general 
procedures employed, and are repeated several times throughout 
the generation of any monoclonal antibody.
As a consequence of this, several advantageous criteria are 
sought, when deciding upon the assay of choice. These include, 
high sensitivity and specificity, the ability to handle a large 
number of test samples (96 per test plate) with relative ease,
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and to give reliable results. In addition, it must be carried out 
in as short a time as possible. This latter point is particularly 
important when early cloning is essential to the success of the 
technique.
3.2 RadioImmunoAssay . —
This assay is routinely used to clinically assess the anti- 
AChR antibody levels in the blood sera of patients suffering from 
the disease, Myasthenia gravis (Introduction, section *5.3.6). 
Consequently, it was the first assay which was investigated 
closely with regards to its suitability for the detection of anti- 
AChR antibodies in culture supernatants. However, it soon became 
apparent that this assay did not fulfil the required criteria 
(Discussion, section 3.1).
It is an extremely labour intensive assay, with procedures 
(Methods, sections 1.6 & 3.2) that make the handling of-large 
numbers of test samples almost impossible. In fact if the basic 
assay is carried out on just one culture plate of transformed 
lymphocytes or hybridomas, with the required triplicate repeats, 
then 96 x 6 sample tubes will be required, in addition to 600 /ul 
of supernatant for each assay and a large quantity of both human 
AChR extract and radiolabelled arBGT. If dilutions and repeats are 
then considered in order to increase the accuracy of the assay, 
then this puts a further strain on the amount of test material 
available, in addition to the assay reagents (human AChR and 
^^I-aBGT). The use of radioactive reagents also requires special
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handling and safety procedures, in addition to detection equipment. 
A modification of the basic procedure was carried out by Walsh 
(1990), in which only one dilution, instead of several, was used, 
when looking at murine hybridomas producing monoclonal anti- . 
Torpedo AChR antibodies, however, this does not improve the 
assays desirability for detecting anti-AChR antibodies in culture 
supernatants as the logistics of both the basic and modified 
assay are the same. Therefore, this assay was deemed to be 
unsuitable for screening large numbers of culture supernatants 
which would be generated during the course of this study. 
Consequently, a direct ELISA assay (Methods, section 3.1), using 
purified Torpedo AChR (Methods, section 1.4) was used as a 
screening assay during the early stages of this study, while a 
suitable alternative was being investigated.
3.3 Direct Torpedo ELISA
Even though this assay fulfils the requirements already 
listed (Discussion, section 3.1), it is based on the use of the 
immunological phenomenon of cross-reactivity. Where cross- 
reactivity is used in this situation, it is essential that the 
antigen used in the assay bears a close similarity to the antigen 
of interest, and that the antigen of interest possesses epitopes 
also present on the assay antigen. However, as already discussed 
(Discussion, section 2) if the assay antigen is only weakly cross- 
reactive, then the majority of antibodies detected will be
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directed against this antigen and not the one of interest. It is 
also possible, when considering Myastenia gravis, that the 
antibodies detected, whether or not they react with human AChR, 
are not of- idiotypes which are active in the disease process. 
Consequently, doubt will always exist where cross-reactivity is 
being used as the basis for detecting antibodies directed against 
a particular antigen. In this case, though, the direct Torpedo 
ELISA was used with some success (Results, section 2.2) in the 
detection of human anti-AChR antibodies in the culture 
supernatants from transformed lymphocytes and heterohybridomas, 
and was used, due to the unsuitability of the RIA and the non­
availability of any other suitable assay.
3.4 Available ELISA Systems For The Detection Of Anti-AChR
Antibodies
Current literature describes several ELISA and EIA systems 
for the assay of anti-AChR antibodies, all of which have been used 
with varying degrees of success (Introduction, section 3.3.6), in 
differing situations. However, of these, several use purified 
AChR (Norcross et al, (1980); Kawanami et al, (1984); Muir & 
Jehanli, (1985)). This is a problem in itself, if human receptor 
is being used (Stephenson et al, (1982); Momoi & Lennon, (1982); 
Turnbull et al, (1985)).the ELISA putting a great strain on the 
amount of purified receptor available. A modification was made 
by Dwyer et al, (1983b), in which assay wells were pre-coated
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with a murine monoclonal anti-AChR antibody, prior to incubation 
with a crude receptor extract. The effect of the pre-coating 
procedure, is to increase the amount of AChR bound to the well. 
However, it is wholly dependent on the availability of a suitable 
coating antibody, and in this caset: one was not available. Similarly 
Furakawa et al, (1984) used HRP conjugated aBGT in an EIA. This 
assay is similar to the RIA in procedure, and requires the 
monitoring of an enzyme/substrate time course, making the assay 
as labour intensive as the RIA, if not more so. Two further 
assays have been described, both of which used crude receptor 
extracts. The first, described by Jailkhani et al, (1986), was a 
direct ELISA, in which crude human receptor was used to coat assay 
wells directly prior to assaying anti-AChR antibodies in diluted 
myasthenic sera. The second, described by Hinman et al, (1983), 
used aBGT to pre-coat the assay wells prior to incubation with 
crude Torpedo receptor extract. In theory, the aBGT will increase 
the binding of receptor to the wells, similar to the use of a 
monoclonal antibody (Dwyer et al, (1983b)). The disadvantage of 
this assay is the fact that anti-site antibodies will not be 
detected, however, they are not detected in the RIA either. Both 
of these assays were investigated with regards to their possible 
use in the screening of cultured lymphoblastoid cells or 
heterohybridomas, as they use crude receptor extracts. However, 
anti-AChR antibodies werenot detected in myasthenic sera nor
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culture supernatants, by either assay. This supported similar 
findings by Walsh (1990, unpublished), and is almost entirely due 
to the low receptor concentration in extracts.
3.3 Idiotypes And Anti-Idiotypes
An alternative approach to the development of an.ELISA...
system was investigated, based on idiotype/anti-idiotype inter­
actions.
Jerne (1938) first postulated the existence of anti- 
idiotypic antibodies, however, it was some years before their 
existence was finally proven. Jerne originally proposed their 
existence, on the basis, that idiotypic determinants on antibodies 
will themselves be antigenic with the subsequent formation of 
antibodies directed against them. These secondary antibodies 
being termed anti-idiotypic antibodies. It will also be noted 
that these secondary antibodies will themselves be antigenic with 
formation of anti-idiotypic antibodies. This is a continuing 
self perpetuating system, forming a subtle regulatory network.
The generation of anti-idiotypic response can be utilised in the 
development of an ELISA for the detection of the original antibody
V
idiotype.
In this case, a purified IgG fraction prepared from the 
serum of a Myasthenic patient was first used to immunise an 
experimental animal, to show that anti-idiotypic antibodies can 
be so raised. Having shown that anti-idiotypic antibodies can be
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raised, the same purified IgG can be used to generate murine 
monoclonal anti-idiotypic antibodies which can then be used in a 
double antibody sandwich ELISA for the detection of human anti- 
AChR antibodies in culture supernatants derived from transformed 
lymphocytes or heterohybridomas. In practise,, a whole array of 
murine anti-idiotypic monoclonal antibodies will be generated for 
the whole range of IgG idiotypes used in the immunisation, most 
with differing antigenic specifities and afinities, and all of 
which will require characterisation. However, the main 
disadvantage of this approach is the fact that the anti-idiotypes 
will be specific for one patient and cannot be used for others, 
unless there is shared idiotypy between patients. Consequently, 
monoclonal anti-idiotypic antibodies will have to be developed 
for each individual patient.
The effectiveness of the ELISA for detecting anti-AChR 
antibodies from one particular patient, using one particular 
monoclonal anti-idiotypic antibody, will largely be dependent on 
the extent of the idiotypic restriction present in the anti-AChR 
antibodies. Otherwise, a pooled anti-idiotypic antibody 
population will be required to coat assay wells, in order to 
detect the whole range of idiotypes present within a particular 
patients myasthenic antibodies, with the resultant loss of 
sensitivity. The demonstration, that a high proportion of the 
anti-AChR antibodies found in patients suffering from myasthenic
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gravis are directed against one particular region on thea-subunit 
of the AChR (Vincent, (1981); Tzartos & Lindstrom, (1980); 
Introduction, section 3.3.7) and are therefore of restricted 
idiotypy, means that the anti-idiotypic approach should be more 
effective. There are, however, anti-AChR antibodies present 
which are directed against other determinants on the AChR, a 
situation which is not wholly unexpected when considering the 
size of the receptor, but these are not believed to form the 
majority of antibodies present and are not thought to be 
pathogenic (Introduction, section 3.3.7).
In this study, one patient was chosen for investigation, 
who consistently showed high serum anti-AChR titres (100.7 nmol/ 
ml) on assay with the conventional RIA, and from whom large 
amounts of serum were available in addition to lymphocytes used 
for transformation. The large amount of serum available, made 
the IgG purification relatively easy (Fig. 46). The whole IgG 
fraction was not however, used for immunisation. In order to 
increase the likelihood of anti-idiotypic antibodies being 
generated, a pepsin digest was carried out on the purified IgG 
fraction. This has the effect of removing the Fc region of the 
antibodies, leaving F(ab) 2  fragments which can be separated from 
the digest by ion-exchange chromatography, the fragments being 
located in the void volume (Methods, section 4; Results, section 
4.1.2). The removal of the Fc region effectively reduces the
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number of dominant antigenic determinants present, increasing the 
chance of anti-idiotypic antibodies being formed. Unfortunately, 
light chains and the first constant region of the heavy chains 
will still be present, and it is to be expected that these will 
be more antigenic than the idiotype itself. The F(ab) 2  fragments 
so formed were characterised by RIA, Immunodiffusion, and SDS 
PAGE (Methods, section 4.3; Results, section 4.1.3), which showed 
their F(ab) 2  nature and the fact that they retained AChR binding 
ability.
The F(ab) 2  fragments were used to immunise an experimental 
rabbit (Methods, section 4.4), the serum of which was tested for 
the presence of anti-idiotypic antibodies (Methods, section 4).
A rabbit was used instead of a balb/C mouse as the test bleeds 
would give rise to a greater amount of serum for testing, even 
though a balb/C mouse would be used for monoclonal anti-idiotypic 
production.
Immunisation and subsequent boosting with the F(ab) 2  
fragments will give rise to a mixed population of antibodies, 
some of which will be anti-idiotypic in nature, but not all 
directed against anti-AChR idiotypes as a mixed IgG population 
was originally used. The majority of the antibodies so generated 
will be directed against the light chains and other determinants 
on the heavy chain. These antibodies were absorbed out of the 
serum by passing the serum over a Sepharose 4B column which had
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normal human IgG attached to it (Methods, section 4.5; Results, 
section 4.2). The theory being, that antibodies directed against 
the light chains and other heavy chain determinants will bind to 
the column leaving the anti-idiotypic antibodies to pass through. 
In addition, by using normal human IgG, anti-idiotypes other than 
those directed against anti-AChR antibodies will also be absorbed 
out, thus enriching the anti-AChR anti-idiotypic antibody content 
of the eluate. It is obvious that this procedure will not remove 
all of the unwanted antibodies present and that some of the anti- 
AChR anti-idiotypic antibodies will also be lost, especially when 
it is considered that autoimmune antibodies are present in normal 
healthy persons and are believed to be essential for health. 
However, these antibodies are not believed to form a significant 
part of an individuals antibody repertoire (Introduction, 
section 2.5).
The anti-idiotypic nature of this fraction was investigated 
by three methods (Methods, section 4.6; Results, section 4.2.1).
Firstly, by competitive RIA, in which the binding of the 
anti-idiotypes to two different myasthenic sera was observed 
(Methods, section 4.6.1; Results, section 4.2.1.i) along with NHS 
used as a control. The numbers of cpm's precipitated decrease on 
increased addition of the anti-idiotypic fraction to the 
myasthenic serum from patient P, this was over and above the 
decrease seen with addition to NHS. The decrease seen with
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patient J matched that seen with the control, indicating that the 
existence of anti-idiotypic antibodies in the fraction and that 
they are specific for patient P.
Secondly, the anti-idiotypic nature of the fraction was 
further confirmed by an ELISA, which investigated the .binding 
ability of the anti-idiotypic fraction to the myasthenic F(ab) 2  
fragments, compared to normal human F(ab) 2  fragments (Methods, 
section 4.6.2; Results, section 4.2.1.ii)). The results showed 
little binding of the anti-idiotypic fraction to normal human 
T(ab ) 2 fragments, but significantly higher binding of the anti­
idiotypes to the myasthenic F(ab) 2  fragments from patient P.
The reaction with myasthenic F(ab) 2  fragments gives good support­
ing evidence to the results obtained from the competitive RIA. 
Binding of the anti-idiotypes to myasthenic F(ab) 2  fragments 
obtained from patient 3 was not investigated.
In addition to these two assays, a third was carried out in 
which a crude IgG preparation of a serum sample obtained from the 
immunised rabbit, was linked to Sepharose 4B, forming an affinity 
column, down which a sample of myasthenic serum from patient P, 
was passed. The anti-AChR antibody titres of the myasthenic 
serum before and after adsorption were then compared by use of 
the conventional RIA (Methods, sections 4.6.3 & 1.6; Results, 
section 4.2.1.iii)). A 22?o decrease was found on adsorption 
suggesting that some of the anti-AChR antibodies were bound to
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the column. The disadvantage of this assay, is the fact that the 
immune rabbit serum did not have the anti-light/heavy chain 
antibodies adsorbed out of it before it was coupled to the 
Sepharose, therefore it is entirely probable that the decrease in 
antibody titre is due to binding through the light chains and 
not the idiotype. Thus making this assay somewhat inconclusive.
It has therefore been shown that anti-idiotypic antibodies 
directed against anti-AChR antibodies can be raised in an 
experimental animal with relative ease. What remained was the 
development of a murine monoclonal anti-idiotypic antibody which 
could be used in an assay. However, this approach was abandoned 
in favour of the more promising avidin/biotin ELISA which was also 
being developed. But the ease by which anti-idiotypes can be 
raised has wide implications for their use as biochemical and 
immunological tools. In particular, anti-idiotypes can'be used 
to purify specific anti-AChR antibodies from sera, which in turn 
can be used to affinity purify human receptor, something which is 
normally very difficult to do (Stephenson et al, (1982); Momoi & 
Lennon, (1982); Turnbull et al, (1983)). By purifying anti-AChR 
antibodies, their binding specificities and characteristics can 
be further investigated. Additionally, if Jerne's theory of the 
operation of regulatory anti-idiotypic networks in an individual 
is correct, then it follows that purified anti-idiotypic 
antibodies and idiotypic antibodies, can be used to investigate
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an individual's anti-idiotypic antibody repertoire, with 
subsequent development of better therapeutic strategies, through 
human monoclonal antibody technology. Several workers have 
demonstrated the existence of idiotype-anti-idiotype networks in 
MG (Schwartz et al, (1978); Fuchs, (1980)), even though others 
have not been able to detect blocking anti-idiotypic antibodies 
in remission phase MG patients (Heininger et al, (1983), or have 
suggested that there may be an anti-idiotypic cause to MG 
(Cleveland et al, (1983); Erlanger et al, (1984)). Thus there is 
enormous scope for the development and investigation of anti­
idiotypes.
3.6 Avidin/Biotin System And Detection Of Anti-AChR Antibodies
In Culture Supernatants
The avidin/biotin system consists of the omnipresent vitamin 
biotin, and the egg white glycoprotein, avidin, which is of 
restricted distribution in nature. Of similar characteristics 
with regards to its ability to bind biotin is, Streptavidin, found 
in the bacterium, Streptomyces avidinii. These two proteins are 
characterised by the strongest known biological recognition and 
subsequent non-covalent interaction which has made it one of the 
most useful systems for a wide variety of biological studies 
(reviewed by Wilchek & Bayer, (1980;1983), Titssen (1985)) in 
particular isolation, localisation and immunological studies. 
Avidin and Streptavidin, both have four binding sites for biotin.
The interaction was first noted by the observation that
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avidin, can interact with the so called 'biotin requiring enzymes' 
where biotin is a natural prosthetic group. Subsequent studies 
identified the precise nature of the interaction, and the 
appropriate means of introducing biotin artificially into 
biological molecules followed.    .•_
Only the ureido ring is required for recognition of the 
biotin molecule. Consequently, the carboxyl group of the valeric 
acid side chain can be modified chemically to obtain reactive 
derivatives, which can introduce the biotin moiety into other 
molecules. The two basic derivatives used are biotinyJ-N-hydroxy- 
succinimide ester, used to biotinylate proteins/amines, and biotin 
hydrazide, used to biotinylate aldehydes/sugars (Fig. 54). The 
effective coupling capacity of biotin to proteins is about 70?o, 
and about 5 biotin molecules per protein is usually required for 
subsequent recognition by avidin probes (Wilchek & Bayer, (1980; 
1983)). Avidin can be adapted into a number of probes, namely, 
fluorescent, radioactive, electron dense, immobilised and enzyme 
conjugated. Of particular interest, with regards to this present 
study, is the use of the system in immunological reactions, 
especially immunoassays, and in the localisation and visualisation 
of AChR's from Torpedo (Holtzman et al, (1982)) and on cultured 
myotubes (Axelrod, (1980)) by using biotinylated aBGT.
The first step in the development of an assay, involved 
labelling of the AChR with biotin. It became obvious that as
Fig.54 - Biotin/ftvidin Systen : Reactions & Use
ft) - shows how the biotinyl group is attached to proteins 
or sugars through the generation of highlg reactive 
interwediates (BNHS - biotinyl-N-hydroxy succininide 
ester; BHZ -biotin hydrazide).
B - biotin group; R - biological Molecule (eg. protein).
B) - shows use of avidin/biotin systeM in iMMunoassays, with 
two procedures being available ie. utilising an avidin 
conjugated probe, or a bio tinylated probe.
Ag - antigen
Ab - antibody
B - biotin group


























AChR's bind with great specificity and affinity to aBGT that it 
would be more appropriate to label the aBGT with biotin, a 
modification which has been used to investigate AChR's on 
cultured myotubes (Axelrod, (1980)). In additioh’aBGT is readily 
obtainable in a reasonably pure form, unlike AChR's, especially 
mammalian. The aBGT was able to be labelled with biotin very 
easily (Methods, section 3.3.1), and separated from non-labelled 
aBGT by cfei filtration'-0- " • The early preparations of
biotinylated aBGT, utilised overnight dialysis to remove the 
biotinylation reagents. However, the molecular weight cut off 
point for dialysis tubing is 8000 MW, which is the molecular 
weight of aBGT (Introduction, section 3.2.2). It is therefore 
possible that some of the BaBGT could be lost through the tubing. 
In order to prevent this, the subsequent preparations of BaBGT 
were separated on a Sephadex G25 column. This is a much easier 
method than dialysis when handling small volumes as none of it is 
lost, and can be carried out in a much shorter time period.
The BaBGT so prepared throughout this study was stable for 
al least 6 months, when stored at -20°C, a shelf life which far 
exceeds that for the equivalent ^^5j_<arBGT (effectively only 3 
weeks), and does not require any special procedural equipment or 
safety precautions, unlike the preparation of radiolabelled aBGT. 
Shelf life becomes important where consistency is required. With 
the conventional RIA, antibody titres in sera, are dependent on
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1 ?  sthe quality and biological activity of the AChR and ^I-aBGT 
preparations. Thus repeat assays of the same sera utilising 
different preparations may result in different titres being 
obtained.
In addition to its stability, BaBGT when compared to its^  
radioactive counterpart in the detection of Torpedo AChR in a 
solid phase assay (Methods, section 3.3.2.i; Results, section 
3.2.1) is found to be more sensitive, with low background. The 
binding of BaBGT to Torpedo AChR was, moreover, shown to be 
specific, through the demonstration that cholinergic ligands 
inhibit its binding, in a manner which exactly parallels that of 
aBGT itself (Methods, section 3.3.2.ii; Results, section 3.2.2). 
An assay based on that developed by Green (1963), determined that 
each aBGT molecule had 4-5 biotin moieties attached (Methods, 
section 3.3.2.ii; Results, section 3.2.3) which matches'the number 
required for effective recognition by avidin probes (Wilchek & 
Bayer, (1983)).
A checkerboard ELISA utilising varying concentrations of 
both Ba BGT and avidin peroxidase conjugate, with excess bound 
Torpedo AChR, established that 1/500 dilutions of both BaBGT and 
avidin peroxidase (representing concentrations of 0.5/ig/ml and 
l^ ug/ml respectively) achieved maximum sensitivity.
Thus is was possible to show that BaBGT binds with great 
specificity and selectivity to Torpedo AChR, with low background
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levels. Having established this is could then be used in an ELISA 
for the detection of human anti-AChR antibodies in culture 
supernatants. Human monoclonal anti-AChR antibodies were not 
available for use in the development of the assay as this would 
be the ultimate use for the assay. However., several murine_ 
monoclonal anti-Torpedo AChR antibodies were, as they had been 
previously developed in the department by Dr. S. Walsh, together 
with a murine monoclonal anti-neurofilament monoclonal antibody 
developed by Dr. A. Rogers, which was available as a control.
These antibodies were therefore used to develop and optimise the 
assay.
The antibodies available were firstly investigated by use 
of a direct Torpedo ELISA, and by RIA using Torpedo and fetal calf 
AChR, with regards to their binding abilities (Methods, section 
3.3.3.i; Results, section 3.3.1). From these results, four 
monoclonal antibodies were chosen for further study. Three of 
these (Cl 1, B11, & E8) cross-reacted with fetal calf AChR, and one 
(C7) did not (Tables 18 &19 give the biochemical properties of 
these antibodies).
The antibody capture ELISA was assessed in terms of its 
ability to detect these murine monoclonal anti-AchR antibodies 
(Methods, section 3.3.3.ii; Results, section 3.3.2). It proved 
to be both reliable and sensitive in the detection of anti-AChR 
antibodies from culture supernatants, with an ability to be able
- 246 -
to readily detect antibody levels of 2 ng/ml (approximately 
2 x 10“^  M aBGT binding sites; Results, section 3.3.2), and even 
as low as 0.2 ng/ml. This represents a 30 fold increase in 
sensitivity over the RIA, when one of the monoclonal antibodies, 
C7, was used. The specificity of the assay was demonstrated by 
the lack of response seen by antibody C7, with fetal calf, and of 
anti-neurofilament antibodies with either Torpedo or fetal calf 
AChR. This agreed with the results obtained by RIA. In addition, 
specificity was further shown by the responses being totally 
abolished in the presence of the cholinergic ligand, decamethonium 
bromide (Results, section 3.3.2).
Having established the essential specificity and sensitivity 
of the assay, the assay conditions were optimised and standardised 
using one of the monoclonal antibodies, C7 (Results, section 
3.3.3). However, it was observed during the course of these 
assays, that high background readings were obtained in blank wells 
which had HRP-avidin added, after being blocked with casein. This 
was something not normally seen as the low background levels are 
a major advantage of the assay. Further studies suggested that 
the HRP-avidin was interacting with the casein present in the 
assay buffers, and used to block the wells. This was attributed 
to the highly basic nature of the avidin, pi = 10 (Wilchek &
Bayer, (1980)). If the avidin interacts with the casein 
incorporated into the assay buffers, then this could effectively
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reduce the concentration of HRP-avidin in the assay, and thereby 
reduce the sensitivity of the assay. Thus it is conceivable that 
the sensitivity of the assay has been underestimated. In order 
to overcome this problem, several alternatives to casein were 
investigated (Results, section 3.3.3.i)).
Casein is recognised to be the most effective blocker of 
non-specific binding. This ability being attributed to it forming 
a mono-molecular film over the plastic assay wells, however, it 
has been suggested that in certain assay systems casein may not 
be the blocker of choice, depending on the requirements of the 
assay (Vogt et al, (1987)). This appears to be the case with 
this particular ELISA.
Tween-20, BSA, FCS, and NGS were all found to be ineffective 
blockers of non-specific binding, supporting similar conclusions 
by other workers (Vogt et al, (1987)). Vogt et al, (1987), 
suggested that an alternative to casein, in systems where it is 
not suitable, is fish skin gelatin. It has been shown to be an 
excellent blocker of nitrocellulose Western blots (Sarais (1984)), 
and in addition it does not solidify even under refrigeration at 
high concentrations. It was found to be an excellent blocker in 
this particular ELISA system, especially when used in conjunction 
with Streptavidin-HRP.
Streptavidin-HRP was used as an alternative to avidin-HRP 
as it is almost neutral, pi = 7.2-7.3, compared to the highly
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basic avidin, consequently, it has been found to be more useful 
in certain systems (Hurt & Taafe, (1987); Wilchek & Bayer, (1980)).
The combination of Streptavidin-HRP with the use of fish
skin gelatin as a non-specific blocker, reduced the non-specific 
binding to the levels previously seen, and a slight increase in 
sensitivity was noted. Consequently, both these modifications 
were adopted as a matter of course in subsequent experiments.
Whilst investigating optimal binding of AChR in the assay, 
it was noted that an AChR concentration of between 0-5 pmol/ml 
achieved saturation, and that a concentration as low as 0.1 pmol/ 
ml gave measureable readings above background. This level of 
sensitivity becomes important when mammalian AChR extracts are 
being used, in particular, human, where concentrations around 
1 pmol/ml are frequently encountered (Results, section 3.3.3.iii).
Due to the lack of success of the human monoclonal
antibodies, the antibody capture ELISA was used to detect anti- 
AChR antibodies in myasthenic sera (Methods, section 3.3.4). Five 
myasthenic sera were chosen for study, which represented a typical 
cross section of antibody titres, as indicated by RIA. The RIA 
utilises an anti-human IgG antiserum to precipitate anti-AChR 
antibodies (Methods, section 1.6), consequently only the anti- 
AChR IgG antibodies are detected, whereas anti-AChR IgM antibodies 
are not. In general, it is the anti-AChR IgG antibodies which 
are deemed to be pathogenic in MG (Introduction, section 3.3.7)
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even though myasthenic sera have been shown to be polyclonal in 
nature, with a variety of isotypes being present. However, if a 
subpopulation of antibodies is responsible for MG, then 
considering that complement mediated lysis is believed to be the 
mechanism responsible for the loss of AChR from the post synaptic 
membrane (Introduction, section 3.3.7), it would not be 
inconceivable that these antibodies are of an IgM isotype, as 
IgM's have a greater complement binding ability than IgG's.
The antibody capture ELISA failed to detect IgG 
antibodies in any of the myasthenic sera, even in high titred sera 
as shown by RIA (Results, section 3.3.4), but human anti-AChR IgM 
antibodies were detected. This could initially be explained by 
the fact that immobilised IgM could in theory bind up to 3 fold 
more AChR than IgG, introducing a type of response amplification. 
The assay showed that all sera tested, including NHS, hdd 
detectable levels of anti-AChR IgM antibodies. This gave 
supporting evidence to the suggestion that even normal healthy 
individuals produce small amounts of autoimmune antibodies which 
tend to be IgM in nature and can be equated to a primary immune 
response (Introduction, section 2). In addition, the ELISA showed 
that two patients (HN & RS), both of whom have high titres by RIA, 
have IgM titres equivalent to those seen in NHS, whereas another 
patient (PT), which also had high titres, had high IgM titres 
above normal, as did two other patients (RA & SH), who had low
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RIA titres (Results, section 3.3.4). The range of IgM titres, 
when compared with those obtained by conventional RIA for IgG, 
tends to lend weight to the suggestion that an isotype switch may 
be important in the generation of an autoimmune response, or at 
least in the generation of a secondary immune response 
(Introduction, section 2). Thus, the patients tested by RIA and 
ELISA, may well be at differing stages in the generation of a 
secondary immune response, as IgG titres tend to increase on the 
development of a secondary immune response, whereas IgM titres 
decrease. In order to provide fairly conclusive evidence of this, 
it will be necessary to follow a patient's titres as they change 
with time, from first diagnosis, through to the development of 
the full blown disease.
It is quite clear that there is scope for further work to 
be carried out on the use of the ELISA in the detection of anti- 
AChR antibodies in myasthenic sera. It is unfortunate that the 
assay could not be tried out on the culture supernatants obtained 
from cultured lymphocytes or heterohybridomas for the reasons 
already discussed (Discussion, section 2).
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FURTHER AIMS
The inability to utilise the biotin/avidin ELISA, in the 
detection of human monoclonal anti-AChR antibodies, means that 
this must be the primary objective of any further study in the 
development of human cell lines secreating antibodies of this 
specificity. Theoretically, the sensitivity of the ELISA in 
detecting anti-AChR antibodies, could be increased through an 
amplification step (Wilchek & Bayer, (1983); fig. 54), and could 
be repeated several times. However, steric hinderance and inter­
ference between bound components of the system, will limit the 
number of times the amplification will be effective. Such a step 
would be particularly useful if human extracts with low levels of 
AChR activity are being used. However, such a refinement was not 
carried out during the course of this present study, and would 
lend itself to further investigation. In addition, such an 
amplification step may have allowed the detection of human anti- 
AChR IgG antibodies in myasthenic sera (Methods, section 3.3.4; 
Results, section 3.3.4), even though it was not used. Coupled 
with this, is the assaying of anti-AChR IgG and IgM antibodies in 
the sera of myasthenic patients where changes in titres are 
monitored with respect to time. These results may then be 
compared to changes in disease severity within the particular 
patient in an attempt to obtain some sort of correlation which is 
lacking at present (Introduction, section 3.3.6 & 3.3.7), and may 
also be related to the development of a secondary immune response.
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Human monoclonal antibody technology itself requires further 
study and refinement. Even up to the present time, very little 
headway has been made in developing a general widely applicable 
technique and a good human fusion partner. Consequently, several 
different techniques are used to generate human monoclonal anti­
bodies, and unless there is a major advance in the technology, 
this diversity is likely to continue (Thompson, (1988)). Thus, 
further work is needed in this area, in particular in the develop­
ment of a suitable fusion partner which displays the favourable 
characteristics seen in the murine myelomas, in particular X63 
(Kearney et al, (1979)). The development of such a cell line 
would make the fusion technique particularly attactive. However, 
the choice of tissue for obtaining lymphocytes will remain a 
problem. In general, peripheral blood is the only tissue 
available even though lymph nodes, spleen and bone marrow cells 
have been shown to be richer in B cells (Thompson, (1988)). Thus, 
lymphocyte enrichment, in vitro stimulation, and EBV 
transformation, will continue to be used in order to improve the 
performance of PBL's.
Having demonstrated that anti-idiotypes can be generated in 
experimental animals (Methods, section 4; Results, section 4), 
then it should be relatively easy to generate murine monoclonal 
anti-idiotypic antibodies. Such antibodies will undoubtedly find 
numerous immunological and biochemical applications in isolation
and characterisation studies, as well as in assays. For example,
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in the isolation and purification of specific idiotypes, which 
may be involved in disease processes with subsequent purification 
of and characterisation of the antigen; labelling of lymphocytes 
carrying the specific idiotype of interest on their cell surface, 
and subsequent separation by FACS, from which monoclonal 
antibodies can be produced; and, in assaying specific idiotypes 
of interest.
Even though this particular study has only had limited 
success, several follow up investigations with regard to the use 
of the biotin/avidin ELISA, development of human monoclonal 
antibodies, and investigation and exploitation of the idiotype- 
anti-idiotype system, are now required.
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An ELISA for the detection of anti-acetylcholine receptor 
antibodies using biotinylated a-bungarotoxin
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An antibody-capture enzyme immunoassay has been developed for the detection of anti-acetylcholine 
receptor (AChR) antibodies in tissue culture supernatants using biotinylated a-bungarotoxin (BaBGT). 
Immunoglobulins in culture supernatants were bound indirectly to microtitre plates via an anti-globulin 
antibody already coupled to polyvinyl plates. Anti-AChR antibodies were then detected by incubation 
with AChR crude extract. Bound AChR was revealed by incubation with BaBGT followed by horseradish 
peroxidase-conjugated avidin. This assay is specific, more sensitive than the commonly used double 
antibody radioimmunoassay, avoids the use of radioactive material, is practical for large numbers of 
samples and is particularly suitable for detecting anti-AChR antibodies in tissue culture supernatants.
Key words: Acetylcholine receptor; a-Bungarotoxin, biotinylated; Monoclonal antibody; ELISA
Introduction
Over the past 10 years there has been consider­
able interest in the production and characterisa­
tion of antibodies to the nicotinic acetylcholine 
receptor (AChR). This interest largely stems from 
the discovery of such autoantibodies in the neuro­
muscular disease, myasthenia gravis (for review, 
see Harrison and Behan, 1986), and experimen­
tally induced antibodies, both polyclonal and 
monoclonal, have proved useful in clarifying, not 
only the pathogenesis of myasthenia, but also 
structure-function relationships of the receptor it­
self (Lindstrom, 1984).
Anti-AChR antibodies in serum are most com­
monly measured by a radioimmunoassay, first de-
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scribed by Lindstrom (1977), which depends upon 
the precipitation of 125I-a-bungarotoxin-labelled 
AChR-antibody complex by second antibody 
(Carter et al., 1981) or by Staphylococcus aureus 
cells (Tindall et al., 1981). A variation of this 
procedure, using horseradish peroxidase-labelled 
AChR and enzyme immunoassay, has been de­
scribed by Furukawa et al. (1984).
Screening of large numbers of cell supernatants 
during the course of monoclonal antibody produc­
tion is most conveniently carried out by solid-phase 
assay using multiwell plates, as in the ELISA and 
IRM A procedures (Voller et al., 1981); of these, 
the ELIS As have the advantage of avoiding the 
use of radioisotopes. A number of ELISAs for 
anti-AChR antibodies have been reported but are 
open to various objections. Thus, those described 
by Norcross et al. (1980), Kawanami et al. (1984) 
and Kobayashi et al. (1984) all use purified AChR, 
which is adsorbed onto the solid phase, prior to 
exposure to test serum and second antibodies. 
While suitable for the readily available AChR
0022-1759/88/S03.50 © 1988 Elsevier Science Publishers B.V. (Biomedical Division)
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from electric fish, this is much less practicable for 
assays using mammalian receptor since the latter 
is present in only very low amounts in skeletal 
muscle (Dolly and Barnard, 1984). The procedures 
of Hinman et al. (1983), and of Dwyer et al.
(1983), on the other hand, do not depend upon 
purification of AChR. That of Hinman et al.
(1983) relies upon the ability of plates, pre-coated 
with a-bungarotoxin, to adsorb specifically AChR 
from crude extracts, while that of Dwyer et al.
(1983) depends upon pre-coating with a m ono­
clonal antibody to achieve the same result. In our 
hands (S. Walsh, unpublished data) the former 
assay was successful with Torpedo receptor but 
less so with AChR from m ammalian sources. The 
latter assay suffers from the obvious disadvantage 
of requiring a suitable monoclonal antibody.
A passive haemagglutination assay previously 
described by one of us (M uir and Jehanli, 1985) 
also requires pure receptor.
We now describe an antibody capture ELISA, 
based on the biotin-avidin system (Bayer and 
Wilchek, 1980), that can be used with crude AChR 
and is particularly suitable for the detection of 
anti-AChR antibodies in tissue culture super­
natants.
Materials and methods
Biotinylation o f a-bungarotoxin (aBGT)
aBG T was biotinylated using a modification of 
the procedure employed for labelling immuno­
globulins (Kendall et al., 1983). aBG T was thor­
oughly dialysed against 0.1 M N a H C 0 3 and its 
concentration adjusted to 5 m g/m l. To this solu­
tion (1 ml), a freshly prepared solution of biotin- 
A-hydroxy-succinimide (Sigma Co., Poole, Eng­
land) in dimethylformamide (0.1 ml, 40 m g/m l) 
was added dropwise with gentle stirring. The mix­
ture was incubated, with stirring, for 2 hfat room 
temperature and then dialysed against phosphate- 
buffered saline (PBS), pH  7.3 (2 litres) for 48 h at 
4 °C . The concentration of biotin-conjugated 
aBG T (BaBGT) was adjusted to 0.5 m g/m l in 
PBS containing bovine serum albumin (10 m g/m l), 
and an equal volume of glycerol was added. 
Aliquots (0.2 ml) were stored at — 20 ° C. For the 
purpose of this study, five lots of conjugate were
made, containing an average of 4 -5  biotin mole­
cules per molecule of aBG T, as determined col- 
ourimetrically by the method of Green (1965). The 
biological activity of BaBG T and its affinity for 
Torpedo AChR were 70% and 25%, respectively, 
compared to those of the native toxin (Lukasie­
wicz et al., 1978).
Purification o f AChR
AChR was purified from the electric organs of 
Torpedo marmorata by detergent extraction and 
affinity chrom atography as previously described 
(M uir and Jehanli, 1985). The purified receptor 
had a protein concentration 0.3-0.5 m g /m l and 
bound 6 -8  nmol aB G T per mg protein as de­
termined by the procedure of Schmidt and Raftery 
(1973). Crude preparations of fetal calf skeletal 
muscle AChR and Torpedo AChR were made by 
detergent extraction only and showed toxin b ind­
ing activities of 0.8-2.5 pm ol/m l, and 2500-3000 
pm o l/m l, respectively.
Characterisation o f binding o f B aB G T  to AChR  
The binding of BaBGT to AChR was char­
acterised by means of a solid-phase enzyme assay. 
Microwell M odule Strips (Nunc, Uxbridge, U.K.) 
were coated by incubation with purified Torpedo 
A ChR in 50 mM sodium carbonate/b icarbonate 
buffer, pH  9.6 (100 jul/well, 5 jug/m l) overnight at 
4 ° C. The strips were then washed three times with 
50 mM T ris /H C l buffer, pH  7.4, containing 0.15 
M NaCl, 0.05% (w /v ) Tween 20 and 1% (w /v) 
casein (assay buffer), and blocked by incubation 
with the same buffer (200 jul) for 30 min. At this 
stage, strips can be used immediately or stored at 
4 ° C  for at least 2 weeks without loss of activity. 
Prior to use, the wells were washed again with 
assay buffer and then incubated with serial dilu­
tions of BaBGT in assay buffer (100 jul/well) for 
3 h at room tem perature or overnight at 4 ° C. The 
wells were washed three times (5 min each) with 
assay buffer and then incubated with appropriate 
dilutions of avidin-horseradish peroxidase con­
jugate (HRP-avidin, 0.5 m g /m l Sigma) in assay 
buffer (100 /xl/well) for 3 h at room temperature. 
In some experiments, a biotin-avidin-HRP com­
plex (Radiochemical Centre, Amersham, Bucks, 
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Fig. 1. Interaction of BaBGT with Torpedo AChR-coated microtitre wells, a: Checkerboard titration of BaBGT concentration and 
HRP-avidin concentration: 1/300 (•), 1/900 (■), 1/2700 (^ )  and 1/8100 (a ). Coating antigen concentration: 5 jug/ml. Absorbance 
in the absence of BaBGT was < 0.05 with all dilutions of HRP-avidin. b: Inhibition of binding of BaBGT (1/500 dil.) to AChR by 
unlabelled aBGT (•), benzoquinonium (■), decamethonium (O) and nicotine (a ). HRP-avidin dilution: 1/500. c: Comparison of 
binding of BaBGT (1/500 dil.) (•), and 125I-aBGT (0.56 pmol) (■) to microtitre wells coated with various concentrations of AChR.
TABLE I
PROPERTIES OF MOUSE MONOCLONAL ANTI-AChR ANTIBODIES
Antibody Subclass IgG concentration 
(jug/ml)
Anti-AChR antibody titre of supernatant (nM) a 
Torpedo AChR Fetal calf AChR
C7 IgG2b 10.0 110 ND b
C ll IgG2b 8.0 139 0.75
B ll IgG2b 7.5 180 4.50
E8 IgG2b 15.0 301 2.32



































Culture S u p e rn a tan t Dilution F ac to r
Fig. 2. Titration of anti-AChR antibodies, a, b: Antibody-capture ELISA for the detection of antibody binding to Torpedo AChR 
and fetal calf AChR, respectively. Monoclonal antibody culture supernatants used were C7 (^ ) , C ll (•), B ll (■), E8 (a ) and
anti-neurofilament (.............. ). Values are the average of triplicate samples. Percentage standard deviation was < 20%. c: Double
antibody RIA for the detection of monoclonal antibody, C7 (+ )  binding to Torpedo AChR (0.1 pmol). Various amounts of C7 
supernatant and normal mouse serum (5 jul) were added and the 125I-aBGT-AChR-antibody complex was precipitated by the 
addition of goat anti-mouse IgG antiserum (40 pi). Total assay volume was 400 p\.
molecule of aBG T (A/r approx. 8000) fails to 
accommodate the bulky complexes necessary for 
amplification of enzyme activity.
Detection o f anti-AChR antibodies
The antibody-capture assay for anti-AChR an­
tibodies was assessed in terms of detection of 
monoclonal antibodies in supernatants from four 
murine hybridomas. Table I shows the properties 
of the respective monoclonal antibodies.
The ELISA procedure permitted reproducible
detection of anti-AChR antibodies against Torpedo 
A ChR (Fig. 2a) and fetal calf AChR (Fig. 2b). 
The minimum detection levels of the different 
antibodies are shown in Table II. The variation in 
titre between the different monoclonals is most 
likely a reflection of differences in affinity.
The ELISA confirmed the lack of cross-reactiv­
ity of monoclonal antibody C7 against fetal calf 
AChR which was initially indicated by radioim­
munoassay (Table I). The specificity of BaBGT in 
the ELISA was further dem onstrated by the assay
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TABLE II
TITRATION OF MOUSE MONOCLONAL ANTI-AChR 
ANTIBODIES BY ELISA
Antibody Minimum detection levels
Torpedo AChR Fetal calf AChR
Super- IgG conc. Super- IgG conc.
natant (ng/ml) natant (ng/ml)
dilution dilution
C l 1/5120 1.95 ND a ND
C ll 1/320 25.0 1/2560 3.1
Bit 1/80 94.0 1/2560 2.9
E8 1/640 23.4 1/1280 11.7
a Not detected.
of monoclonal anti-neurofilament antibodies (a- 
NF), which showed no response against either 
type of AChR. Responses in the assay to anti- 
AChR antibodies were inhibited by the presence 
of 20 mM decamethonium bromide.
Direct comparison of the antibody-capture 
ELISA with the conventional double-antibody ra­
dioimmunoassay, using monoclonal anti-AChR 
antibody, C7, showed the ELISA to be consider­
ably more sensitive, detecting minimum levels of 
protein of 2 ng /m l (1/5120 dil.) compared with 
62.5 ng /m l (1/160 dil.) for the radioimmunoassay 
(Fig. 2c).
Discussion
The avidin-biotin system has a number of ad­
vantages in immunoassay procedures. Biotin can, 
in general, be readily coupled to proteins with 
minimal loss of biological activity while avidin, 
which binds with very high affinity ( K d, 10~15M) 
to biotin, can be labelled in many ways, e.g., with 
fluorescent, radioisotope or enzyme probes (Tijs- 
sen, 1985). This means that, once characterised, 
the protein-biotin conjugate can be detected by a 
range of techniques, requiring little further devel­
opment. The presence of multiple binding sites for 
biotin on the avidin molecule offers the possibility 
of response amplification using avidin-biotin probe 
complexes in place of avidin-probe conjugates 
(Hsu and Raine, 1981).
BaBGT prepared in this study was stable for at 
least 6 months when stored at -  20 ° C, which far 
exceeds the shelf-life of 125I-aBGT (about 4 weeks).
Furthermore, when compared to 125I-BGT in the 
solid-phase assay, BaBGT was found to provide a 
more sensitive detection of Torpedo AChR. Bind­
ing was, moreover, shown to be specific and sus­
ceptible to cholinergic ligands in a manner exactly 
parallelling that of aBG T itself. To our knowl­
edge, the only reported use of biotinylated aBGT 
is that by Axelrod (1980) who described its 
histochemical application, together with fluo­
rescent avidin, in the cross-linking and visualisa­
tion of AChR on myotubes.
The use of BaBGT in the antibody capture 
ELISA proved to be both reliable and sensitive for 
the detection of anti-AChR antibodies in super­
natants from monoclonal antibody-producing hy­
bridomas. Antibody levels of 2 ng /m l (approxi­
mately 2 X 10“ 11 M aBGT binding sites) were 
readily detected; a degree of sensitivity some 30- 
fold higher than that obtained in the conventional 
double immunoprecipitation radioimmunoassay 
applied to C7 (Fig. 2c). The specificity of the 
assay was demonstrated by the lack of response to 
antibody C7, with fetal calf AChR as antigen, and 
to anti-neurofilament antibodies with both Torpedo 
and fetal calf receptors. All responses were, more­
over, abolished by decamethonium bromide.
We are currently routinely using the antibody- 
capture ELISA for the detection of anti-AChR 
antibodies produced by Epstein-Barr virus trans­
formed lymphocytes from myasthenic patients. 
Such supernatants commonly contain approxi­
mately 1-100 n g /m l immunoglobulin and are 
readily amenable to anti-AChR antibody assay by 
this method using either fetal calf or human muscle 
AChR.
The sensitivity and convenience of the anti­
body-capture ELISA are particularly appropriate 
for the assay of anti-AChR antibodies in prepara­
tions where the relevant antibody fraction is mostly 
of the desired specificity, e.g., cell supernatants. 
The binding properties and detection levels of 
BaBGT itself strongly suggest its extended use in 
histochemical analysis of AChR.
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